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 Chapter 1   
 
 Genera l  in t roduc t ion  
 and  ou t l ine  of  t his  t hes is
What is FSHD?
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common muscular 
dystrophies in adulthood with an estimated prevalence of 1:8000.[1]  Muscular 
dystrophies are marked clinically by progressive skeletal muscle weakness and atrophy 
and is caused by defects in genetic, biochemical and structural components of muscle, 
which lead to muscle cells death and tissue loss. “FSHD” refers to the progressive loss of 
skeletal muscle mass and strength noticeable across facial (facio), shoulders (scapula), 
and upper arm (humeral) muscles. The hip girdle, trunk and leg muscles are also affected 
in many patients. Muscle weakness often sets in asymmetrically, but rarely affecting only 
one arm or one leg. Signs of muscular weakness may manifest early, sometimes years 
before a formal diagnosis. Figures 1 and 2 and box 1 summarize the main clinical features.
Figure 1:  Characteristic signs of facioscapulohumeral muscular dystrophy (Adapted from [2])
 12
B O X  1
 
Clinical characteristics of FSHD, in bold the most characteristic features [2, 3]
Epidemiology
• The estimated prevalence of FSHD is 1: 8.000
Typical clinical features
• Early involvement of facial muscles weakness.
• Involvement of the upper before the lower extremities.
• Striking asymmetry of muscle weakness and atrophy.
•  Facial muscle involvement, often asymmetrical and frequently not recognized by 
the patients and their relatives, can be demonstrated in more than 90% of the 
cases at the time of diagnosis.
•  Severe abdominal muscle weakness, pelvic girdle and back extensor muscle 
weakness contribute to the increased and sometimes extreme lumbar lordosis.
Disease course
•  FSHD is a slowly progressive muscular dystrophy that manifests at age 15–30 
years in most cases.
•  Onset has been defined as the moment a patient becomes aware of having 
FSHD, or as the moment a patient suffers impairment caused by FSHD. With 
this definition, approximately one third of patients (clinically detectable gene 
carriers) do not complain of the disease.
•  The start of symptoms and their progression follows a rather unique and 
characteristic pattern. It starts with weakness of the facial and shoulder girdle 
muscles followed by the abdominal muscles and ankle dorsiflexors and finally the 
upperarm and pelvic girdle muscles.
•  Approximately 20% of patients become wheelchair dependent, usually above 
the age of 50. Approximately 20%-30% of the gene carriers are asymptomatic 
and/or minimally affected. 
•  Although FSHD does not typically shorten the life span, it can result in significant 
morbidity and loss of the ability to earn a living. 
Interindividual variation
•  Considerable inter- and intrafamilial variability of disease onset, progression and 
severeity exist. 
•  A mild gender effect has been observed: women tend to be more often 
asymptomatic, have a slightly later onset and a somewhat milder course of the 
disease.
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Associated clinical features
•  Approximately 80% of patients with FSHD experience moderately severe chronic 
pain, mostly in the lower back, legs, shoulder region and neck.[4]
•  Around 60% experience severe chronic fatigue, related to multiple perpetuating 
factors including pain, sleep disturbance, physical activity and impairment.[5]
•  The prevalence of asymptomatic, mild cardiac conduction defects (incomplete 
right bundle block in the absence of cardiomyopathy) is increased, but this 
appeared not progressive in a cohort of ambulant FSHD patients. Therefore, 
standard cardiac screening or surveillance is not required in FSHD patients 
without cardiac complaints.[6]
•  Retinal vasculopathy is associated with FSHD. It is usually subclinical but can, 
mostly in severely affected early onset cases with very short repeat sizes, 
progress to Coat’s like syndrome.[7]
•  High-frequency hearing loss may occur in patients with FSHD and also remains 
mostly subclinical. Patients with early onset severe disease may develop hearing 
loss requiring hearing aids.[8]
•  Mild scoliosis and lumbar hyperlordosis (related to axial muscle weakness), can 
be found in one-third of FSHD patients, is usually mild, and more likely to be 
found in early-onset cases. It may cause postural instability.[9]
•  Pectus excavatum occurs in 5%–16% of patients with FSHD and occasionally 
may be severe.[10]
•  There are a few case reports of mental retardation and/or epilepsy in patients 
with severe FSHD.[11]
Differential diagnosis [2]
• Limb girdle syndromes (e.g. LGMD2A (CAPN3))
• Myotonic Dystrophy type 1 and 2 (DM1 and DM2 (PROMM))
• Inclusion Body Myositis
• Dermatomyositis
•  Scapuloperoneal syndromes
 -  nemaline myopathy type 3 (ACTA1)
 -  Emery Dreifuss muscular dystrophy
 -  acid maltase deficiency (Pompe disease)
 -  myophosphorylase deficiency (McArdle disease)
 -  mitochondrial myopathies
 -  Reducing body myopathy (Adult onset) (FHL1)
 -   Scapuloperoneal MD (SPMD) with Hyaline bodies (Type 1: FHL1;  
Type 2 and 3: MYH7)
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Figure 2:   A 70-year old patient with genetically confirmed FSHD (repeat length of 8 D4Z4 units).  
He was diagnosed with a myopathy at the age of 32. At the age of 70, he reported severe difficulties 
walking stairs. Physical examination showed very mildly asymmetrical forceful eye closure, 
asymmetrical lip touting, and inability to blow the cheeks. The pectus excavatum was still present, 
he had severe atrophy of the pectoralis muscles, with horizontal axillary folds. Shoulder abduction 
was limited to approximately 60 degrees, with winging and overriding scapulae There is atrophy 
of upper arms and posterior upper legs. The lumbar lordosis is increased due to weakness of the 
abdominal wall muscles. The clinical severity score (see above) was 7.
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Genetic mechanism
FSHD is caused by an epigenetic derepression of the DUX4 gene embedded in the most 
distal D4Z4 unit of the D4Z4 repeat array and the subsequent production of DUX4 protein 
with several presently unknown myotoxic downstream effects leading to muscular 
dystrophy.[12]  In control individuals the D4Z4 array ranges between 11 and 100 units 
and the DUX4 gene is repressed by CpG methylation and epigenetic modifications. 
The derepression of DUX4 in FSHD is caused either by a reduction of D4Z4 repeats to 
1-10 units on a 4qA specific FSHD-permissive haplotype (FSHD1), or by mutations in 
the SMCHD1 gene on chromosome 18 or in the DNMT3B gene on chromosome 20 in 
combination with a 4qA allele (FSHD2). This genetic mechanism is illustrated in Box 2 and 
Figure 3. 
B O X  2 : 
Genetic characteristics of FSHD 
•  Two genetic forms of FSHD are known. The most common form, FSHD1, is caused 
by contraction of the D4Z4 repeat array (D4Z4 units) on chromosome 4q to a 
size of 1-10 units. Repeat size is commonly studied by Southern blot, in which 
fragments of ≤ 38kb are consistent with FSHD.
•  A high percentage of cases, perhaps 10%–30%, are caused by de novo mutations
•  A severe course is most often seen in early onset and associated with small D4Z4 
repeat arrays. 
•  A rough inverse correlation is suggested between the clinical severity and D4Z4 
repeat size.
17
 Figure 3: In controls the D4Z4 repeat arrays vary between 11 and 100 units and adopt a  
repressed chromatin structure (dark grey wavy lines) characterized by high CpG methylation 
(me = methylation). Each D4Z4 repeat contains a copy of the DUX4 gene, without a polyadenylation 
signal (PAS). This prevents the expression of DUX4.
FSHD1, the most common form of FSHD, is caused by contraction of the D4Z4 repeat array 
(triangels) on chromosome 4q to a size of 1-10 units. Only the presence of both a repeat 
contraction (1-10 D4Z4 units) and a PAS immediately distal to the D4Z4 repeat (only present  
on 4qA and not on 4qB chromosomes) allows chromatin relaxation (associated with reduced  
CpG methylation; light grey wavy lines), resulting in DUX4 transcription and stabilization of  
the DUX4 RNA. This enables the production of the DUX4 protein and might be responsible for  
the myotoxic effect.
Heterozygous mutations in the chromatin modifier structural maintenance of chromosome flexible 
hinge domain containing 1 (SMCHD1) gene have been identified as the most common cause of 
FSHD2. Recently, heterozygous mutations in the DNA methyltransferase 3B (DNMT3B) gene were 
identified in two FSHD2 families without SMCHD1 mutation. Mutations in both genes also result 
in chromatin relaxation (associated with reduced CpG methylation; light grey wavy lines), DUX4 
transcription and, in case of a 4qA allel stabilization of the DUX4 RNA. 
Furthermore, mutations in SMCHD1 and DNMT3B can also act as a modifier of disease severity in 
FSHD1.(Reprinted with permission of PUBLISHER [13]) 
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History of FSHD research and aims of this study
Landouzy and Déjerine first described the disease in 1885, and proved it to be a 
myopathy with a familial pattern in most cases. They emphasized the onset in facial and 
shoulder girdle muscles to distinguish facioscapulohumeral muscular dystrophy (FSHD) 
from Duchenne muscular dystrophy.[3]  Padberg described the clinical features of FSHD in 
detail by examining large pedigrees in the Netherlands. Disease severity was considered 
age-dependent, and penetrance was considered to be almost complete (>95%) by the 
age of 20.[3,14,15]  The genetic studies in these large families led to the identification 
of the locus for FSHD on the subtelomere of chromosome 4, the identification of the 
D4Z4 repeat and its deletion in the majority of cases. Genetic testing became available 
in the early nineties. Genetic testing elucidated the inheritance pattern in many families 
(> 95%), but at the same time raised new questions. Many family studies included 
asymptomatic gene carriers, and the correlation between disease severity and repeat 
length appeared less strong than previously thought, especially in the patients with 
the intermediate repeat length. This led to the hypothesis of mosaicism as possible 
explanation of non-penetrance in some cases and the suggestion of epigenetic 
factors that contribute to disease severity. Another phenomenon that came up was the 
difference between male and female carriers: males appeared to be affected earlier and 
more severely. This resulted in our plan in 2002 to repeat the Padberg study on large, 
unpublished pedigrees confirming and studying clinical aspects based on genetic testing 
and epigenetic screening (Chapter 10). While exploring families for phenotype-genotype 
studies we came across several clinical problems that were unexplored so far. This is 
illustrate in de cases below.
Case 1: Respiratory weakness in FSHD?
At first encounter, a 40-year-old FSHD patient shared his concern about his future 
respiratory function. His mother (in her sixties) was recently operated and was found 
respiratory insufficient since then, for which she required nocturnal non-invasive 
ventilation. Her pulmonologist had informed them that the muscular dystrophy was 
the cause of the respiratory problems. However, although acknowledged in several 
other neuromuscular disorders, respiratory weakness had not been reported in FSHD 
at that time, and we had not met FSHD patients with respiratory insufficiency before. 
Consequently we could not give our patient a reliable prognosis of his respiratory 
function.
Case 2: Genotype – phenotype correlation?
Two asymptomatic children of a FSHD patient, a brother and sister of 22 and 25 years 
respectively, were referred to our neuromuscular centre for counselling. Genetic testing 
confirmed a 9 unit D4Z4 allele in both children, which was expected to be associated with 
a mild disease course. However, their father and his older sister were severely affected 
with wheelchair dependency. While we were used to tell such gene carriers that there 
is a rough correlation between repeat size and severity, this family with a mild repeat 
contraction seemed to contradict the common knowledge at that time.  
19
We were not able to give adequate information about the expected course given the 
obvious family experience.
 
Case 3: Non-penetrance in adulthood?
One of the first patients that participated in our family study was a FSHD patient and 
his two asymptomatic daughters of 30 years and 32 years, far beyond the age of 20 
years that was considered to mark almost complete penetrance at that time. Their father 
became symptomatic in early adolescence and was diagnosed with FSHD at the age of 
37 years. After genetic counseling, the daughters expressed their wish to be informed 
about the results of the genetic analyses. To our surprise, both daughters turned out to be 
carriers of the FSHD gene. This raised the question of the prevalence of non-penetrance 
in adults above 30 years of age and the risk to have offspring with symptomatic FSHD.
Case 4: Unaffected if not symptomatic at the age of 30? 
Another example of variable penetrance of FSHD in adulthood is illustrated by the 
following case, referred to our FSDH expertise centre. This 58-year old women presented 
with chronic lower back pain and difficulties raising her arms above her shoulders, walking 
or standing still. Her 63-year old brother with FSHD was diagnosed in his early 30s and 
was told at that time (in the premolecular era) that his sibs would be unaffected if not 
symptomatic at the age of 30. Therefore, she never contributed her symptom to FSHD and 
had a long patient and doctor delay. Physical examination revealed many signs of FSHD, 
with a clinical severity score of 7/10. After the genetic diagnosis was confirmed, she was 
referred to the rehabilitation specialist which proved to be very helpful. 
Aims
These clinical cases were the reason to start the research described in this thesis, which 
resulted in several important lessons we have learned at both the mild and the severe end 
of the disease spectrum. The overall aim of this thesis was to assess phenotype-genotype 
correlations with help of familial FSHD and severely affected cases. The family-based 
study was designed for penetrance estimations for different repeat sizes, including repeat 
sizes of 8-10 units. Ultimately, we aimed to increase understanding of the striking inter- 
and intra-individual variation in FSHD. Several observations during our examination of 
the families called for further research.
As illustrated by Case 1, concern about the need for ventilatory support in severely 
affected patients was raised by FSHD patients and the need for study was emphasized by 
the patient organization. We therefore started early on a separate project to investigate 
ventilatory insufficiency in FSHD and this resulted in the studies described in Chapter 
2,3 and 4. Furthermore, other clinical and genetic questions raised along the way 
resulted in the studies on dysphagia (Chapter 5), compound heterozygosity for the 
D4Z4 allele (Chapter 7), heterozygosity for the 4qA/4qB polymorphism (Chapter 8) and 
hypomethylation (Chapter 9). The last study in large families with FSHD enabled the P
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estimation of prevalences of penetrance of symptomatic and asymptomatic FSHD.  
These studies illustrate that the detailed clinical studies in specific families and patients 
also enabled more basic studies on genetic aspects of FSHD.
Outline of the thesis 
Following this introduction (Chapter 1, Part I), the second part (Part II) of the thesis 
describes some long neglected symptoms in moderately to severely affected patients 
with FSHD. As illustrated by Case 1, information on respiratory function in FSHD was 
not available at the onset of this study. We therefore conducted an assessment of 
the characteristics of ten FSHD patients with need for (nocturnal) ventilatory support 
(Chapter 2 and 3), who were identified by the Dutch Centers for Home Mechanical 
Ventilation. Assessment of respiratory function with use of spirometry is often 
complicated in FSHD because of air leakage during blowing due to facial weakness.  
We therefore had to develop spirometry equipment adjusted with a facial mask.  
We first conducted a study to compare the face mask and the conventional mouthpiece 
for the measurement of spirometry and of respiratory pressures in 22 healthy subjects. 
We subsequently obtained normal values in 252 healthy volunteers and derived 
prediction equations for face mask spirometry and maximal respiratory pressure (Chapter 
2). In order to test the hypothesis that wheelchair dependency and (kypho-)scoliosis are 
risk factors for developing respiratory insufficiency in FSHD, we subsequently examined 
81 patients with varying degrees of severity ranging from ambulatory patients to 
wheelchair-dependent patients (Chapter 4). Wheelchair-dependent patients in this study 
reported dysphagia more often than ambulant patients. However, at that time physicians 
treating patients with FSHD were not focused on symptoms of dysphagia because 
involvement of the lingual and pharyngeal muscles was considered an exclusion criterion 
for FSHD. In the study in Chapter 5, we aimed to assess dysphagia by speech therapy 
assessment, videofluoroscopy, and MRI of the tongue in patients with FSHD who reported 
swallowing problems.
As demonstrated by Case 2, predicting disease severity based on the genotype is difficult. 
Part III focuses on genetic and epigenetic factors contributing to disease severity of 
FSHD. Chapter 6 reports two families with compound heterozygous mutations in FSHD. 
At the time of study, homozygosity or compound heterozygosity for FSHD alleles had 
not been reported, and it was debated whether this was because of rarity or the lethality 
of the disorder. In Chapter 7 we studied the two allelic variants of chromosome 4q 
(4qA and 4qB) existing in the region distal to D4Z4. Although both variants are almost 
equally frequent in the population, FSHD appeared to be associated exclusively with the 
4qA allele. We identified three families with FSHD in which each proband carried two 
FSHD-sized alleles and was heterozygous for the 4qA/4qB polymorphism. This enabled 
segregation analysis of the 4qA and 4qB allel in these families, showing that the 4qB 
allele is not pathogenic and that FSHD develops only with 4qA alleles.
21
The next important step in understanding the pathogenesis of FSHD was the study of 
methylation of the DZ4Z repeat. Patients with FSHD show a contraction of the D4Z4 
repeat array in the subtelomere of chromosome 4qA in association with significant 
allele-specific hypomethylation of the repeat. In Chapter 8 we aimed to understand 
this mechanism of hypomethylation by investigating the differences and similarities in 
phenotypic FSHD and immunodeficiency, centromeric instability, and facial anomalies 
(ICF) syndrome, an unrelated disease that is also characterized by hypomethylation of 
D4Z4 but does not present with muscular dystrophy. Together, these studies offered 
important building blocks for an unifying genetic model of FSHD.[12]
Case 3 and 4 illustrate the difficulties of the transition from the premolecular era to the 
time of availability of genetic testing. In the pre-molecular era, estimation of penetrance 
of FSHD was based on clinical diagnostic criteria and examination of large pedigrees. 
It was considered age-dependent with almost complete (>95%) penetrance by the age 
of 20.[3,14,15]  More recent studies based on genotyping have shown penetrance to 
be incomplete even at older age, and reported controversial figures of 32%-53% non-
penetrance dependent on repeat size.[16-20]. As these observations were incompatible 
with earlier findings of approximately 50% affected and 50% non-affected sibs in 
extensively examined sibships, we set out a cross-sectional, observational single 
center study in 10 families with at least two affected family members, encompassing 10 
probands and 140 first and second degree relatives. (Part IV: Chapter 9). This enabled the 
calculation of the penetrance for symptomatic and asymptomatic FSHD1.
This thesis concludes with a general Discussion (Part V, Chapter 10) and provides an 
overview of the findings and conclusions described in this thesis and directions for future 
research.
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Abstract
Spirometry and maximal respiratory pressures are pulmonary function parameters 
commonly used to evaluate respiratory function. Prediction values are available for 
conventional lung function devices using a standard tube or flanged type of mouthpiece 
connection. This equipment is not suitable for patients with facial or buccal muscle 
weakness, because of air leakage around the mouthpiece. A face mask was used for the 
portable lung function devices used in the neuromuscular department. 
The aim of this study was to compare the face mask and the conventional mouthpiece for 
the measurement of spirometry and of respiratory pressures in 22 healthy subjects. 
Values obtained with the conventional mouthpiece differed significantly from values 
obtained with the face mask. With the mask, forced vital capacity and forced expiratory 
volume in one second were 200 mL lower, and maximal expiratory pressure was 3.2 kPa 
lower than with the mouthpiece. Subsequently, new prediction values for face mask 
spirometry and maximal respiratory pressures were obtained from 252 other healthy 
subjects, from which new prediction equations were derived. 
It was concluded that the face mask connection to the lung function device is a valid 
alternative, is easy to use and is most useful to monitor changes in patients. This study 
confirms the importance of appropriate prediction equations, depending on subject-
instrument interfaces.
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Introduction
Measurement of vital capacity (VC) and maximal respiratory pressures is commonly 
used to evaluate respiratory function and respiratory muscle strength in patients with 
chronic obstructive pulmonary disease or neuromuscular diseases [1–3]. Portable 
devices are useful for rapid and simple assessment of respiratory function in the 
office and at the bedside. Prediction values of spirometry and maximal respiratory 
pressures are available for portable and non-portable devices with a standard tube 
or a flanged type of mouthpiece connection [4–8]. This equipment is only suitable 
for subjects capable of making a good seal with their lips around the mouthpiece. 
However, patients with neuromuscular diseases characterised by facial or bulbar muscle 
weakness, e.g. amyotrophic lateral sclerosis, myasthenia gravis, myotonic dystrophy and 
facioscapulohumeral muscular dystrophy, often cannot effectively seal the lips around 
the mouthpiece, especially during forced manoeuvres such as spirometric and maximal 
respiratory pressure measurements [9, 10]. In these cases, the conventional equipment 
with a tube or flanged type of mouthpiece is not adequate to evaluate respiratory muscle 
function. Therefore, a face mask adjusted to a portable spirometer and manometer was 
used to minimise air leakage in neuromuscular patients. 
The objective of this study was two-fold. First, possible differences in measurements 
between the original devices with the conventional mouthpiece and the face mask-
adjusted devices were studied in healthy subjects. Secondly, a study to render new 
prediction equations for face mask spirometry and maximal respiratory pressures in 
healthy subjects was conducted.
Methods
Subjects
Healthy volunteers (n=22) were studied using the face mask and the conventional 
mouthpiece, in a randomised order, for comparison of the connection to the instruments 
for measurements of spirometry and maximal respiratory pressure. Using the face 
mask, 20 healthy volunteers performed spirometry and maximal respiratory pressure 
measurements at day 1 and day 4, to study the within-subject variance. 
In 15 subjects, the spirometric and the maximal respiratory pressure measurements of 
two different sizes of masks with different volumes were compared (Leardal mask number 
4 and Leardal mask number 5, with volumes of 210 and 150 mL, respectively; Leardal, 
London, UK). 
Subsequently, 252 additional healthy subjects were recruited to render new prediction 
equations for the face mask spirometry and face mask maximal respiratory pressures. 
Nearly all subjects (99%) were partners accompanying neurological patients visiting 
the outpatient clinic and all gave their informed consent. Subjects were recruited P
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consecutively, until 20 males and 20 females in each decade from 18–80 yrs 
were included. Exclusion criteria comprised ages of <18 yrs, cardiopulmonary and 
neuromuscular disease, any chronic disease and use of medication except for sporadic 
analgesic use and use of oral contraceptives. Data on sex, age, height, weight, smoking 
status and the lung function parameters were recorded.
Spirometry
Forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and the 
FEV1/FVC ratio were measured with a Morgan Spirometer (type PM2000; P.K. Morgan 
Ltd, Rainham, UK). Calibration checks were performed daily with a 3-L syringe. Sitting 
subjects were connected to the spirometer via the conventional mouthpiece, which is a 
cardboard tube, or via a rigid noncompressable face mask (a Leardal adult mask number 
5). All subjects were unfamiliar with the techniques and all subjects received the same 
instructions. The spirometer with the face mask was held and pressed tightly against the 
subject’s face by the investigator, while the conventional device using the cardboard tube 
was held by the subject. At least three efforts were performed until two readings within a 
5% range were obtained. An interval of 1 min was taken between two efforts. The highest 
combination of FVC and FEV1 of one effort was recorded. The manoeuvre was rejected if 
the investigator noticed any air leakage around the mask.
Maximal respiratory pressures
Maximal inspiratory mouth pressure (MIP) at residual volume and maximal expiratory 
mouth pressure (MEP) at total lung capacity were obtained in sitting subjects connected 
to a Morgan manometer (type Pmax) containing a small leak (internal diameter 2 mm, 2 cm 
length) preventing buccal muscles from producing significant pressures and preventing 
closing of the glottis. The conventional flanged mouthpiece was tested versus the face 
mask. This measuring system was calibrated monthly with a water manometer. The system 
never had to be corrected during the study. The accuracy of the device is to 4 cmH2O. All 
subjects received the same instructions. Pressures were measured with a noseclip when 
using the mouthpiece. Pressures had to be maintained for 1 s and the plateau level was 
recorded. The highest pressure of at least three efforts with a maximum of 5% variability 
was documented. If close observation and listening indicated any air leakage around 
the mask, or if maximal pressure was not maintained for at least 1 s, the manoeuvre was 
rejected. All experiments were conducted by one experienced investigator.
Statistical methods
One way analysis of variance was used to estimate the within-subject SD, and the 
corresponding coefficient of variation (CV), of the repeated values measured at day 1 
and day 4. The dependent variables were FVC, FEV1, MIP and MEP, and the independent 
random variable was the subject. The statistical method for assessing the agreement 
between the face mask measurements and the conventional mouthpiece measurements 
was performed according to BLAND and ALTMAN [11], using each spirometric and 
respiratory measurement separately. Multiple regression analysis was performed to 
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derive prediction equations for each spirometric or respiratory measurement separately. 
The dependent variable was the spirometric or respiratory measurement, and the 
independent variables in each regression model were sex, age, height and weight. The 
prediction equations obtained were compared with the literature and for the ease of 
interpretation, those from the literature that were presented by sex were combined into 
one equation.
Results
In the first part of the study 22 subjects (nine males and 13 females; mean age 33.4±9.4 
yrs, height 176±8.5 cm and weight 75±5 kg) performed two sets of measurements, one 
using the conventional mouthpiece and one using the face mask connection to the 
devices. Table 1 shows the results of the comparison of the two different mouthpiece 
connections for spirometric and maximal respiratory pressures. Values obtained with 
the conventional mouthpiece were significantly higher than values obtained with 
the face mask (paired t-test, p<0.001), except for the MIP (paired t-test, p=0.26). The 
(differences in) means are not solely used to compare methods. Also the variances are of 
interest. Therefore, the ratio of SD using the face mask to the SD using the mouthpiece 
was calculated. The between-subject variance of all spirometry and all respiratory 
measurements with the mouthpiece were greater compared with those obtained with 
the face mask. The between-subject variance of the FVC, FEV1, FEV1/FVC and MIP was 
20–82% higher using the conventional mouthpiece, while for the MEP the variance using 
the mouthpiece was 3.28-times higher then using the face mask device (table 1). 
Bland and Altman plots of the differences and their means between mouthpiece and mask 
showed a lack of agreement. The plots showed that the difference increases as the FVC, 
FEV1 and MEP increase, while this is less for MIP. Figure 1 shows the plots of FEV1 and 
MIP. Subjects with the largest differences between mouthpiece and mask were those who 
produced the highest values measured with the mouthpiece connection.
For the follow-up of neuromuscular patients, the within subject variation is needed. 
Using the face mask, the within-subject CV of FVC, FEV1, MEP and MIP, estimated from 
repeated measurements at day 1 and day 4 in a group of 20 healthy subjects, was 
1.4%, 2.1%, 6.4% and 5.4%, respectively. From these results, it was concluded that the 
pressure measurements obtained using the conventional mouthpiece and the face mask 
connection cannot be used interchangeably. 
Additional measurements with two different masks with different volumes showed no 
statistically significant differences for mean differences in FVC (0.01 L, p=0.73), FEV1 
(0.06 L, p=0.19), MIP (0.04 kPa, p=0.76) and MEP (0.19 kPa, p=0.26). 
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Subsequently, new reference values for spirometry and manometry variables using the 
face mask-adjusted devices were derived from 252 subjects, 126 males and 126 females. 
Table 2 shows the mean±SD height and weight by age group and by sex. There were 64 
smokers or former smokers, 34 males and 30 females. Smoking did not have a significant 
contribution to the prediction equations, therefore smokers and former smokers were 
included in the analyses. 
Table 3 presents the spirometric and maximal respiratory pressure values by age group 
and by sex. The influence of age and sex is strong on the mean values of FVC, FEV1, 
MIP and MEP. Decreasing mean values of FVC, FEV1, MIP and MEP were observed with 
increasing age, and females systematically showed lower values in all variables, implying 
a strong sex effect. Tables 4 and 5 show the regression equations of multiple regression 
analyses of all variables. All variables were influenced by age and sex, except for the 
FEV1/FVC ratio with only age as a predictor. The prediction equations for the FVC and 
FEV1 also had height as an explanatory variable. The maximal respiratory pressures were 
influenced by weight, age and sex (table 5). 
Although prediction equations of both FVC and FEV1 were in line with those reported in 
the literature, considering the SE of the regression coefficients (table 4), the predicted 
values of an average male and an average female were consistently higher using the 
face mask (table 6) as with the ratio of FEV1/FVC. A direct comparison of the prediction 
equation for MEP values as well for the MIP values was not possible because of the 
different explaining variables (height and weight) in the equations. However, the 
predicted values using the face mask and those presented in the literature were similar 
considering the residual SD. Table 6 shows the predicted values of an average adult male 
and an average adult female.
Table 1  Spirometry and maximal respiratory pressures comparison of the conventional mouthpiece 
and face mask connection in 22 subjects
    
Function	 Tube	 Mask	 ΔTube-mask#	 Variance	 Correlation		
parameter	 	 	 	 tube/mask¶	 mean/Δtube-mask
FVC L 5.8±1.4 5.6±1.2 0.2±0.2 ** 1.20 0.52 *
FEV1 L 5.3±1.2 5.1±1.1 0.2±0.2 ** 1.21 0.61 *
FEV1/FVC 0.91±0.04 0.91±0.037 0.001±0.02 1.82 0.13
MEP kPa 13.7±4.3 11.4±2.4 2.2±2.5 ** 3.28 0.78 *
MIP kPa 9.2±2.5 8.9±2.2 0.3±1.2 1.31 0.28
Data are presented as mean±SD unless otherwise stated. FVC: forced vital capacity; FEV1: forced expiratory 
volume in one second; MEP: maximal expiratory pressure; MIP: maximal inspiratory pressure; tube: conventional 
spirometer or manometer; mask: face mask-adjusted spirometer and manometer. #: difference in mean between 
tube and mask; ¶: ratio of the tube variance to the mask variance. *: p<0.05 using Pearson rank correlation test; 
**: p<0.01 using t-test.
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Figure 1:  Bland and Altman plots of the difference against the average of the conventional 
mouthpiece and the face mask for a) the forced expiratory volume in one second (FEV1) 
and b) the maximal inspiratory mouth pressure (MIP). The solid line indicates no difference 
and the dotted lines represent the mean±1.96 SD.
Discussion
This study demonstrated that face mask adjustment is a valid and easy method to 
measure respiratory function and respiratory muscle strength in healthy persons. 
Comparison of the conventional mouthpiece with the face mask connection to the 
instruments showed that they cannot be used interchangeably. New prediction equations 
for face mask adjusted pulmonary portable devices were derived from 252 healthy 
subjects. P
ar
t 
II
   
- 
  C
h
ap
te
r 
2 
Fa
ce
 m
as
k 
sp
ir
o
m
et
ry
 a
n
d
 r
es
p
ir
at
o
ry
 p
re
ss
u
re
s 
in
 n
o
rm
al
 s
u
b
je
ct
s
36
Table 2 Height and weight by age group and by sex
Age yrs Subjects n Sex Height cm Weight kg Smokers %
18-29 20 M 182.6±6 79.7±11 25
 23 F 169.6±8 67.1±8 17
30-39 20 M 183.9±8 85.2±15 25
 20 F 169.7±9 67.3±10 15
40-49 25 M 180.2±8 85.9±13 20
 21 F 167.9±7 71.9±12 38
50-59 20 M 179.7±6 83.2±11 40
 22 F 167.5±6 68.4±11 36
60-69 21 M 176.6±6 78.5±10 28
 20 F 164.4±7 66.1±8 25
≥70 20 M 175.3±7 74.7±7 25
 20 F 164.0±6 67.0±7 20
Data are presented as mean±SD unless otherwise stated. Smokers: smokers and former smokers; M: male; F: 
female. Of the total number of smokers, 39% stopped smoking ≥0.5 yrs ago.
Table 3 Spirometry and maximal respiratory pressures by sex and by age group
Age yrs Sex FVC (L) FEV1 (L) FEV1/FVC (%) MIP kPa MEP kPa
18-29 M 6.4±0.5 5.9±0.4 93±4 11.3±1.8 14.6±2.4
 F 4.6±0.7 4.1±0.7 90±4 8.8±1.4 10.7±2.1
30-39 M 6.2±0.8 5.5±0.9 89±5 11.0±3.0 14.7±3.9
 F 4.5±0.9 4.0± 0.8 90±4 8.0±1.7 10.8±2.1
40-49 M 5.7±1.1 5.0±0.9 89±4 10.1±1.8 14.0±2.4
 F 4.3±1.0 3.7±0.8 86±6 7.2±1.3 10.2±2.2
50-59 M 5.1±0.8 4.4±0.7 87±4 9.5±2.0 12.5±3.0
 F 4.0±0.6 3.5±0.6 88±4 7.5±1.2 9.4±1.6
60-69 M 4.6±0.7 3.9±0.6 85±4 7.9±1.3 11.1±2.1
 F 3.1±0.5 2.7±0.4 86±6 6.8±0.9 8.8±1.3
≥70 M 3.8±0.7 3.2±0.7 85±5 7.5±1.2 9.5±1.6
 F 2.6±0.4 2.2±0.3 83±6 6.3±0.6 7.7±0.8
Data are presented as mean±SD unless otherwise stated. FVC: forced vital capacity; FEV1: forced expiratory 
volume in one second; MIP: maximal inspiratory pressure; MEP: maximal expiratory pressure; M: male; F: female.
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Table 4 Prediction equations for face mask spirometry for adults aged 18-80 yrs
 
  RSD R2
FVC= -3.92 − (0.039xA) + (0.058xH) + (0.76xS) (1) 0.63 78%
         (1.147)      (0.003)        (0.006)        (0.116)   
FVCq= -2.89 – (0.026xA) + (0.044xH) − (1.45xS) + (0.013xHxS) (2) 0.61#/0.43¶ NA
FEV1= -2.84 − (0.035xA) + (0.047xH) + (1.29xS) – (0.011xSxA) (3) 0.55 81%
           (1.01)       (0.003)         (0.006)        (0.25)            (0.004)   
FEV1q= -2.60 − (0.025xA) + (0.040xH) + (0.11xS) + (0.003xHxS) - (0.004xSxA) (4) 0.51#/0.38¶ NA
FEV1/FVC= 94.70 – (0.14xA) (5) 4.65 23%
                    (1.02)       (0.02)   
FEV1/FVCq= 89.10 − (0.19xA) − (1.89xS) + (0.01xSxA) (6) 7.17#/6.51¶ NA
   
RSD: residual standard deviation; R2: the percentage explained variance; FVC: forced vital capacity (L); A: age 
(yrs); H: standing height (cm); S: sex; q: prediction equations according to [6] presented by sex (S) are combined 
to one equation (this can easily be checked using S=1 for obtaining the separate equation for males and S=0 for 
females); FEV1: forced expiratory volume in one second (L); NA: not available (see [6]). #: males; ¶: females. Data 
in the brackets underneath equations 1, 3 and 5 are SE values of the regression coefficients.
Table 5 Prediction equations of maximal respiratory pressures for adults aged 18-80 yrs
 
  RSD R2
MEP= 9.887 − (0.055xA) + (0.035xW) + (5.224xS) − (0.049xSxA) (6) 2.23 50%
         (1.083)      (0.011)          (0.013)        (0.897)             (0.017)   
MEPw= 0.35 + (17.65xS) − (0.091xAxS) + (0.055xH) − (0.055xHxS) (7) NA NA
MIP= 7.224 − (0.040xA) + (0.032xW) + (3.745xS) − (0.041xSxA) (8) 1.58 51%
         (0.766)       (0.008)          (0.009)         (0.635)               (0.012)   
MIPw= −4.3 + (18.5xS) − (0.103xAxS) + (0.071xH) − (0.071xHxS) (9) NA NA
RSD: residual standard deviation; R2: the percentage explained variance; MEP: maximal expiratory pressure (kPa); 
A: age (yrs); W: weight (kg); S: sex; w: prediction equations according to [8] presented by sex (S) are combined 
to one equation (this can easily be checked using S=1 for obtaining the separate equation for males and S=0 for 
females); MIP: maximal inspiratory pressure (kPa); NA: not available (see [8]). Data in the brackets underneath 
equations 7 and 9 are SE values of the regression coefficients.
Although, the results of the spirometric measurements with the tube mouthpiece  
are statistically significantly higher than with the face mask connection, a difference  
in VC of 100–200 mL may not be of clinical importance for a single measurement. 
However, in the lower ranges a difference of 200 mL may be worth noticing, especially in 
follow-up measurements within neuromuscular patients for early detection of respiratory 
failure. From the literature, it is known that the average within-subject SD of repeated 
measurements of the VC is 90–200 mL [6]. An acceptable low CV for the FVC of 1.4% was 
found, showing that the face mask measurements have an excellent reproducibility. The 
differences in FVC and FEV1 between tube and mask are very similar, suggesting that 
the main differences occur in the beginning of the forced manoeuvres. To investigate P
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the possibility of the influence of the volume of the mask being used, additional 
measurements were performed to test two different masks with different volumes. The 
results showed no significant differences between the two masks for FVC and FEV1 and 
they can be used interchangeably. 
The  only difference in measurement conditions was that in the mouthpiece situation 
the subjects themselves held the instruments, whereas in the face mask situation, the 
instrument was held by the observer. It is possible that the subjects did not make full 
maximal efforts in the latter situation. 
The maximal respiratory pressures obtained with the flanged mouthpiece were higher 
than the ones obtained with the face mask. Activation of buccal muscles may explain the 
differences, in spite of the small leak in the pressure transducer. The between-subject 
variance using the flanged type of mouthpiece was much higher compared with the 
face mask variance. For the face mask experiments, it was decided that the investigator 
should hold the instrument. The investigator had to press the mask tightly against the 
subjects face to prevent air leakage. The impression was that, especially during the forced 
manoeuvres i.e. during the FVC and MEP measurements, a few subjects appeared to hold 
back. This could have influenced the predicted values for these manoeuvres negatively, 
especially for the higher values. Another probable explanation can be the relative 
fixation of the head when placing the mask against the subject’s face by the investigator, 
whereas in the mouthpiece measurements the instruments were held by the subjects. 
The slight head movement of the subjects in the mouthpiece group may have influenced 
the measurements and resulted in higher values. Both the buccal muscles activation, 
the hold-back hypothesis and head fixation may explain the differences in values and in 
variance particularly in the higher ranges.
Table 6  Predicted spirometric values and maximal respiratory pressures calculated by the present 
study and references [6] and [8], respectively, for an average adult male (M) and an average 
adult female (F) 
 Sex Face mask Ref.[8] Ref.[6]
MEP kPa M 13.4 14.4 -
 F 10.1 9.7 -
MIP kPa M 10.0 10.1 -
 F 7.9 7.8 -
FVC L M 5.14 - 4.31
 F 4.38 - 3.55
FEV1 L M 4.58 - 3.66
 F 3.75 - 3.20
FEV1/FVC M 89.1 - 80.0
 F 89.1 - 81.5
 
MEP: maximal expiratory pressure; MIP: maximal inspiratory pressure; FVC: forced vital capacity; FEV1: forced 
expiratory volume in one second. The average values for both M and F subjects were 40 yrs of age, height 170 cm 
and weight 70 kg.
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There were no significant differences between mask number 4 and number 5 for the MIP 
and MEP measurements. For the pressure measurements, it is suggested that the size 
and type of mask is not crucial. In the second part of the study, new reference values 
were obtained in healthy adults, and new prediction equations derived by multivariate 
regression analysis. For the spirometry, the same explanatory variables in the equations 
as those in the prediction equations of QUANJER et al.[6] are of importance. The results 
of both conventional spirometry and face mask spirometry were higher compared with 
the predicted reference values of QUANJER et al.[6]. In males, the values of FVC varied 
from 20% higher at the age of 20 yrs to 8% higher at the age of 70 yrs compared 
with the predicted values of QUANJER et al.[6]. The same pattern is seen in females at 
different levels of FVC. Similar trends of decreasing differences with increasing age were 
noticed in the comparison of the predicted values for FEV1 and for the ratio FEV1/FVC. 
The predicted equations of QUANJER et al.[6] are commonly used in Europe and several 
studies have indicated that these equations significantly underestimate predicted FEV1 
and FVC [12–15]. The present results confirm this indication. Possible causes, such as 
population/selection criteria, cohort effect and technical factors, remain uncertain. 
Both smokers and former smokers were included in the present study, because there 
was no significant effect nor was there an age-related effect of smoking on prediction 
values. This is surprising, because several studies did show a negative effect of smoking 
on predicted values [15] especially on predicted FEV1 and to a lesser extent on FVC. In 
this study, however, 39% of the smokers were former smokers and stopped smoking ≥6 
months ago, which may explain the absence of a smoking effect.
 
Comparison of the face mask prediction equations of the maximal respiratory pressures 
with the predicted equations of WILSON et al.[8] is more difficult, because of the 
different explanatory variables. The difference in the final prediction equations cannot 
be explained by the statistical method being used, because the same variables i.e. age, 
height and weight, were included in the stepwise regression analyses. In this study, 
weight and age are significant in predicting maximal respiratory pressures (table 5). 
The usefulness of maximal respiratory pressures is often debated because of the 
remarkably large interstudy variability in reference values in the literature [4, 7, 8, 16–19]. 
KOULOURIS et al.[20] and TULLY et al.[21] reported that maximal respiratory pressures 
depend much on the type of mouthpiece being used. The tube mouthpiece used by 
RINGQVIST [19], by BLACK and HYATT [4] and by ROCHESTER and ARORA [22] showed 
higher values than the flanged mouthpiece used by WILSON et al.[8], by LEECH et al.[17] 
and by VINCKEN et al.[7]. COOK et al.[16] suggested that higher expiratory pressures 
would be obtained using a tube-type mouthpiece, because it prevented air leakage 
around the mouthpiece, whereas KOULOURIS et al.[20] claimed that the manner in which 
the mouthpiece is used is important. The present data matched that of KOULOURIS 
et al.[20] because audible air leakage was an exclusion criteria in this study. In a few 
subjects, the presence of a moustache or beard precluded a proper sealing of the mask 
against the face. In these cases unnoticed leakage could not be excluded and therefore 
these subjects were withdrawn from this study. P
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Next  to the type of mouthpiece connection, measurement of maximal respiratory 
pressures depends strongly on the skill of the investigator, population features and 
sample size. Moreover, interindividual factors as degrees of cooperation and coordination 
of the different respiratory muscles seem to be of great importance. In this study, the face 
mask devices were held by the investigator instead of the subjects, because patients with 
neuromuscular disease often have weakness of the arm muscles. This lack of control of 
the subject, being connected to the apparatus may preclude a real maximal effort. The 
same investigator performed all measurements to avoid possible interinvestigator bias. 
Both smokers and nonsmokers were included in this study. In line with the literature on 
reference values [4, 5, 7, 8], smoking status was not significant in predicted values of MIP 
and MEP. 
A marked between-subject variability is seen throughout the literature (25–40%) and 
was noticed in this study as well. To date, the best explanation is that it may reflect the 
different (use of) musculature of individuals [5] and the uncontrollable aspect of the 
voluntary effort by the subject. When taking the population and the technique into 
account, the present face mask data matched best with those of WILSON et al.[8], who 
had a similar population and methodology. The results show that measurements obtained 
using the face mask manometer are closely related to those obtained by the flanged 
mouthpiece as in the VINCKEN et al.[7] and WILSON et al.[8] studies. Although MEP values 
obtained with a face mask device are lower, this will not be of clinical importance if the 
appropriate reference ranges are used. Moreover, the most important information in 
individual patients is obtained by monitoring intraindividual changes in MIP and MEP over 
time. In this study the within-subject variability is much smaller compared with the CVs 
for MEP of 7.1% and for MIP of 10.2 % in the study by WILSON et al.[8]. 
FIZ et al.[23] suggested the technique of manually holding the lips around the mouthpiece 
in patients with facial weakness to prevent air leakage. Some prefer the sniff nasal 
inspiratory pressure in assessing inspiratory muscle force in patients. CHAUDRI et 
al.[24] used a tight-fitting face mask to measure VC, and both MIP and MEP in some of 
the patients with difficulty in inserting or holding the mouthpiece, but refrained from 
commenting on the reference values. 
The present study showed that using a face mask is an adequate method for ventilatory 
assessment in healthy adult persons at an outpatient clinic. The use of a face mask is 
recommended in patients with neuromuscular disease or more specifically in patients 
with facial weakness for screening purposes. It is a simple and effective alternative 
method, which can be most useful in monitoring changes in patients. Furthermore, it can 
be used for studies on natural course and respiratory function in neuromuscular disease. 
Finally, this study confirms the importance of using appropriate prediction values.
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Abstract
Respiratory insufficiency due to respiratory muscle weakness is a common 
complication of many neuromuscular diseases. The prevalence of respiratory failure in 
facioscapulohumeral muscular dystrophy (FSHD) is unknown. The authors identified 10 
FSHD patients on nocturnal ventilatory support at home, representing approximately 
1% of the Dutch FSHD population. Severe muscle disease, wheelchair dependency, and 
kyphoscoliosis appeared to be risk factors for respiratory failure.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant muscle 
disorder and is associated with contraction of the D4Z4 repeat array on chromosome 
4q35 in 95% of cases. FSHD has a variable age at onset and a variable rate of progression. 
Initially, the facial and shoulder girdle muscles are affected; during disease progression, 
pelvic and lower limb muscles get involved. Approximately 10 to 20% of the patients 
become wheelchair dependent, but an equal percentage remains asymptomatic.[1] 
Although the life expectancy in FSHD is said to be normal, this is based largely on family 
studies involving patients with small to moderate D4Z4 contractions.[2] 
Ventilatory insufficiency often in association with aspiration and infection is a 
common complication or cause of death in several neuromuscular disorders.[3,4]  Early 
manifestation of respiratory insufficiency is nocturnal hypoventilation with hypercapnia 
during REM sleep.[4]  Symptoms of nocturnal hypoventilation are easily overlooked 
and include disturbed sleep, morning headaches, daytime fatigue, and somnolence.[4] 
Early recognition of chronic hypoventilation is clinically important, because noninvasive 
assisted ventilation diminishes the associated high morbidity and mortality and can 
improve quality of life.
Causes of death have not been studied in detail in FSHD, and respiratory insufficiency has 
been described in only a few severely affected patients.[3,5,6]  The prevalence of FSHD 
in the Netherlands is estimated to be 1:20,000, [1]  and all neuromuscular patients using 
domiciliary ventilation are registered. A nationwide study was conducted to investigate 
the prevalence of, and risk factors for, respiratory insufficiency in FSHD.
Patients and methods  
Patient selection
The four Dutch Centers for Home Mechanical Ventilation (domestic ventilator support) 
collaborated to identify the registered FSHD patients on ventilator support. Potentially 
eligible patients were contacted by their own center and asked to participate. Only 
patients with a clinical and genetically supported diagnosis of FSHD were included.[1]  
The local ethics committee approved the study, and informed consent was obtained from 
all patients.
Methods
All patients were examined at home between May 1999 and February 2000; therefore, 
only simple spirometric and respiratory pressure measurements were used. Patient 
history was reviewed, with particular emphasis on neuromuscular, cardiac, and respiratory 
history, including age at onset of FSHD, age at wheelchair dependency, symptoms 
of respiratory insufficiency, and previous data on blood gas analysis and spirometry. 
Hypoventilation was defined when the arterial carbon dioxide tension (PaCO2) was P
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>45 mm Hg. Mechanical ventilation was started when the patient had nocturnal 
hypoventilation and the arterial PaCO2 was >50 to 55 mm Hg. Physical examination 
included manual muscle testing of 36 pairs of muscles and chest examination (percussion 
and auscultation of the lungs). Thoracic deformities including spinal deformity 
(kyphoscoliosis, lumbar lordosis, and pectus excavatum) were scored as present (mild, 
moderate, or severe) or absent. Maximal inspiratory (MIP) and expiratory (MEP) mouth 
pressures were measured using a Morgan pressure manometer (type Pmax; Haverhill, 
MA) with a standard facemask to avoid air leakage.[7,8]  Forced vital capacity (FVC) and 
forced expiratory volume in 1 second (FEV1) were measured with a facemask-adjusted 
Morgan spirometer (type PM2000).[7,8]  Spirometric and maximal respiratory pressure 
measurements were compared with reference values for normal subjects using facemask-
adjusted devices.[8]  FEV1/FVC ratio was calculated to differentiate between restrictive 
and obstructive pulmonary disease. An FEV1/FVC ratio of <70% of the predicted value is 
indicative of chronic obstructive disease. The likelihood of restrictive pulmonary disease 
increases with the FVC <80% of the predicted value and the FEV1/FVC ratio is normal or 
increased.
Results
Eleven potentially eligible patients were identified, of whom 10 fulfilled both clinical 
and genetic criteria for FSHD.[1]  One patient with a non-4q35-related scapuloperoneal 
syndrome was excluded. All relevant clinical data are summarized in the table. Disease 
onset varied from <5 to 23 years of age, duration of wheelchair dependency varied 
from 5 to 62 years, and time from disease onset to ventilatory support varied from 
22 to 59 years. In three patients, respiratory insufficiency, became manifest after an 
acute respiratory infection. Patient 1 presented with acute respiratory insufficiency a 
few days after giving birth to her first child and has needed nocturnal support since 
then. Patient 9 presented with pneumonia and developed bullous emphysema under 
ventilatory support; he was the only ex-smoker among the patients and underwent a 
right lower lobectomy 1 year later. None of the other patients or their relatives had a 
history of pulmonary disease. Eight patients had four or more symptoms of nocturnal 
hypoventilation (see the table).[4]  These symptoms rapidly resolved with ventilatory 
support, and one patient could even resume her part-time job as a secretary. One female 
patient, who had required nocturnal ventilatory support for almost 14 years, became 
dependent on 24-hour support. All but one patient had severe muscle weakness (global 
Medical Research Council [MRC] grade 1 to 3). Only patient 8 had relatively mild muscle 
weakness (global MRC grade 4) and showed relatively higher respiratory mouth pressures. 
She was on nocturnal support because polysomnography revealed obstructive and 
central apneas. All patients had moderate to severe (kypho-) scoliosis and severe lumbar 
lordosis. Three patients had a pectus excavatum. The FEV1/FVC ratio in all patients was ≥ 
87%, confirming that no additional obstructive lung disease was present (see the table). 
Patients 4, 5, and 7 are siblings from an asymptomatic mother with somatic mosaicism. 
Patient 10  was compound heterozygous for FSHD-sized 4q35 alleles (17 and 24 kb).[9] 
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Discussion
Respiratory insufficiency requiring ventilatory support is rare in FSHD, affecting about 
1% in the Dutch FSHD population (10/800 estimated FSHD patients). The risk profile for 
ventilatory dependency can be delineated as the severely affected wheelchair-bound 
FSHD patient with moderate to severe (kypho-) scoliosis and lumbar hyperlordosis. As 
pectus excavatum runs in 5% of the FSHD patients, its frequency in the patients on 
ventilatory support (3/10) suggests it to be a risk factor as well.
The size of the 4q35-EcoRI fragment is reported to be associated with age at onset of 
symptoms, rate of progression, and age at loss of ambulation.[10]  We did not find a 
correlation between duration of wheelchair dependency and onset of ventilation or an 
association between residual EcoRI fragment size and ventilatory dependency.
The results of this study suggest that ventilatory insufficiency develops relatively late in 
the course of the disease. This is in contrast to earlier findings, predominantly for juvenile 
FSHD patients.[5,6] 
All our patients had moderate to severe (kypho-) scoliosis, a well-known cause of 
ventilator failure.[4]  In general, sternal deformities alone rarely cause respiratory failure, 
but in our patients, such deformities may reflect the severity of the deformity of the 
thoracic cage.
Retrospectively, all but two patients had symptoms of nocturnal hypoventilation before 
respiratory insufficiency was diagnosed. Symptoms of nocturnal hypoventilation are often 
not recognized, and physicians should pay particular attention to these in wheelchair-
dependent FSHD patients. All patients had strongly decreased MIP and MEP values, 
indicative of respiratory muscle weakness. Maximal respiratory pressures are reported to 
be more sensitive than spirometric values early in the course of respiratory insufficiency 
in neuromuscular disease.[7]  Facemask-adjusted lung function devices are preferred to 
minimize air leakage as facial muscle weakness in these patients precludes adequate 
measurements with the conventional tube or flanged type of mouthpiece.[8]
 
Our current, possibly overcautious management is annual measurement of MIP, MEP, and 
FVC in FSHD patients who have the above-mentioned risk profile even in absence of 
symptoms of nocturnal hypoventilation. The frequency of monitoring, however, depends 
on the rate of progression. When VC drops below 50% predicted or MIP drops below 
30% of predicted value, further investigation is needed (daytime arterial blood gas 
analysis, followed by nocturnal investigation in case of complaints of hypoventilation).[4]  
Although not formally tested, all patients reported that their quality of life improved on 
ventilatory support.
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Abstract
To test the hypothesis that wheelchair dependency and (kypho-)scoliosis are risk factors 
for developing respiratory insufficiency in facioscapulohumeral muscular dystrophy, 
we examined 81 patients with facioscapulohumeral muscular dystrophy 1 of varying 
degrees of severity ranging from ambulatory patients to wheelchair-bound patients. 
We examined the patients neurologically and by conducting pulmonary function 
tests: Forced Vital Capacity, Forced Expiratory Volume in 1 second, and static maximal 
inspiratory and expiratory mouth pressures. We did not find pulmonary function test 
abnormalities in ambulant facioscapulohumeral muscular dystrophy patients.  
Even though none of the patients complained of respiratory dysfunction, mild to severe 
respiratory insufficiency was found in more than one third of the wheelchairdependent 
patients. Maximal inspiratory pressures and maximal expiratory pressures were 
decreased in most patients, with a trend that maximal expiratory pressures were more 
affected than maximal inspiratory pressures. Wheelchair-dependent patients with 
(kypho-)scoliosis showed the most restricted lung function. Wheelchair-dependent 
patients with (kypho-)scoliosis are at risk for developing respiratory function 
impairment. We advise examining this group of facioscapulohumeral muscular dystrophy 
patients periodically, even in the absence of symptoms of respiratory insufficiency, 
given its frequency and impact on daily life and the therapeutic consequences.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common hereditary 
muscular dystrophies. It is a slowly progressive autosomal dominant myopathy with an 
estimated prevalence of 1 in 8000 [1]. Initially, the facial and shoulder girdle muscles 
are affected. Over time, the humeral, abdominal, pelvic girdle, and foot extensor muscles 
can become involved. The dystrophy is characterized by variability in age at onset, 
variable progression, and an asymmetry in muscle involvement. Approximately 20% of 
the patients become wheelchair-dependent. An equal percentage remains asymptomatic 
[2,3].
In most cases FSHD is associated with a contraction of the subtelomeric D4Z4 repeat on 
chromosome 4q35 (FSHD1). Together with a specific adjacent distal sequence called 4A, 
this contraction is responsible for the production of a double homeobox transcription 
factor DUX4 with a toxic gain of function [4]. Patients with a clinical FSHD phenotype 
without a contraction of D4Z4, but a mutation in SMCHD1 and a 4qA allele, are labelled 
FSHD2 [5].
Respiratory insufficiency is not a well-recognized feature of FSHD and its frequency 
is unknown. Respiratory insufficiency requiring non-invasive ventilation is rare in 
FSHD. In the Dutch population approximately 1% of FSHD1 patients are on assisted 
(nocturnal) ventilation [6]. Respiratory failure most commonly occurs in infantile 
cases with wheelchair dependency and small D4Z4 repeat sizes [7,8]. In ambulant 
FSHD1 patients, mild global respiratory muscle weakness can be found as well [9–11]. 
Systematic studies of pulmonary function in FSHD have often included less severely 
affected patients and spinal deformities were often not mentioned [9–14]. Respiratory 
insufficiency in neuromuscular diseases manifests early as nocturnal hypoventilation. 
Symptoms of nocturnal hypoventilation include disturbed sleep, morning headaches, 
daytime fatigue and somnolence. Progressive respiratory muscle weakness may lead to 
chronic respiratory failure. More frequently, acute respiratory failure can occur due to an 
upper respiratory tract infection or after general anesthesia and intubation for surgical 
procedures. Therefore, detecting respiratory insufficiency is important to effectively 
manage FSHD [15–17]. Based on the data of the study of patients on ventilatory support, 
we hypothesized that wheelchair dependency and moderate to severe (kypho-)scoliosis 
are risk factors for respiratory insufficiency [6]. 
The purpose of the present study is to test this hypothesis by assessing pulmonary 
function tests in a large group of mildly to moderately affected FSHD1 patients and in 
a group of wheelchair-bound FSHD1 patients with or without spinal deformities in the 
absence of symptoms of respiratory insufficiency.
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Methods
Patient selection
We selected a cohort of FSHD1 patients by approaching all the participants of our 
previous trial on albuterol and training [18] (n = 77) and all wheelchair-bound FSHD1 
patients from our database (n = 18). Their clinical diagnosis was genetically confirmed 
as all included patients, or a first degree relative had a D4Z4 deletion at 4q35 with 
EcoRI fragments smaller than 37 kb after double digestion with BlnI [2]. In our cohort 
ambulatory was defined as ability to walk without walking aids. Ankle-foot orthoses were 
accepted. We excluded 4 participants from the trial with a walking distance of less than 
10 meters. In addition 10 patients were excluded because of the presence of pulmonary 
or cardiovascular disease, the use of sympathicomimetics or the use of beta-blockers as 
reported by the patients [18]. As a result, 81 patients with a clinical and genetic diagnosis 
of FSHD1 were included and divided into three groups: ambulatory FSHD1 patients 
(n = 63), wheelchair bound patients without (kypho-)scoliosis (n=10)and wheelchair 
dependent patients with (kypho-)scoliosis (n = 8) (Table 1). The protocol was approved by 
the local CME and informed consent was obtained.
Neurological and pulmonary examination
The following data were obtained: demographic data (age, sex, weight and length), age of 
onset of FSHD, age of wheelchair dependency and EcoRI fragment size. 
Cardiac and pulmonary symptoms, symptoms of nocturnal hypoventilation and symptoms 
of dysphagia were assessed with a questionnaire. Physical examination was done by the 
first author with special attention to thoracic and spinal deformities, position of the hips, 
signs of dyspnea and paradoxical breathing. The spine was examined in erect position and 
when bending forward. (Kypho-)scoliosis was found positive when observing a gibbus. As 
standard pulmonary function tests (PFTs) have proven unreliable for patients with FSHD, 
face mask-adjusted devices were used as previously described and validated [19]. Forced 
Vital Capacity (FVC) and Forced Expiratory Volume in one second (FEV1) were obtained 
with a Morgan spirometer (type PM2000). FVC was defined as abnormal if it was less than 
80% of the predicted value. A FVC between 60% and 80% of the predicted value was 
considered mild restricted lung disease, 51–60% moderate and below 50% severe [12]. 
In wheelchair-bound patients, FVC was measured in the sitting and supine positions. A 
decline in FVC of more than 20% from the sitting to supine position and/or paradoxical 
abdominal movement is indicative of diaphragm weakness [20,21]. Respiratory muscle 
strength was estimated by measuring PImax and PEmax using a Morgan pressure 
manometer (type Pmax) [19]. Pulmonary function tests in the ambulatory patients 
(participants of the albuterol and training trial) were measured before intervention of the 
trial [18].
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Statistics
Analysis of variance was used to study the differences between the three groups 
(ambulant, wheelchair-dependent and wheelchair-dependent with (kypho-)scoliosis) 
for each of the patient characteristics and the pulmonary function tests separately. In 
addition, the Tukey’s contrast test was used to test the differences between the groups. 
The means with the appropriate standard error are presented.
Results
The characteristics of the patients are shown by group in Table 1.
In 4 patients the exact reduction of the EcoRI fragment was not found in the patient file. 
One wheelchair bound patient could not recall his age at onset. In the ambulant group the 
average age at examination was 38.5 years (range 25–53 years) with 66.7% (42/63) men. 
In the wheelchair-dependent group of patients without (kypho)scoliosis mean age was 
51.8 years (range 27–70 years) with 60% (6/10) men. In the group wheelchair-dependent 
patients with (kypho-)scoliosis mean age was 31.0 years (range 20–39 years) with 62.5% 
(5/8) men.
 
Age of onset was 19.3 years [standard error (SE) 1.2] in the ambulatory group compared to 
14.2 years (SE 2.9) in the wheelchair-dependent group without (kypho)-scoliosis and 8.6 
years (SE 2.0) with (kypho-)scoliosis respectively. Ambulatory patients had a mean D4Z4 
contraction of 25.8 kb (range 18–36 kb) compared to 24.0 kb (range 10–27 kb) in the 
wheelchair-dependent group and 16.0 kb (range 10–24 kb) in the wheelchair-dependent 
group with (kypho-)scoliosis. None of the ambulatory patients had a visible gibbus. 
Sixty-five percent of the 81 patients were male, which was not statistically significantly 
different between the three groups (Chi-square test, p = 0.814). Significant differences 
were found in age at onset between the three groups of patients (Tukey contrast,  
p = 0.002).The wheelchair-dependent patients without (kypho-)scoliosis were 
significantly older than the patients with (kypho-)scoliosis (T-Test, p < 0.001) and the 
EcoRI fragment was significantly smaller in the patient group with (kypho-)scoliosis (Tukey 
contrast, p = 0.004). 
Based on the data from the questionnaire, none of the patients suffered from relevant 
comorbidity which could interfere with their pulmonary function. None of the patients 
suffered from symptoms of nocturnal hypoventilation nor did they have a history of 
recurrent pulmonary tract infections. The answers to the questionnaire items were not 
significantly different between the ambulant and the wheelchair-dependent patients, 
except for those about dysphagia (Tukey contrast p = 0.008) which was reported more 
by the wheelchair-dependent patients. The percentage of patients who had never 
smoked was larger in the group of wheelchair-dependent patients with (kypho-)scoliosis 
(75%) compared to both the group of ambulatory patients and the group of wheelchair-
dependent patients without spinal deformities (32% and 40%, respectively). 
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However, these differences did not reach the level of statistical significance (Chi-square 
test, p = 0.051). 
The mean (SE) of the pulmonary function tests by group is shown in Table 1. In the 
ambulatory patients, FVC and PImax were within the normal range, with slightly 
decreased PEmax. Wheelchair-dependent patients with (kypho-)scoliosis showed 
moderately to severely restricted lung function with severely decreased mouth pressures 
(Figure 1). Moreover, FVC declined more than 20% in 4 wheelchair-bound patients when 
changing from a sitting to a supine position. Of all the wheelchair-dependent patients 
included, 39% (7/18) had a moderately to severely impaired PFT. Two patients who had 
(kypho-)scoliosis and pectus excavatum had the most restricted pulmonary function. The 
first patient was a 22 year old man who became wheelchair dependent at the age of 15 
and showed 50% of predicted FVC with mouth pressures below 50%.The second patient 
was a 27 year old woman who became wheelchair dependent at the age of 16 and showed 
44% of predicted FVC, with maximal inspiratory and expiratory pressures below 60% of 
predicted value.
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Figure 1  Lung function (FVC % of normal) in wheelchair bound patients with and without 
kyphoscoliosis.
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Discussion
This is the largest study comparing pulmonary function in mild to moderately and 
severely affected FSHD1 patients in the absence of symptoms of respiratory insufficiency. 
In 39% (7/18) of the wheelchair-bound FSHD1 patients, moderate to severe PFT 
abnormalities were found, though none of these patients reported any symptoms 
of respiratory insufficiency. In addition, all ambulatory FSHD1 patients had normal 
pulmonary function. The greatest impairment in vital capacity was found in wheelchair-
bound patients with (kypho-)scoliosis. These patients had an earlier onset of disease, 
an early age of wheelchair dependency and smaller D4Z4 repeat sizes. In a study on the 
contribution of chest wall kinematics on respiratory insufficiency, 7 out of 11 patients 
with respiratory insufficiency were wheelchair users. However, unlike our patients,  
these patients were all still ambulatory [10]. A study on 53 FSHD1 patients showed 
restrictive pulmonary function in 4 patients, of which 3 were wheelchair users but still 
ambulatory [9]. 
Similar to our results, a significantly lower FVC in patients with spinal deformity compared 
to those without spinal deformity was found previously among infantile FSHD patients 
[7]. Here, 7 out of 9 patients had moderately to severely restricted pulmonary function, 
of whom 5 patients had a (kypho-)scoliosis, including the 4 wheelchair users [7]. In other 
studies the presence of (kypho-)scoliosis was not mentioned or not studied in relation to 
the pulmonary function tests [9,11,12]. However, in FSHD, spinal deformity is reported in 
approximately 20%-30% of cases. It involves predominantly lumbar hyperlordosis and 
relatively mild scoliosis, which is non-progressive and is often unnoticed by the patient. 
In infantile cases it can be severe [3]. Although scoliosis does not affect the respiratory 
muscles per se, it limits the ability of the thorax to expand, decreasing the compliance 
of the thoracic wall and increasing the workload of the respiratory muscles. In mild 
respiratory impairment, maximum respiratory pressures are probably more sensitive 
than other pulmonary function tests because FVC may not fall below normal limits 
until muscle strength has been reduced by 50%. However, abdominal muscles seem to 
become affected early in the course of the disease and are probably severely affected 
in patients with an early onset of disease and a (kypho-)scoliosis. Our study showed 
that patients with PFT abnormalities may not have respiratory complaints. In a recent 
study 9 out of 53 FSHD1 and 3 out of 8 FSHD2 patients reported breathing problems 
by themselves, but it was not mentioned whether these patients showed a restrictive 
lung function, nor if they were more severely affected [9]. Other studies do not mention 
whether patients have respiratory complaints [10,12]. Respiratory complaints can include 
those caused by nocturnal hypoventilation, which can be expected when vital capacity 
is 40% or lower than predicted. This threshold can help identify patients at risk and 
determine the need to perform additional sleep studies for diagnostic confirmation when 
no complaints are mentioned. Although hypoventilation can be an early symptom of 
FSHD1, in ambulant mildly affected patients who lack symptoms or signs of respiratory 
impairment, it is generally not necessary to monitor respiratory muscle weakness [22,23]. 
However, according to most guidelines, it is recommended to annually measure overnight 
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pulse oximetry or polysomnography when the FVC is lower than 60% of predicted 
values [21]. As none of the patients in this study with a vital capacity about 40% of 
the predicted value complained about symptoms of nocturnal hypoventilation, we 
recommend these guidelines to be followed. A limitation of this study is that pulmonary 
function testing does not necessarily give information of the presence of clinically 
ventilatory insufficiency. In neuromuscular patients early manifestation of ventilatory 
insufficiency occurs during sleep and can be found without clinical complaints. Additional 
polysomnography or nocturnal oximetry and blood gas analysis in patients with a 
restrictive lung involvement would provide relevant information on the diagnostic value 
of pulmonary function tests to identify the patients at risk for ventilatory insufficiency. 
Recently, a non-invasive therapy to improve pulmonary function in neuromuscular 
patients, called lung volume recruitment (LVR) therapy (also called air-stacking), has 
attracted attention. In DMD patients, the rate of FVC decline improves dramatically with 
the initiation of regular LVR[24].  It would be interesting to study the effects of LVR on 
FSHD patients with respiratory dysfunction. In conclusion, in FSHD1 patients severe 
proximal lower extremity muscle weakness with wheelchair dependency and (kypho-)
scoliosis is an early indicator for respiratory muscles involvement. We recommend that 
these patients be periodically screened and that pulmonary function tests be performed 
on a regular basis,even in the absence of symptoms of hypoventilation.
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Abstract
Dysphagia is not considered a symptom of facioscapulohumeral muscular dystrophy 
(FSHD). In this study, the authors found that dysphagia does occur in patients with 
advanced FSHD showing mild involvement of the jaw and lingual muscles. Dysphagia is 
seldom life threatening in these patients. The authors conclude that dysphagia should 
not be considered an exclusion criterion for FSHD. 
Introduction
Facioscapulohumeral muscular dystrophy (FSHD: MIM 158900) is the third most common 
form of muscular dystrophy (prevalence is 1:20,000) and is characterized by progressive 
weakness of the facial and shoulder girdle muscles and a gradual spread in time to 
abdominal and foot-extensor muscles. In most patients, the muscles of the upper arm and 
pelvic girdle become involved with disease progression, and 20% of patients become 
wheelchair dependent by the fifth decade.[1,2]  The disease has an autosomal dominant 
pattern of inheritance and is associated with contraction of the D4Z4 repeat array on 
chromosome 4q35 in 95% of cases.[3]
Physicians treating patients with FSHD are not focused on symptoms of dysphagia 
because involvement of the lingual and pharyngeal muscles is still considered an 
exclusion criterion for FSHD.[2]  In a series of 151 Japanese FSHD patients, seven 
patients (4.6%) with an early onset of the disease had an atrophic tongue, two of 
whom had difficulty swallowing.[4]  Swallowing, however, has not yet been examined 
in FSHD. In an earlier study (unpublished data) of pulmonary function in patients with 
FSHD, both ambulant and wheelchair dependent, 10 of 87 patients were found to have 
swallowing difficulties. Eight of these patients consented to additional studies including 
videofluoroscopy and MRI of the tongue. In this study, we sought to demonstrate 
dysphagia in patients with FSHD who reported swallowing problems and to identify its 
cause.
Methods
Patients who reported swallowing difficulties among patients with FSHD who took part 
in an earlier questionnaire survey of pulmonary symptoms were recruited for this study. 
All patients had a clinical and a genetically confirmed diagnosis of FSHD.[2]  Ten patients 
reported one or more problems with swallowing. These patients were approached for 
additional information about their medical history and for informed consent. The protocol 
was approved by the local medical ethics committee.
A speech therapist assessed the oral muscles by observing the tongue, jaws, and lips at 
rest and during activity. The strength of the jaws, lips, and tongue was assessed clinically 
(e.g., biting a spatula, protrusion of the tongue, and pressure of the tongue against the 
inner cheek), as were qualitative features such as position (open mouth, position of 
tongue), mobility, velocity, volume, and resistance to palpation. Weakness was scored as 
mild, moderate, or severe. The patient was then observed while drinking (150 mL water) 
and eating semisolid (150 mL yogurt) and solid (a cheese sandwich) food.[5,6] 
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Videofluoroscopy
Oropharyngeal swallowing was visualized by videofluoroscopy. Patients were asked 
to swallow boluses of 5 and 10 mL of thin liquid and thick liquid barium. They were 
then asked to eat a small piece of bread dipped in barium and, when possible, drink a 
cup of thin liquid barium. Patients were sitting in an upright position. Two experienced 
evaluators blinded to the clinical status of the patients evaluated all recordings, based 
on consensus regarding problems with (a) oral transit, (b) pharyngeal delay, (c) laryngeal 
penetration or aspiration, (d) pharyngeal transit, and (e) pharyngeal residue or individual 
compensations.[7] 
All symptoms were scored with the Dysphagia Outcome Severity Scale (DOSS), a reliable 
scale based on videofluoroscopic and clinical findings.[8]  Scores range from 1 (severe 
oropharyngeal dysphagia necessitating nonoral nutrition) to 7 (normal in all situations).
MRI of the tongue
All examinations were performed according to a protocol adapted from Stuck et al.[9] on 
a 1.5-T MR scanner (Symphony, Siemens), using a standard head coil. T1-weighted (450/40 
TR/TE) and T2-weighted (5000/114 TR/TE) images were obtained in three orthogonal 
planes with a slice thickness of 3 mm and a slice interval of 0.3 mm. Tongue volume was 
measured on the sagittal T1-weighted images, using the VOXAR (Agfa) software program 
(release vs 4.1) with a three-dimensional volumetric measurement capability.
Results
Eight (six men) of the 10 eligible patients took part in the study (table 1). Mean age was 39 
years (range 26 to 53). All patients showed signs of weakness of the jaws, lips, or tongue 
(table 1 and figure). Analysis of the videofluoroscopic investigations (table 2) showed 
piecemeal deglutition in six patients and pharyngeal delay in four patients (see video E1 
on the Neurology Web site at www. neurology.org). MRI of the tongue was performed in 
seven patients (table 2): three patients (Patients 3, 5, and 8) had a small tongue volume 
and the tongue appeared to be atrophic. The signal intensity of the tongue was normal in 
all patients, and there were no signs of fatty degeneration of muscle. 
Discussion
This is the first study of dysphagia in FSHD. Analysis of oropharyngeal function in 
symptomatic patients with FSHD showed distinct, but mild to moderate, abnormalities of 
swallowing in seven of eight patients examined, and most patients had weakness of the 
tongue and jaw muscles. Six patients had tongue atrophy. Although there are no reliable 
reference values for tongue volume measured with MRI, three of the patients (Patients 3, 
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Table 1    Patient characteristics and results of orofacial examination and evaluation of eating and 
drinking. 
    Pt 1 Pt 2 Pt 3 Pt 4 Pt 5 Pt 6 Pt 7 Pt 8
characteristics        
 Gender M M F M F M M M
 Age, y 45 52 29 41 35 33 53 26
 Age of onset FSHD, y >20 >20 4 7 11 >20 20 8
 Wheelchair-dependent, y 40 – 15 30 26 – – 15
 EcoRI fragment size, kb 30 27 12 14 17 30 24 10
oro-facial examination
 Weakness jaws + – + + + – + +
 Weakness lips + + ++ ++ ++ ++ + +
 Weakness tongue + + + ++ + + – –
 Atrophy tongue – – + + + + + ±
evaluation of eating and drinking
 Slowness + + + ± + + + –
 Leakage food or liquid + + + + – + – ±
 Frequent swallowing + + + + – + – –
 Moving head backwards solid solid solid – solid – – –
 Adapting head position – – – – + – – –
 Residue pharynx + + – – – – – –
 Coughing + + – + + – – +
 Wet phonation – – – + – – – –
 Shortness of breath after swallowing + – – – – + – –
 
EcoRI = EcoRI (D4Z4) fragments range from 38 to 300 kb in healthy control subjects, patients with FSHD usually 
have fragments <38 kb. – = absent; ± = minimal signs; + = clear signs; ++ = severe weakness or atrophy; solid = 
sign only seen when eating. 
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Figure (A, B)     The tongue of a patient with facioscapulohumeral muscular dystrophy (Patient 3 in 
table 1) showing tongue atrophy, predominantly on the lateral sides of the tongue
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72
Ta
bl
e 
2 
Re
su
lt
s 
of
 v
id
eo
fl
uo
ro
sc
op
ic
 e
va
lu
at
io
n,
 D
O
SS
-s
co
re
 a
nd
 M
R
I o
f t
he
 to
ng
ue
. 
 
Pr
ob
le
m
s 
 
La
ry
ng
ea
l 
 
 
 
To
ng
ue
 
  P
t 
w
it
h 
Ph
ar
yn
ge
al
 
pe
ne
tr
at
io
n/
 
Pr
ob
le
m
s 
w
it
h 
ph
ar
yn
ge
al
 
Ph
ar
yn
ge
al
 
D
O
SS
- 
vo
lu
m
e 
 
or
al
 t
ra
ns
it
 
de
la
y 
as
pi
ra
ti
on
 
tr
an
sp
or
t a
nd
 c
om
pe
ns
at
io
ns
* 
re
si
du
e 
sc
or
e 
cm
3
†
  1
 
N
o 
N
o 
O
nc
e 
Re
du
ce
d 
to
ng
ue
 b
as
e 
re
tr
ac
ti
on
,  
 
Ye
s 
(s
c)
 
4 
13
1.
3 
 
 
 
as
pi
ra
ti
on
,  
Ex
te
nd
ed
 p
ha
ry
ng
ea
l 
 
 
 
w
it
h 
co
ug
h 
tr
an
si
t/
la
ry
ng
ea
l e
le
va
ti
on
 *
(m
), 
 
 
 
 
M
ul
ti
pl
e 
sw
al
lo
w
s 
to
 c
le
ar
 th
e 
ph
ar
yn
x*
  2
 
pi
ec
em
ea
l 
Ye
s‡
 
N
o 
Re
du
ce
d 
to
ng
ue
 b
as
e 
re
tr
ac
ti
on
, 
Ye
s 
(s
c)
 
5 
11
7.
8 
 
de
gl
ut
it
io
n 
 
 
M
ul
ti
pl
e 
sw
al
lo
w
s 
to
 c
le
ar
 
 
 
 
 
ph
ar
yn
ge
al
 re
si
du
e*
 
  3
 
pi
ec
em
ea
l  
Ye
s‡
 
N
o 
Sl
ig
ht
 s
tr
ug
gl
e 
w
it
h 
ph
ar
yn
ge
al
 tr
an
si
t 
N
o 
5 
66
.2
 
 
de
gl
ut
it
io
n
  4
 
pi
ec
em
ea
l  
Ye
s‡
 
N
o 
Re
du
ce
d 
to
ng
ue
 b
as
e 
re
tr
ac
ti
on
, 
Ye
s 
(s
c)
 
5 
10
3.
5 
 
de
gl
ut
it
io
n 
 
 
Sl
ig
ht
 s
tr
ug
gl
e 
w
it
h 
ph
ar
yn
ge
al
 t
ra
ns
it
  
 
 
  5
 
pi
ec
em
ea
l  
Ye
s‡
 
N
o 
M
ov
in
g 
he
ad
 b
ac
kw
ar
ds
 to
 fa
ci
lit
at
e 
N
o 
5 
63
.2
 
 
de
gl
ut
it
io
n 
 
 
bo
lu
s 
tr
an
si
t t
hr
ou
gh
 th
e 
ph
ar
yn
x*
 
  6
 
pi
ec
em
ea
l  
N
o 
N
o 
Ex
te
nd
ed
 la
ry
ng
ea
l e
le
va
ti
on
 to
 
N
o 
5 
10
6
.8
 
 
de
gl
ut
it
io
n 
 
 
fa
ci
lit
at
e 
ph
ar
yn
ge
al
 tr
an
si
t *
(m
) 
  7
 
N
o 
N
o 
N
o 
Im
pa
ir
ed
 o
es
op
ha
ge
al
 t
ra
ns
it
 
N
o 
7 
N
a
  8
 
pi
ec
em
ea
l  
Ye
s‡
 
O
nc
e 
 
Re
du
ce
d 
to
ng
ue
 b
as
e 
re
tr
ac
ti
on
 
N
o 
5 
89
.8
 
 
de
gl
ut
it
io
n 
 
as
pi
ra
ti
on
,  
 
 
 
 
 
 
 
w
it
h 
co
ug
h
* 
 C
om
p
en
sa
ti
on
.
† 
 T
on
gu
e 
vo
lu
m
e 
w
it
h 
M
R
I.
‡ 
 W
he
n 
liq
ui
d 
co
nt
ra
st
 is
 in
 v
al
le
cu
la
e.
D
O
SS
 =
 D
ys
ph
ag
ia
 O
ut
co
m
e 
an
d 
Se
ve
ri
ty
 S
co
re
 (r
ef
) (
7 
= 
no
rm
al
, 6
 =
 w
it
hi
n 
fu
nc
ti
on
al
 li
m
it
s,
 5
 =
 m
ild
, 4
 =
 m
ild
-m
od
er
at
e,
 3
 =
 m
od
er
at
e,
 2
 =
 m
od
er
at
e-
se
ve
re
, 
1 
= 
se
ve
re
 d
ys
ph
ag
ia
); 
sc
 =
 s
po
nt
an
eo
us
ly
 c
le
ar
ed
; *
(m
) =
 li
ke
 a
 s
po
nt
an
eo
us
 M
en
de
ls
oh
n 
m
an
eu
ve
r;
 N
a:
 n
ot
 a
ss
es
se
d,
 M
R
I o
f t
he
 to
ng
ue
 w
as
 p
re
m
at
ur
el
y 
di
sc
on
ti
nu
ed
 b
ec
au
se
 o
f 
to
o 
m
an
y 
ar
ti
fa
ct
s.
73
5, and 8) appeared to have a small tongue volume on MRI, findings that could be related to 
disease severity, and two (Patients 1 and 2) appeared to have a large tongue volume. We 
did not find differences in tongue intensity, i.e., fat replacement of muscle, in contrast to 
previous findings.[4]  Therefore, by MRI we did not find morphologic signs of a pathologic 
condition of the tongue.
Because tongue strength is essential to the transport of food through the oral cavity 
into the pharynx,[6] the finding that the tongue muscles were weak or atrophic in six 
patients is consistent with the delayed oral and pharyngeal transport of food shown by 
videofluoroscopy. Most patients showed compensatory behavior: four patients extended 
their head to facilitate bolus transit through the pharynx.
In 1885, Landouzy and Dejeurine emphasized the clinical and histologic integrity of the 
muscles of the tongue, pharynx, larynx and masseter in FSHD.[1]
Since then, there have been no detailed studies of the involvement of these muscles. 
We found subtle involvement of the lingual muscles and possible involvement of the 
masseter muscle, but no evidence of deterioration or atrophy of the pharyngeal or 
laryngeal muscles. These findings suggest that the patients’ swallowing problems were 
a consequence of weakness of the orofacial muscles only. Although patients with mild 
D4Z4 contractions with less severe disease also reported swallowing problems, these 
patients had pronounced facial muscle weakness. We found tongue atrophy in the more 
severely affected patients only. As the patients were selected by disease severity and 
disease characteristics, their clinical picture is not representative of the overall FSHD 
population, and therefore we cannot determine the prevalence of dysphagia in FSHD 
based on our study.
We refer patients with swallowing difficulties to a speech therapist who is often able 
to help patients by making them aware of inadequate adaptation mechanisms and by 
teaching them to use effective compensation strategies.
P
ar
t 
II
   
- 
  C
h
ap
te
r 
5 
D
ys
p
h
ag
ia
 i
n
 f
ac
io
sc
ap
u
lo
h
u
m
er
al
 m
us
cu
la
r 
d
ys
tr
o
p
h
y

75
 References
[1]  Padberg GW. Facioscapulohumeral disease. Thesis, Leiden University, 1982.
[2]  Padberg GW, Lunt PW, Koch M, Fardeau M. Facioscapulohumeral muscular dystrophy.  
In: Emery AEH, ed. Diagnostic criteria for neuromuscular disorders.  
The Netherlands: European Neuromuscular Center, 1997; 9-15.
[3]  Lemmers RJ, De Kievit P, Van Geel M, et al. Complete allele information in the diagnosis  
of facioscapulohumeral muscular dystrophy by triple DNA analysis.  
Ann Neurol 2001; 50: 816-819.
[4]  Yamanaka G, Goto K, Matsumura T, et al. Tongue atrophy in facioscapulohumeral  
muscular dystrophy. Neurology 2001; 57: 733-735.
[5]  Clark HM, Henson PA, Barber WD, Stierwalt JAG, Sherrill M. Relationships among 
subjective and objective measures of tongue strength and oral phase swallowing 
impairments. Am J Speech Lang Pathol 2003; 12: 40-50.
[6]  Schulze-Delrieu KS, Miller RM. Clinical assessment of dysphagia. In: Perlmann AL,  
Schulze-Delrieu KS, eds. Deglutition and its disorders.  
San Diego/London: Singular Publishing Group, 1997: 125-152. 
[7]  Logemann JA. Manual for the videofluorographic study of swallowing.  
Austin, TX: Pro-Ed, 1993.
[8]  O’Neil KH, Purdy M, Falk J, Gallo L. The Dysphagia Outcome and Severity Scale.  
Dysphagia 1999; 14: 139-145.
[9]  Stuck BA, Kopke J, Maurer JT, et al. Evaluating the upper airway with standardized 
magnetic resonance imaging. Laryngoscope 2002; 112: 552-558.
P
ar
t 
II
   
- 
  C
h
ap
te
r 
5 
D
ys
p
h
ag
ia
 i
n
 f
ac
io
sc
ap
u
lo
h
u
m
er
al
 m
us
cu
la
r 
d
ys
tr
o
p
h
y
76
77
Pa r t  I I I   Cont r ibut ions  
to  genet ic 
diag nos is
78
79
 Chapter 6   
  Poss ib le  phenot y pic 
dos age  ef fec t  in  pat ient s 
compound  heteroz ygous  
for  FSHD -s ized  4 q35 a l le les  
 
 
 
 
 
 
 Published as: 
  M. Wohlgemuth  
R.J. Lemmers,  
E.L. van der Koo 
M.J. van der Wielen 
P.G. van Overveld  
H. Dauwerse  
E. Bakker  
R.R. Frants  
G.W. Padberg  
S.M. van der Maarel  
 
Neurology  2003; 61: 909–913. 
Abstract
Objective: Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) 
is associated with a contraction of the D4Z4 repeat array on chromosome 4. So far, 
homozygosity or compound heterozygosity for FSHD alleles has not been described, and 
it has been debated whether the absence of such subjects is because of the rarity or the 
lethality of the disorder.
Methods: Two unrelated families in which the probands are compound heterozygous 
for two FSHD-sized alleles were studied. Clinical examination, pulsed-field gel 
electrophoresis (PFGE) studies of DNA with probes proximal and distal to D4Z4, and 
cytogenetic analysis of metaphase chromosomes by FISH were performed.
Results: Complementary molecular and cytogenetic approaches confirmed the 
chromosome 4qA origin of all FSHD-sized repeat arrays that segregate in the families.
Conclusions: Heterozygosity for FSHD-sized alleles is compatible with life in men and 
women. A possible dosage effect was observed in both probands in whom each 4qA 
allele contributed to the FSHD phenotype. Because at least one of the FSHD alleles in 
both families showed an unusual low penetrance, the authors propose that susceptibility 
for FSHD is partly determined by intrinsic properties of the disease allele other than the 
residual D4Z4 repeat size alone.
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Introduction 
Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD; MIM 158900) is 
characterized by progressive atrophy and weakness of the facial, shoulder, and upper 
arm muscles, usually starting in the second decade of life. Subclinical symptoms such as 
sensorineural deafness and retinal vasculopathy are part of the disease.[1,2] 
FSHD is associated with contraction of the subtelomeric D4Z4 repeat array on 
chromosome 4q. In healthy persons, this polymorphic repeat array varies between 11 
and 150 KpnI units (D4Z4), each 3.3 kb in size. Patients carry, because of deletion of an 
integral number of D4Z4 units, one array of 1 to 10 units. These arrays are visualized in 
EcoRI-digested DNA with probe p13E-11, which recognizes the region just proximal to 
the D4Z4 repeat array.[3,4]  On chromosome 10qter, a highly homologous polymorphic 
repeat array is localized. In contrast to chromosome 4qter, small repeat arrays on 
chromosome 10qter are nonpathogenic.[5-8]  Two restriction enzymes can be used to 
distinguish 4qter-derived arrays from 10qter-derived arrays: BlnI recognizes 10-derived 
units,[9] whereas XapI specifically recognizes 4-derived units.[10]  Moreover, two allelic 
variations of 4qter have recently been described. These variations, 4qA and 4qB, differ 
by a few insertion and deletion polymorphisms distal to D4Z4.[11]  Although both alleles 
are almost equally common in the Dutch control population, FSHD disease alleles are 
exclusively of the 4qA type.[12]  Because both alleles display an equal propensity to 
recombine, a functional difference between 4qA and 4qB must underlie this unique 
association of FSHD with 4qA. Thus, two prerequisites are required to develop FSHD: 1) a 
D4Z4 repeat of 1 to 10 units, and 2) this repeat array must reside on chromosome 4qA. 
So far, patients with FSHD have been described carrying only one disease allele, in 
accordance with the dominant inheritance pattern. It has been debated whether the 
absence of patients with two disease alleles is because of the rarity of the disorder, 
estimated to be 1:20,000 in the Dutch population,[1] or because of the lethality of such 
an allele constitution. Because no fewer than 3% of the Dutch population carries a 
4-derived repeat unit <38 kb,[13] it was anticipated that, if heterozygosity for two disease 
alleles is not lethal, such constitutions should be encountered in the FSHD population. 
Here, we describe two unrelated FSHD patients heterozygous for FSHD alleles on both 4q 
chromosomes.
Materials and methods
Family A. The proband (Patient II-7) is a 71-year-old woman with normal motor milestones 
who has never been able to run (figure 1). She has been completely dependent on a 
wheelchair since aged 12 years, and she has been on nocturnal ventilatory support for 
8 years. On examination, she has hypoplastic-paralyzed legs, with severe contractures 
in knees and ankles, extreme lumbar lordosis, and kyphoscoliosis. The facial muscles are 
almost completely paralyzed. Severe weakness and atrophy are present in the scapula 
stabilizer muscles, proximal arms, and abdominal and leg muscles (Medical Research 
Council [MRC] grade 1 to 3), with relatively sparing of the wrist, finger, and foot flexors.
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Both parents allegedly had no muscular signs. The mother died at age 47 years because 
of liver failure, and the father died at 52 years because of a heart attack. The oldest 
brother (Subject II-1) was not believed to have FSHD and died at 63 years from myocardial 
infarction. The oldest sister (Patient II-2) died at age 48 years of bronchitis and had a 
severe form of muscle weakness. The second brother (Subject II-3) had no symptoms or 
signs of FSHD at examination. He had a myocardial infarction when he was in his early 
40s. His two children and six grandchildren were said to have no complaints of muscle 
weakness. Sister II-5 died at 63 years from complications of gastric cancer. Neither her 
children nor her grandchildren were suspected to have FSHD. Brother II-6 died young, at 
age 17 years, in a traffic accident and was probably affected. Brother II-8 had facial and 
shoulder weakness. Middle-aged, he had a waddling gait and difficulty getting up from a 
chair and climbing stairs. He died suddenly, probably from a heart attack, several years 
before this study. The youngest brother (Patient II-9) had difficulties walking at age 11 
Family A 
II-1 II-2 
I-1 I-2 
II-3 II-4 II-5 II-6 II-7 II-8 II-9 II-10 II-11 
III-1 
I-1 I-2 
II-1 II-2 II-3 
Family B 
Figure 1  Pedigrees of the two kindreds (families A and B) with facioscapulohumeral 
muscular dystrophy (FSHD).
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years and was wheelchair-bound at age 14 years. He died at age 47 years allegedly from 
a heart attack. His 29-year-old daughter (Patient III-1) quit sports at school when she was 
aged 14 years because of muscle weakness. On examination, she had an asymmetrical 
facial paresis, weakness of the scapular and upper arm muscles, and moderate weakness 
of the abdominal, pelvic girdle, and foot extensor muscles (MRC grade 4+). The youngest 
sister (Subject II-11) of the proband did not have symptoms or signs of FSHD at 
examination. Her only son was said to have no muscle complaints or weakness.
Family B. The proband (Patient I-1) noticed progressive weakness in his arms since aged 
16 years (see figure 1). At age 50 years, he developed progressive pelvic girdle weakness 
and a stooped gait. On examination (at age 66 years), he had a symmetric facial paresis 
and atrophy and weakness of the scapula fixators, pectorales muscles, and upper arm 
muscles with sparing of the deltoid muscles. He had weak abdominal muscles and a 
waddling gait. He could climb stairs with little support and had only slight foot extensor 
weakness (MRC grade 4+). His father had always been in good health until he had a gastric 
carcinoma. His mother was said to have difficulties walking at an older age and to trip 
frequently. His two brothers died at ages 18 and 26 years from tuberculosis. His sister, 
aged 79 years, is said to be without muscle weakness. The proband’s three children, aged 
33, 30, and 28 years, had no muscle complaints or weakness at examination.
DNA isolation and analysis. DNA was isolated from peripheral blood lymphocytes.[14] 
For allele sizing, agarose-embedded DNA plugs were double digested with EcoRI/HindIII 
and EcoRI/ BlnI, or digested with XapI. For the analysis with chromosome 4-specific 
probes, DNA plugs were digested with NotI, whereas for analysis of the allelic variation 
at 4qter (probes 4qA and 4qB), DNA plugs were digested with HindIII only, all according 
to the manufacturers’ instructions. All enzymes were purchased from MBI Fermentas (St. 
Leon-Rot, Germany), except for BlnI, which was purchased from Amersham-Pharmacia 
(Buckinghamshire, UK).
DNA digested for allele sizing and typing was separated for 22 hours on a 0.8% agarose 
gel (MP agarose, Boehringer, Mannheim, Germany) by pulsed-field gel electrophoresis 
(PFGE) at 8.5 V/cm at 21 °C in 0.5x TBE supplemented with 150 pg/mL ethidium bromide. 
PFGE was done in four identical cycles (5.5 hours) with a switch time increasing linearly 
from 1 second at the beginning to 16 seconds at the end of each cycle. Membranes 
for allele sizing were hybridized with probe p13E-11, and those for allele typing were 
hybridized with probes 4qA and 4qB.
NotI-digested DNA was separated in four identical cycles of 11.5 hours with increasing 
switch times from 3 to 35 seconds at 8.5 V/cm. Subsequently, the DNA was transferred 
to a Hybond XL membrane (Amersham-Pharmacia) and hybridized in a buffer containing 
0.125 mol/L Na2HPO4 (pH 7.2), 10% PEG6000, 0.25 mol/L NaCl, 1 mmol/L EDTA, and 
7% SDS for at least 16 hours at 65 °C.[8]  NotI membranes were hybridized with the 
chromosome 4-specific probe B31 located in intron 1 of FRG1 before hybridization with 
p13E-11.[15] P
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After hybridization, blots were washed twice in 2x SSC/0.1% SDS for 10 minutes (and 
subsequently with 0.1x SSC/0.1% SDS for probe B31) or more stringently in 1x SSC/0.1% 
SDS for 15 minutes (probes 4qA and 4qB).[12]  Blots were exposed for 16 to 24 hours 
to phosphorimager screens and analyzed with the ImageQuant software program 
(Amersham). All HindIII blots were rehybridized with p13E-11 after hybridization with 
probes 4qA and 4qB to confirm the identity of the fragments.[12] 
Fluorescence in situ hybridization. Metaphase chromosome spreads of cultured 
lymphocytes and cultured lymphoblastoid cell lines were hybridized with a 4.9-kb 
KpnI fragment on which p13E-11 resides.[7]  The probe was labeled by nick translation 
with biotin-16-dUTP (Roche, Basel, Switzerland).[16]  To identify chromosome 4, a 
chromosome 4-specific paint [17] was accordingly labeled with digoxigenin-11-dUTP 
(Roche). Chromosome 10 centromeres were visualized with digoxigenin-11-dUTP–labeled 
chromosome 10-specific alpha satellite DNA (D10Z1). Hybridization, washing, and staining 
were performed as described previously.[18]  Signal intensities were scored by visual 
inspection of at least 20 metaphase spreads of each patient.
Results
PFGE analysis of the DNA of the probands (families A and B) showed the presence of two 
4-type FSHD-sized repeat arrays in both patients based on the resistance of the arrays to 
BlnI and their sensitivity to XapI. Patient II-7 in family A carries chromosome 4-type arrays 
of 17 kb and 24 kb and 10-derived arrays of 115 kb and 190 kb. Patient I-1 of family B 
carries three 4-type arrays of 33 kb, 36 kb, and 60 kb and one 10-type array of 80 kb 
(figure 2A). To determine the chromosomal origin of the three 4-type arrays in family 
B and to exclude 4;10 translocations in family A, their chromosomal origin was further 
determined by three complementary approaches: additional PFGE studies, fluorescence in 
situ hybridization (FISH) analysis of metaphase chromosomes, and segregation analysis.
Additional PFGE analyses were performed using NotI-digested DNA hybridized with the 
chromosome 4-specific probe B31. Analogous to probe E8,[7] this probe specifically 
recognizes the terminal NotI fragment of chromosome 4 on which D4Z4 resides. This 
PFGE analysis demonstrates that both FSHD-sized alleles in each proband originate 
from chromosome 4, whereas the 60 kb-sized 4-type allele in family B is translocated to 
chromosome 10qter (figure 2B).
We previously demonstrated that the 4.9-kb KpnI fragment containing p13E-11 can be 
used to determine the repeat array size by FISH analysis on metaphase chromosome 
spreads.[7]  In agreement with the NotI analysis, FISH analysis of metaphase spreads of 
each proband confirms the chromosome 4 origin of both FSHD-sized alleles because the 
signal intensities of the repeat arrays on chromosome 4qter are significantly lower than 
those on chromosome 10qter (figure 3).
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Figure 2. (A) Pulsed-field gel electrophoresis (PFGE) analysis of DNA of families A and B. Fragment sizes 
(lambda concatamers) of the marker lanes are indicated at the left of each gel. DNA of these subjects 
was digested with EcoRI and HindIII (H) or with EcoRI and BlnI (B), separated in adjacent lanes, blotted, 
and subsequently hybridized with probe p13E-11. The proband of family A (II-7, left panel) carries two 
4-derived alleles, one of 17 kb and one of 24 kb. The 24-kb allele is also present in her younger sister 
(Subject II-11), who is not affected with facioscapulohumeral muscular dystrophy (FSHD) and carries in 
addition three 10-type alleles (monosomic). The daughter of her younger brother (Patient II-9) carries the 
17-kb allele and is affected with FSHD. The proband of family B (I-1, right panel) carries three 4-derived 
alleles, sized 33 kb, 36 kb, and 60 kb. The 33-kb allele is transmitted to the children II-1 and II-3, whereas 
the second son (Subject II-2) inherits the 36-kb and 60-kb allele. None of the three children is affected. 
The mother (Subject I-2) and the eldest son (Subject II-1) carry comigrating 4-derived and 10-derived 
alleles of 140 kb as inferred from additional XapI analysis (data not shown). Below the PFGE results is 
a schematic presentation of the D4Z4 locus and its homologue on chromosome 10. The repeat units 
are represented by an arrow and may vary in number (n). The region recognized by probe p13-E11 is 
shaded. The restriction sites for EcoRI (E) and BlnI (B) are indicated. Below the chromosome (qter), the 
restriction fragments after digestion with E and B are visualized for 4qter and 10qter. (B) PFGE analysis 
of DNA of the probands II-7 and I-1 of families A and B. Fragment sizes of the marker lanes are indicated 
at the left of each gel. DNA of these subjects was digested with NotI and hybridized with probes p13E-11 
(E-11) and B31, the latter specifically recognizing the most distal NotI fragment of chromosome 4 on 
which D4Z4 resides. The most distal NotI site on 4qter is localized in the promotor region of FRG1 at 
125-kb distance of the D4Z4 repeat (see the schematic representation below the PFGE results). The size 
difference between chromosome 4qterderived EcoRI fragments and NotI fragments is approximately 185 
kb because of the 125-kb sequence proximal and sequences distal to D4Z4. On chromosome 10, the most 
distal NotI site is at 220-kb distance; therefore, the size difference between EcoRI and NotI fragments is 
approximately 280 kb. In Patient I-1 of family B, a strong hybridizing fragment is present of approximately P
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200 kb representing the 33-kb and 36-kb (+185 kb) chromosome 4-derived EcoRI fragments (arrows). 
Subsequent hybridization with p13E-11 reveals that in addition to the chromosome 4-derived fragments, 
two fragments of 340 kb (60 + 280) and 360 kb (80 + 280) derived from chromosome 10 (arrows). 
Therefore, the chromosome 4-type array of 60 kb resides on chromosome 10. The same holds for Patient 
II-7 from family A in whom, on hybridization with B31, only the 4-derived NotI fragments of 202 kb (17 
+ 185) and 209 kb (24 + 185) are visualized, whereas on hybridization of p13E-11, the chromosome 
10-derived fragments of 380 kb (100 + 280) and 470 kb (190 + 280) are also visualized.
 
Figure 3. Fluorescence in situ hybridization (FISH) analysis of metaphase spreads of Patient II-7 of family 
A (= 214) and all members of family B (= 47). Metaphase chromosomes were hybridized with digoxigenin-
labeled chromosome 4 paint and chromosome 10 centromere probe (green). The D4Z4 repeat arrays on 
chromosome 4qter (arrowheads) and its homologous repeat arrays on chromosome 10qter (arrows) were 
visualized with a biotin-labeled 4.9-kb KpnI fragment on which p13E-11 resides (red). The signal intensity 
of this probe roughly correlates with the D4Z4 repeat size. Patient II-7 of family A has weak D4Z4 signals 
on 4qter compared with the signals on 10qter consistent with the chromosome 4 origin of the 17-kb 
and 24-kb repeat array fragments and the chromosome 10 origin of the 105-kb and 185-kb repeat 
array fragments. Analogous to this subject, Patient I-1 of family B has, in comparison to chromosome 
10qter, weak 4qter signals, consistent with a chromosome 4 origin of the 33-kb and 36-kb repeat array 
fragments and the chromosome 10 origin of the 60-kb and 80-kb repeat array fragments. This is further 
substantiated by the signal intensity of the chromosome 4qter signals in his offspring: Patients II-1, II-2, 
and II-3. Each of these children has inherited one of the FSHD-sized alleles from the father (33 kb, 33 kb, 
and 36 kb; yellow arrowheads) and one large allele from the mother (140 kb, 140 kb, and 96 kb; white 
arrowheads) as visualized by the presence of one weak and one strong chromosome 4qter signal in each 
metaphase spread. The mother (Patient I-2) carries chromosome 4 alleles of 96 kb and 140 kb, resulting in 
relatively strong hybridization signals on 4qter.
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Segregation analysis in family A showed the presence of the 17-kb 4qA allele in the 
affected Patient III-1. Remarkably, Subject II-11, carrying the 24-kb 4qA allele, is not 
affected. Similarly, in family B, all three children inherited a short D4Z4 allele, either the 
33-kb 4qA allele (Subjects II-1 and II-3) or the 36-kb 4qA allele (Subject II-2), although 
none of these children were clinically affected. Furthermore, we analyzed all members 
of both families for the presence of 4qA or 4qB alleles. In both families, the FSHD-sized 
alleles were observed in the 4qA variant of the 4qsubtelomere.All10-typearraysalsohybri
dizedwithprobe 4qA and the translocated 60-kb 4-type allele in family B.
Discussion
In this study, we demonstrate that compound heterozygosity for FSHD-sized alleles 
is compatible with life in men and women by describing two independent cases. 
Complementary molecular and cytogenetic approaches confirmed that in both patients 
these FSHD-sized alleles reside on chromosome 4 and, more specifically, on chromosome 
4qA, the variant of 4qter that is uniquely associated with FSHD.[12]
Reduced penetrance for FSHD-sized alleles is a prominent feature in the families studied 
here. Apart from the proband in family A, Patient III-1, carrying the 17-kb D4Z4 array, 
is affected, whereas Subject II-11, carrying the 24-kb D4Z4 array, does not have any 
symptoms of FSHD. Likewise, all three children of the proband in family B are not affected 
although carriers of a disease 4qA allele of either 33 kb or 36 kb. These unaffected 
carriers in both families are at ages when the disease usually has manifested itself. 
Penetrance for FSHD based on clinical examination of patients at risk is age dependent 
with estimates between 83% and 95% from age 20 years, with a significantly higher 
penetrance in men than in women.[19,20] 
Nonpenetrance is estimated to be less than 2% after age 50 years and is more likely with 
large fragment sizes (>30 kb).[21]  Interestingly, asymptomatic gene carriers seem to be 
more prominent in some families, and nonpenetrance was even found in carriers of a 25-
kb EcoRI fragment in one of these families.[20] 
We propose that the phenotype in both probands is the result of a dosage effect caused 
by contraction of the D4Z4 repeat array on both 4q35 chromosomes. In family A, the 
presence of a low-penetrant 24-kb allele in addition to the 17-kb allele with normal 
penetrance results in an extremely severe phenotype with contractures and respiratory 
insufficiency. In contrast, in family B, the additive effect of two low penetrant alleles 
causes a normal course of disease, while each of the alleles themselves is not sufficient 
to cause FSHD in the children. In this latter case, it may resemble a recessive mode of 
inheritance. Unfortunately, in this family and in family A, no more relatives were available 
precluding further study of penetrance of the separate alleles. Because an inverse 
relationship has been established between the residual D4Z4 repeat size and the severity 
and progression of the disease,[19,21,22] the penetrance of these alleles may be in part a P
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consequence of their respective repeat array sizes: 17 kb and 24 kb in family A and 33 kb 
and 36 kb in family B. 
Patients with FSHD usually show D4Z4 fragments of <38 kb, whereas healthy control 
subjects normally carry fragments ranging from 38 kb to 300 kb. Nevertheless, D4Z4 
repeat arrays <38 kb were encountered in 3% of 200 control subjects in a Dutch study.
[13]  These arrays are mostly in the upper region of the FSHD array size range. From these 
population studies, we estimate that 1% may be translocated to chromosome 10,[7] 
whereas recent studies demonstrate that these arrays are equally distributed over 4qA 
and 4qB alleles (R. Lemmers, unpublished results). Notably, all arrays residing on 4qA are 
within the highest range of FSHD (38 kb). It is unlikely that the disease is unnoticed in the 
remaining 1% of control subjects carrying such FSHD-sized 4qA allele. Rather, because 
penetrance seems to be related to residual repeat size, the penetrance may be close to 
zero in a substantial proportion of 35 kb to 38 kb-sized repeat arrays.
The presence of low-penetrant alleles may suggest that susceptibility for FSHD is not only 
determined by genetic background as recently demonstrated in the Shanghai population 
(M. Jeanpierre, personal communication) but also by the intrinsic properties of the 
disease allele other than the residual repeat size alone. Recently, it was demonstrated 
that a transcriptional repressor complex binds to D4Z4 and that partial loss of this 
complex leads to the transcriptional upregulation of several genes on 4qter.[23] 
Therefore, other possible epigenetic factors, such as affinity for this repressor complex or 
DNA methylation, may contribute to the severity and progression of the disease.
This study emphasizes the complexity of the genetics of FSHD. Similar cases with 
extended families accessible for examination would be welcomed.
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Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is associated with contractions of the 
D4Z4 repeat in the subtelomere of chromosome 4q. Two allelic variants of chromosome 
4q (4qA and 4qB) exist in the region distal to D4Z4. Although both variants are almost 
equally frequent in the population, FSHD is associated exclusively with the 4qA allele.  
We identified three families with FSHD in which each proband carries two FSHD-sized 
alleles and is heterozygous for the 4qA/4qB polymorphism. Segregation analysis 
demonstrated that FSHD-sized 4qB alleles are not associated with disease, since these 
were present in unaffected family members. Thus, in addition to a contraction of D4Z4, 
additional cis-acting elements on 4qA may be required for the development of FSHD. 
Alternatively, 4qB subtelomeres may contain elements that prevent FSHD pathogenesis.
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Introduction 
Facioscapulohumeral muscular dystrophy (FSHD or FSHD1A [MIM 158900]) is a 
progressive myopathy that is mainly characterized by an often-asymmetric wasting and 
weakness of the facial, shoulder, and upper-arm muscles. FSHD displays a large clinical 
variability in expression and progression and can also present with non-muscular 
features like hearing impairment and subclinical retinovasculopathy.[1]  In severe cases, 
CNS symptoms such as mental retardation and epileptic seizures can be present.[2,3]
In the vast majority of patients, autosomal dominant FSHD is associated with a 
contraction of the D4Z4 repeat in the subtelomere of chromosome 4q. The D4Z4 repeat 
normally consists of a polymorphic array of 11–100 KpnI units, each 3.3 kb in size. In 
patients with FSHD, the D4Z4 repeat is reduced to 1–10 units.[4,5]  A rough inverse 
relationship has been established between the severity and progression of the disease 
and the residual D4Z4 repeat size.[6,7]
A homologous and equally polymorphic repeat is present on chromosome 10q, but 
contractions of this repeat have not been associated with disease.[8-10]  Moreover, 
completely or partially translocated repeats have been identified on chromosomes 4 and 
10 in ~20% of the population.[11,12]  Nevertheless, only small repeats on chromosome 4 
have been reported in patients with FSHD.
The D4Z4 repeat can be visualized on EcoRI-HindIII–double-digested DNA that has been 
hybridized with probe p13E-11 after separation by pulsed field gel electrophoresis 
(PFGE).[4]  This probe recognizes the D4F104S1 locus that lies just proximal to D4Z4 on 
chromosomes 4 and 10. Thus, after hybridization, four fragments will be visualized, two 
from each chromosome. Small sequence variations between chromosome 4–derived and 
chromosome 10–derived repeat units allow differentiation between both chromosomes 
by the use of specific restriction enzymes: chromosome 4–derived units are resistant to 
BlnI and are sensitive to XapI, whereas chromosome 10–derived units have the opposite 
characteristics.[13,9]
There is increasing evidence that the contraction of D4Z4 causes a local chromatin 
alteration as well as the transcriptional deregulation of genes by cis- or transacting 
mechanisms.[14-16]  A change in local chromatin conformation is corroborated by the 
observation that FSHD alleles are hypomethylated at D4Z4.[17]
Apparently, a contraction of the D4Z4 repeat on chromosome 4 is not sufficient to cause 
disease, since FSHD is uniquely associated with only one of the two variants of 4qter. The 
two 4qter alleles (4qA and 4qB) differ by sequence variations distal to D4Z4. Although 
both alleles are almost equally common in the population, FSHD alleles are always of 
the 4qA type.[18,19]  Since, in the control population, both alleles have an equal mitotic 
propensity to rearrange, it was proposed that a functional difference between both 
chromosome ends must explain the unique association of FSHD with 4qA.  P
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However, since these studies were performed using samples from anonymous 
blood donors, we could not exclude the possibility that small D4Z4 repeats on 4qB 
chromosomes are pathogenic. By studying three families (~1% of Dutch patients 
with FSHD) that were ascertained by the unusual observation that all probands were 
heterozygous for an FSHD-sized allele, we here provide strong evidence that 4qB 
chromosomes that carry FSHD-sized D4Z4 repeats do not cause disease. The probes used 
for detailed D4Z4 repeat analysis, as well as their positions in the restriction map  
of chromosomes 4 and 10, are depicted in figure 1.
Figure 1.  Schematic presentation of the telomeric regions of chromosome 10q26 and the two variants 
of chromosome 4q35, 4qA and 4qB. The region distal to D4S2463 shows 98% homology between 
chromosomes 10q and 4q, except for the region distal to D4Z4 on the 4qB variant. Both 4q alleles are 
almost equally present in the population, but FSHD has been associated with only the 4qA variant. 
Chromosome 4–type D4Z4 repeats are depicted as blackened triangles, and the chromosome 10 D4Z4 
repeats are shown as unblackened triangles. The locations of the EcoRI (E) and HindIII (H) restriction sites 
adjacent to D4Z4 are shown, as well as probes p13E-11 (blackened box), 4qB (blackened box), and 4qA 
(unblackened box). Chromosomal assignment depicted in figure 2G–2I makes use of the NotI restriction 
site (N) proximal to the chromosome 4–specific probe B31 (unblackened box).
In the first family (Rf215 [fig. 2A]), the proband (III-1) already had severe symptoms of 
FSHD at the age of 12 years. In addition, he presented with telecanthus, heterochromia 
iridis, and a white forelock, all features of Waardenburg syndrome (WS).[20]   However, 
he had no hypertelorism. The father (II-1), paternal grandfather (I-1), and paternal uncle 
all had a slowly progressing form of FSHD; there was no history of muscle disease in 
the family of the mother (II-2) throughout three generations. Physical and neurological 
examinations of the mother, the maternal uncle (II-3), and the grandmother (I-4) were 
normal. PFGE analysis of the proband (III-1) demonstrated the presence of two BlnI-
resistant D4Z4 repeats of 20 kb and 26 kb. In addition, chromosome 10–derived alleles of 
70 kb and 145 kb were identified on the basis of their sensitivity to BlnI (fig. 2A).
The allelic origin of all D4Z4 fragments was determined on HindIII-digested DNA with 
the use of probes 4qA and 4qB. This showed that the 20-kb repeat was located on a 4qA 
D4Z4 repeat 
1<N<11 units
FSHD
No FSHD
No FSHD
H
H
4q35
qter
10q26 qter
D4Z4
D4Z4
qter
4qA
4qA
4qB
98% Homology
p13E-11
p13E-11
B31
E E H
H
EEN
D4S2463
chromosome, whereas the 26-kb fragment originated from a 4qB allele. As expected, both 
chromosome 10 alleles hybridized with probe 4qA (fig. 2D).
To identify the chromosomal origin of these fragments, NotI-digested DNA was hybridized 
with the chromosome 4–specific probe B31. The chromosome 4–specific probe B31 
recognized the terminal NotI fragment on which D4Z4 resides; this yielded a fragment 
that was 185 kb larger than the observed D4Z4-containing EcoRI-HindIII fragment.[21]
Hybridization of probe B31 with NotI-digested DNA of the proband yielded chromosome 
4–derived fragments of 205 kb (20 kb + 185 kb) and 211 kb (26 kb + 185 kb) (fig. 2G), 
which confirmed the chromosome 4 origin of both of the FSHD-sized D4Z4 repeats.
Segregation analysis demonstrated that the 20 kb 4qA allele was also present in the 
affected family members. Consequently, the 26 kb 4qB allele found in the proband was 
inherited from his healthy mother (II-2). This allele was also present in the unaffected 
grandmother (I-4) and in the unaffected uncle (II-3) of the proband (fig. 2A).
Since mutations in PAX3 have been associated with WS and since the first homeodomain 
of DUX4, a putative gene residing in each D4Z4 unit [22], is highly homologous to that of 
PAX3, we performed a mutation analysis for PAX3 in the proband by PCR amplification of 
all protein-encoding exons, including splice-donor and splice-acceptor sites, followed by 
direct sequence analysis.[23]  No mutations were detected in PAX3 (data not shown).
In the second family (Rf202 [fig. 2B]), the proband (I-2) had been identified as having 
FSHD at the age of 33 years. At the age of 63 years, she presented with typical FSHD, 
including moderate, sometimes asymmetric, weakness and wasting of the facial, shoulder 
girdle, and upperarm muscles. Her husband (I-1) was 64 years old and presented no 
abnormalities on clinical and neurological examination. All daughters (II-1, II-2, and II-3) 
showed a slowly progressing form of FSHD, with mild-to-moderate facial weakness, 
moderate-to-severe asymmetric shoulder girdle weakness, and moderate abdominal 
weakness. All three siblings also suffered from common but unrelated autoimmune 
diseases, including primary hypothyroidism and hypoparathyroidism (II-1); chronic 
aspecific respiratory affections and sarcoidosis (II-2); and ulcerative colitis, sclerotic 
cholangitis, and activated protein C resistance (II-3).
PFGE analysis revealed that all three sisters carried chromosome 4–derived D4Z4 repeats 
of 25 kb and 30 kb and a chromosome 10–derived D4Z4 repeat of 70 kb. In addition, 
individual II-2 carried a chromosome 10 allele of 300 kb, whereas individuals II-1 and II-3 
carried a translocated chromosome 4–type D4Z4 repeat of 45 kb on chromosome 10  
(fig. 2B).
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Figure 2   A–F, Southern blot analysis of samples from three families with FSHD (Rf215, Rf202, and 
Rf207). DNA was double-digested with EcoRI-HindIII (E) and EcoRI-BlnI (B), separated by PFGE, and 
hybridized with probe p13E-11. The FSHD-sized 4qB alleles (unblackened circles) of 26 kb, 30 kb, and 34 
kb, respectively, are underlined (A–C). FSHD-causing 4qA alleles are indicated with blackened circles. For 
allelotyping (4qA/4qB), DNA was digested with HindIII, separated by PFGE, and subsequently hybridized 
with probes 4qA and 4qB (D–F). Marker sizes (in kb) are indicated on the right. A and D, In family Rf215, 
the affected proband (III-1) carried two chromosome 4–type FSHD sized D4Z4 repeats. Allelotyping 
shows that the 20-kb D4Z4 repeat is of 4qA origin and was inherited from the affected father. The 
26-kb D4Z4 repeat was inherited from the healthy mother and is of 4qB origin (D). Furthermore, the 
affected child carried chromosome 10 repeats of 70 kb and 145 kb. Segregation analysis showed that 
the FSHD-causing allele was inherited from the affected grandfather (I-1) and that the nonpathogenic 
short 4qB allele was inherited from the healthy maternal grandmother (I-4) and is also observed in a 
healthy uncle (II-3) of the affected proband (III-1) (A). B and E, In family Rf202, three affected sisters (II-1, 
II-2, and II-3) were identified as carriers of two FSHD-sized D4Z4 repeats. Allele-sizing and allelotyping 
identified a 25-kb 4qA allele and a 30-kb 4qB allele (B and E). The 30-kb 4qB allele was inherited from the 
healthy father (I-1), and the FSHD-causing 25-kb 4qA allele was inherited from the affected mother (I-2). 
Comigrating chromosome 10 alleles of 75 kb in the father are marked with “*1.” The mother carried a 45-
kb chromosome 4–type allele (marked with “*2”), which originated from chromosome 10 (translocated 
chromosome 4–type repeat) and was passed to her daughters II-1 and II-3. C and F, In family Rf207, the 
oldest affected daughter (II-1) carried two FSHD-sized repeats. Allele-sizing and allelotyping identified 
a 27-kb 4qA allele and a 34-kb 4qB allele (C and F). The 34-kb 4qB allele was inherited from the healthy 
father (I-1), and the FSHD-causing 27-kb 4qA allele was inherited from the affected mother (I-2). Further 
analyses show that the FSHD allele in the mother comigrates with a chromosome 10 allele of 27 kb 
(marked with “*3”). G–I, Chromosome assignment of the D4Z4 repeats in three families with FSHD (Rf215, 
Rf202, and Rf207). NotI-digested DNA plugs and the chromosome 4–specific probe B31 were used. The 
NotI fragment is 185 kb larger than the EcoRI-HindIII fragment on chromosome 4. Marker sizes (in kb) are 
indicated on the right. G, The two chromosome 4–derived repeats of 20 kb and 26 kb in the compound 
heterozygous affected proband (III-1) in family Rf215 are visualized at 205 kb (20 kb + 185 kb) and 211 
kb (26 kb + 185 kb). These results show that both FSHD-sized repeats do indeed reside on chromosome 
4. Furthermore, the chromosomal assignment reveals that the chromosome 4–type 75-kb repeat in the 
father resides on chromosome 4 (75 kb + 185 kb = 260 kb), just like the 200-kb repeat in the mother (200 
kb + 185 kb = 385 kb). H, Chromosomal assignment in family Rf202 shows that the two FSHD-sized alleles 
inherited by the three affected sisters (II-1, II-2, and II-3) are both located on chromosome 4. They are 
visualized at 210 kb (25 kb + 185 kb) and 215 kb (30 kb + 185 kb), corresponding to the paternal 25-kb 
repeat and the maternal 30-kb repeat, respectively. The other chromosome 4 alleles from the father and 
the mother are visualized at 281 kb (96 kb + 185 kb) and 240 kb (55 kb + 185 kb), respectively. I, The two 
FSHD-sized alleles in the affected daughter (II-1) of family Rf207 are located on chromosome 4 and are 
visible at 212 kb (27 kb + 185 kb) and 219 kb (34 kb + 185 kb).
Allelotyping performed using probes 4qA and 4qB showed that the 25 kb chromosome 
4–derived repeat resides on 4qA, whereas the 30 kb repeat is located on a 4qB 
chromosome. The pathogenic 25 kb D4Z4 repeat was also identified in other affected 
family members (data not shown). The chromosome 10–derived repeats were recognized 
by probe 4qA, and the translocated 45 kb chromosome 4–derived repeat on chromosome 
10 in individual I-2 was of 4qA origin (fig. 2E). As expected, the affected mother carried 
the 25 kb D4Z4 repeat on 4qA, whereas the healthy father carried the 30 kb 4qB-derived 
D4Z4 repeat.
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After hybridization with probe B31, the chromosomal assignment revealed NotI fragments 
of 210 kb (25 kb + 185 kb) and 215 kb (30 kb + 185 kb) in all three sisters, which 
confirmed the presence of the 25 kb and 30 kb D4Z4 fragments on chromosome 4 (fig. 
2H). In agreement with these findings, hybridization with probe p13E-11 revealed the 
additional chromosome 10 fragments and confirmed that the 45 kb chromosome 4–like 
allele in individuals I-2, II-1, and II-3 is translocated to chromosome 10 (data not shown).
Finally, in the third family (Rf207 [fig. 2C]), the mother (I-2) of the proband was identified 
as having FSHD at the age of 49 years. She showed mild facial weakness, moderate-to-
severe shoulder girdle weakness, and bilateral foot extensor weakness. Her husband had 
no symptoms or signs of FSHD at examination. Her oldest daughter (II-1) had a medical 
history of Klippel-Trenaunay-Weber (KTW) syndrome and presented with mild facial 
weakness and asymmetric weakness and atrophy of the shoulder girdle and foot extensor 
muscles. The youngest daughter (II-2) presented with mild facial and shoulder paresis.
PFGE analysis revealed that patient II-1 carried the familial FSHD allele of 27 kb, which, 
as expected, resided on a 4qA chromosome. In addition, she carried a chromosome 4–
derived repeat of 34 kb of 4qB origin and chromosome 10–derived repeats of 55 kb and 
110 kb (fig. 2F). Again, all chromosome assignments were based on the sensitivity of the 
repeats for BlnI or XapI and were confirmed on NotI-digested DNA, which was hybridized 
with probe B31 (fig. 2C and 2I).
Patient II-1 inherited the disease allele from her affected mother, who also carried a 4qB 
allele of 135 kb and chromosome 10–derived repeats of 27 kb and 55 kb. Thus, the 34 kb 
repeat of 4qB origin was inherited from the healthy father.
Discussion
Heterozygosity or homozygosity for two FSHD-sized D4Z4 alleles is very uncommon (~1% 
in Dutch patients with FSHD). Recently, we described two families in which each proband 
was heterozygous for two D4Z4 repeats <38 kb and presented with a typical FSHD 
phenotype.[24]  In addition, a patient was described who was homozygous for an FSHD 
allele because of consanguinity.[25]  All these alleles were on a 4qA allele/chromosome, 
the subtelomeric variant of 4q that is associated with the disease. It was suggested that 
a dose effect of both alleles might aggravate the disease, although this could not be 
confirmed in the homozygous patient.
In contrast to these patients, the heterozygous individuals reported here had one 
repeat that resided on a 4qA chromosome and another repeat that was located on a 4qB 
chromosome. In these cases, the repeat that comigrates with disease in these families 
resides on the 4qA chromosome, whereas the FSHD-sized repeat on the 4qB chromosome 
is always inherited from a healthy parent. Therefore, the presence of an FSHD-sized D4Z4 
repeat on a 4qB chromosome in five healthy individuals without any myopathic features 
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strongly suggests that contracted D4Z4 repeats on 4qB chromosomes are not associated 
with FSHD. Formerly, we could not rule out the possibility that D4Z4 repeats <38 kb on 
4qB chromosomes might be associated with disease, since these data were derived from 
anonymous blood donors.[18]  However, in the present study, all 4qB repeats are well 
within the FSHD size range, and, despite the fact that nonpenetrance seems to be more 
prominent in the upper size range of the D4Z4 repeat [26,27], some myopathic features 
should have been noted in these individuals if D4Z4 repeats <38 kb on 4qB chromosomes 
cause FSHD. This nonpathogenicity of short D4Z4 repeats on 4qB chromosomes may also 
explain the rare finding of FSHD-sized D4Z4 repeats that do not cosegregate with disease 
in families with unrelated neuromuscular disorders.[28]
It is interesting to note that all heterozygous patients described here showed additional 
diseases that are normally not associated with FSHD. At present, it is unclear whether 
or not these additional diseases are independent of the heterozygosity for FSHD-sized 
alleles on chromosomes 4qA and 4qB. 
All three siblings in family Rf202 suffered from common but unrelated autoimmune 
diseases. A potential autoimmune mechanism in the muscle pathology of FSHD has 
long been debated. In at least 40% of biopsies, inflammatory infiltrations with a T-cell 
repertoire different from that in patients with myositis or other muscular dystrophies 
can be seen in the muscle of patients with FSHD.[29]  In addition, a few cases have been 
reported in which the onset of FSHD seems to be related to the onset of a viral infection 
or vaccination.[30,31]
The index patient in family Rf207 had KTW syndrome. KTW syndrome is commonly 
sporadic and might be a genetic condition. Putative loci, including the recently discovered 
susceptibility gene VG5Q [32], are not related to the FSHD locus. Nevertheless, it is 
interesting that both KTW syndrome and FSHD have been suggested to be caused by a 
similar disease model involving transcriptional derepression of essential disease genes.
[33]
Patient III-1 in family Rf215 showed several features common to WS, which is often 
caused by mutations in the transcription factor PAX3.[34,35,20]  Nevertheless, we did 
not find evidence of the presence of mutations in the PAX3 gene in this patient, although 
the mutation detection strategy does not exclude the presence of large exonic deletions, 
intronic mutations, or mutations affecting PAX3 gene transcription regulation. PAX3 and 
its orthologue, PAX7, are involved in muscle differentiation during embryogenesis and in 
adult muscle regeneration [36], and their homeodomains are closely related to the first 
homeodomain of the FSHD candidate gene DUX4. Although expression analyses of DUX4 
have failed to identify its gene product, evidence of the DUX4 protein was recently found 
in myoblast cultures of patients with FSHD.[37]  It is tempting to speculate that ectopic 
expression of DUX4 may have caused this WS-like phenotype, but this hypothesis cannot 
be pursued, since muscle biopsies from this patient are currently unavailable.
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This study demonstrates that D4Z4 repeats <38 kb that reside on chromosome 4qB do 
not cause FSHD. Therefore, in addition to a contraction of D4Z4, additional cis-acting 
elements on 4qA may be required for the development of FSHD. Alternatively, 4qB 
subtelomeres may contain elements that prevent FSHD pathogenesis. Regardless of the 
exact mechanism, this study demonstrates that common subtelomeric polymorphisms 
can be of importance to the development of human disease. Since large variant alleles 
also exist for other chromosome ends [38-41], it will be interesting to study their role in 
common diseases that are often associated with subtelomeric rearrangements, such as 
idiopathic mental retardation.[42]
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Abstract
Background: Patients with facioscapulohumeral muscular dystrophy (FSHD) show a 
contraction of the D4Z4 repeat array in the subtelomere of chromosome 4q. This D4Z4 
contraction is associated with significant allele-specific hypomethylation of the repeat. 
Hypomethylation of D4Z4 is also observed in patients with phenotypic FSHD without 
contraction of D4Z4 and in patients with the immunodeficiency, centromeric instability, 
and facial anomalies (ICF) syndrome, an unrelated disease that does not present with 
muscular dystrophy and is in part caused by DNMT3B mutations. 
Methods: In order to identify the gene defect and to find the pathogenetic epigenetic 
pathway in phenotypic FSHD, we have aimed to identify the differences and 
commonalities in phenotypic FSHD and ICF by 1) investigation of DNA methylation 
of non-D4Z4 repeat arrays, 2) analysis of mitogen-stimulated lymphocytes to detect 
pericentromeric abnormalities involving chromosomes 1, 9, and 16, 3) determination 
of IgA, IgG, and IgM levels, and 4) mutational analysis of candidate genes to identify a 
second disease locus involved in the pathogenesis of phenotypic FSHD.
Results: Our results do not show epigenetic or phenotypic commonalities between 
phenotypic FSHD and ICF other than the earlier observed D4Z4 hypomethylation. We 
could not identify any mutations in the candidate genes tested for. 
Conclusion: Our data suggest that in phenotypic FSHD hypomethylation is restricted 
to D4Z4 and that phenotypic FSHD and ICF do not share a defect in the same molecular 
pathway.
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Introduction
Autosomal dominant facioscapulohumeral muscular dystrophy (FSHD) presents with 
progressive muscular weakness and wasting of the face, shoulders, and upper arms.
[1]  FSHD is caused by contraction of the polymorphic macrosatellite repeat D4Z4 on 
the subtelomere of chromosome 4q.[2]  In patients with FSHD, this contraction is always 
associated with a specific variant of chromosome 4, termed 4qA.[3,4]  
Few patients with FSHD, referred to as patients with phenotypic FSHD, show normal-sized 
D4Z4 repeats on both chromosomes 4. Interestingly, in both 4q-linked and patients with 
phenotypic FSHD, the D4Z4 repeat shows reduced levels of DNA methylation. The D4Z4 
hypomethylation is more prominent and present on both chromosomes 4 in phenotypic 
FSHD, whereas in 4q-linked FSHD it is restricted to the disease chromosome.[5]
Low methylation levels of D4Z4 are also found in patients with the immunodeficiency, 
centromeric instability, and facial anomalies (ICF) syndrome.[6]  Patients with ICF 
syndrome have recurrent respiratory and gastrointestinal infections, as a result of 
a reduction in serum immunoglobulin levels. Further, because of decondensation 
of juxtacentromeric heterochromatin regions, characteristic rearrangements of 
chromosomes 1, 9, and 16 are found in phytohemagglutinin-stimulated lymphocytes 
of these patients. Patients with ICF show a wide variety of facial anomalies but do not 
present any myopathic symptoms.[7]
ICF syndrome is caused in 60% of patients by mutations in the DNA methyltransferase 
gene DNMT3B.[8,9]  Mutations in the catalytic domain of DNMT3B reduce its 
methyltransferase activity, resulting in hypomethylation of the classic repeat arrays 
satellite 2 (Sat2) and satellite 3 (Sat3), the NBL2 repeat, and the D4Z4 repeat.[8]  
Approximately 40% of patients do not have mutations in DNMT3B (ICF2). Nevertheless, in 
patients with ICF2, these repeats are also hypomethylated in addition to hypomethylation 
of α-satellite DNA.[10]  
As patients with phenotypic FSHD and patients with ICF share an epigenetic hallmark, 
we hypothesized that a more genome-wide impairment of DNA methylation, as seen in 
ICF, may explain the pathogenesis of phenotypic FSHD. To determine whether phenotypic 
FSHD is caused by a defect in the same molecular pathway as ICF, we compared patients 
with phenotypic FSHD and patients with ICF at the phenotypic and the epigenetic level.
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Figure 1   Seven Dutch families with phenotypic facioscapulohumeral muscular dystrophy (FSHD) 
included in the study 
 Closed circles/squares represent affected individuals; open circles/squares represent unaffected family 
members. All patients were referred under the diagnosis of FSHD on a clinical basis and all patients and their 
relatives were examined by one of the authors (M.W., G.P.) familiar with FSHD, as represented in the figure by x. 
Family 1 consists of three patients (1.1, 1.2, and 1.3) and two nonaffected family members (1.4 and 1.5). Family 
member 1.5 showed an asymmetric mouth and her eyelashes on the right side did not disappear while closing 
her eyes tightly, which was insufficient clinical certainty of FSHD. Family 2 consists of an affected sibling pair 
(2.3 and 2.4) and two healthy parents (2.1 and 2.2); the mother in this family also shows D4Z4 hypomethylation 
but no muscular symptoms. Patients 3.1 and 3.2 have the same family name and grew up in the same region of 
the Netherlands. The parents of both patients lost contact with their family, but they are possibly related to each 
other. Patient 3.1 showed disputable signs of facial weakness and weakness of the right shoulder girdle muscles 
weakness without wasting. Family members of Patient 3.2, such as his affected father, were not available for our 
examination. In Family 4, one individual is affected (4.2), while his two brothers are unaffected (4.1 and 4.3). 
Both Families 5 and 6 consist of an affected child (5.2 and 6.2) and an unaffected parent (5.1 and 6.1). Patient 5.2 
previously presented with a scapuloperoneal syndrome and at age of examination his pelvic girdle muscles were 
affected as well. Family 7 consists of an affected (7.2) and an unaffected (7.1) brother. 
 
Methods
Subjects. Seven Dutch phenotypic FSHD families were included in this study (figure 
1). Families 1, 2, and 3 were reported earlier on basis of their D4Z4 hypomethylation.
[5]  The other families are reported here for the first time. Although D4Z4 methylation is 
not very low in Families 6 and 7, these families were included on basis of their FSHD-like 
phenotype. All patients were referred under the diagnosis of FSHD on a clinical basis 
and all patients and their relatives were examined by one of the authors (M.W. and G.P.) 
familiar with FSHD. For this study, DNA was not available for all clinical examined family 
members.
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The clinical diagnosis of FSHD is based on asymmetric weakness and atrophy of the 
facial and shoulder girdle muscles with early scapular winging and elevation of the 
scapula when trying to anteflex the arms. Focal involvement of the deltoid muscle, 
severe and often asymmetric upper arm weakness, early involvement of abdominal 
muscles, and asymmetric weakness of the foot-extensors is present in more advanced 
disease.1 Patients with phenotypic FSHD are patients with the clinical diagnosis of FSHD 
but without contraction of the D4Z4 repeat array. A muscle biopsy was performed in 
all families, except Family 4 (table 1). The biopsies showed mild aspecific dystrophic or 
nonspecific myopathic findings as varying of muscle fiber diameter with no indications 
of specific myopathies such as acid maltase deficiency or inclusion body myositis. Most 
biopsies were performed at a time when extensive immunohistochemistry was not 
available. Genetic testing or immunobiochemical analysis in muscle tissue to exclude 
dominant or recessive limb girdle dystrophies was performed in two patients (table 1). 
Family members were assigned as nonaffected when they did not show any symptoms 
or signs of FSHD on examination at 20 years or older. A summary of the clinical findings, 
including clinical severity scores, and D4Z4 allele sizes and D4Z4 methylation levels of 
all individuals is presented in table 1.[11,12]  All phenotypic FSHD cases showed normal-
sized D4Z4 alleles, as determined by pulsed field gel electrophoresis.[13]  
Genomic DNA was isolated from peripheral blood lymphocytes using a standard salt 
extraction protocol.[14]  DNA from a patient with 4q-linked FSHD (C1) and a nonaffected 
relative (C2) were included as negative controls. Also, DNA was isolated from both ICF 
type 1 (I1) and ICF type 2 (I2) EBV-transformed lymphoblastoid cell lines (LCLs) as positive 
controls.
 
Southern blot analysis using methylation-sensitive restriction enzymes. Digestions were 
performed using the following restriction enzymes: Eco52I, Bsp119I, HhaI, and HpaII (MBI 
Fermentas, Germany). For HpaII digestion, its non-methylation-sensitive isoschizomere 
MspI (MBI Fermentas, Germany) was used as a control for complete digestion. In short, 
2 μg of genomic DNA was digested with 20 units of the appropriate restriction enzyme 
according to the manufacturer’s specifications. DNA digests were separated on a 0.8% 
agarose gel and blotted overnight on a hybond-XL membrane (Amersham Bioscience, 
Piscataway, NJ). Probes were labeled by random priming with [32]P-dCTP using the 
Megaprime DNA labeling system (Amersham Pharmacia Biotech, Piscataway, NJ). The 
probes targeted against the NBL2 repeat and the α-satellite repeats on chromosomes 3, 
9, 11, 13/21, 16, and 18 were obtained through standard PCR, followed by ligation of the 
PCR products into the pCR2.1-TOPO vector and transformation of the vector into Top 10 
chemically competent E coli (Invitrogen Carlsbad, CA). The primers for the NBL2 probe 
were described previously, whereas the primers for the various α-satellite repeats were 
designed using Primer3 software (Whitehead Institute for Biomedical Research) based 
upon the probes used in earlier studies.[6,15]  Primer sequences are available upon 
request. For sequence verification, all probes were sequenced by the Leiden Genome 
Technology Center (LUMC, Leiden, The Netherlands). The oligonucleotide probes for 
classic satellites 2 and 3 were as described previously.[10]  Hybridizations were carried  
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out overnight at 65 °C with 100 μg/mL fish sperm DNA (Roche, Basel, Switzerland) in 
formamide hybridization mixture, except for the hybridization with the NBL2 probe, which 
was performed in NaPi/PEG/ SDS hybridization mixture.[16]  After washing in SSC/SDS 
buffers with a diminishing gradient, digestion patterns were visualized using a phosphor-
imaging screen (Storm, Amersham Bioscience). For the Sat 2 and Sat 3 oligonucleotide 
probes, hybridization and washing was carried out at 45 °C in SSPE/SDS buffer.
Pericentromeric abnormalities involving chromosomes 1,9,and16. Cytogenetic analysis 
was performed on lymphocytes from peripheral blood cultures after stimulation with 
phytohemagglutinin for 96 hours. A minimum of 50 GTG-banded metaphases were 
examined for pericentromeric abnormalities.[17]  
Hypogammaglobulinemia. White blood cell counts and morphologic differentiations were 
performed on a hematology analyzer (Advia, Bayer). The immunoglobulins (IgG, IgA, and 
IgM) were quantified by an Immage nephelometer from Beckman Coulter. All reagents 
were obtained from Beckman Coulter. Immunophenotyping studies were performed on 
heparinized blood specimens. Immune fluorescent staining was performed on 100 μL 
whole blood with fluorochrome-labeled antibodies against CD3, CD4, CD8, CD19, CD56, 
and CD45. All antibodies were purchased from Beckman Coulter (Miami, FL), except CD56 
(Becton, Dickinson and Company, San Jose, CA). Next, all erythrocytes were lysed for 10 
minutes in the dark by means of icecold 155 mM NH4Cl (pH 7.4) according to the lyse/
no wash method. Staining of cells was determined in four-color analysis using a Beckman 
Coulter Epics XL flow cytometer (Beckman Coulter, Hialeah, FL). All measurements were 
performed on a minimum of 50,000 cells. Data (collected in list mode) were analyzed 
using the EXPO32 ADC software (Beckman Coulter). 
Table 2  Candidate genes for phenotypic facioscapulohumeral muscular dystrophy
UniGeneID Gene name Function Chromosome
Hs.202672 DNMT1 Maintenance DNA methyltransferase 19p13.2
Hs.515840 DNMT3A de novo DNA methyltransferase 2p23
Hs.643024 DNMT3B de novo DNA methyltransferase 20q11.2
Hs.592165 DNMT3L Stimulation of DNMT3B 21q22.3
Hs.459049 MTHFS Component of folate cycle 15q24.3
Hs.594444 LMNA Component of nuclear lamina 1q21.2-q21.3
Hs.368410 CBX2 Component of the PRC1 complex 17q25.3
Hs.632724 CBX5 Component of heterochromatin 12q13.13
Hs.522639 SUV39H1 Histone methyltransferase Xp11.23 
 
The coding regions of several candidate genes playing a role in chromatin structure were sequenced inthree 
patients with phenotypic facioscapulohumeral muscular dystrophy.
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Mutational analyses of candidate genes. The coding regions of several candidate genes 
for phenotypic FSHD were sequenced (table 2). Each exon was amplified by PCR using 
primers in flanking introns. Primer sequences are available upon request. PCR was 
performed for 35 cycles using SilverStar DNA polymerase (Eurogentec, Seraing, Belgium) 
in 1.5 mM MgCl2 PCR buffer (pH 9.0). After an initial denaturation at 94 °C for 3 minutes, 
PCR cycles were as follows: 40 seconds at 94 °C, 40 seconds at 55 °C, and 1 minute 
at 72 °C, to be concluded with a final extension at 72 °C for 5 minutes. Sequencing 
reactions were performed by the Leiden Genome Technology Center (LUMC, Leiden, The 
Netherlands).
Statistical analysis. Independent-sample t tests were performed to compare serum IgG, 
IgA, and IgM levels between the patients with phenotypic FSHD and their nonaffected 
family members (p < 0.05 was considered as significant).
Results
Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD. To determine 
whether an overall impairment of DNA methylation in repeat arrays is also present 
in phenotypic FSHD, the non-D4Z4 repeats known to be hypomethylated in ICF were 
investigated by Southern blot analysis using methylation-sensitive restriction enzymes. 
The methylation status of the NBL2 repeat, the classic satellite repeats Sat2 and Sat3, 
and the α-satellite DNA repeat on chromosomes 3, 9, 11, 13/21, 16, and 18 was studied in 
three Dutch phenotypic FSHD families, both in patients and their healthy relatives (figure 
1; Families 1, 2, and 3). As a negative control, the methylation status from a 4q-linked 
FSHD patient and a nonaffected relative were studied. As a positive control, DNA of two 
patients with ICF (both ICF1 and ICF2) was included in the study. 
Significant hypomethylation of the NBL2, Sat2, and Sat3 repeat arrays was only detected 
in the two patients with ICF, while hypomethylation of the α-satellite DNA repeat array 
was restricted to the patient with ICF2, as reported previously.[10]  Non-D4Z4 repeats 
were not hypomethylated in patients with phenotypic FSHD. Their methylation levels 
were comparable to their unaffected family members and the patient with 4q-linked 
FSHD and a nonaffected relative. In figure 2, results of the NBL2 Southern blot analysis 
for Families 1 and 2 and the α-satellite on chromosome 11 Southern blot analysis for 
Families 2 and 3 are shown. All results, including the results for the other repeat arrays, 
are summarized in table 3.
No heterochromatic abnormalities involving chromosomes 1, 9 and 16 inphenotypic 
FSHD. To search for pericentromeric abnormalities in patients with phenotypic FSHD, 50 
phytohemagglutininstimulated lymphocyte metaphases were studied for the presence of 
characteristic rearrangements involving chromosomes 1, 9, and 16. 
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All members of the seven phenotypic FSHD families, including the nonaffected relatives, 
were studied. Abnormalities involving the heterochromatic regions of chromosomes 
1, 9, and 16, such as whole-arm deletions, pericentromeric breaks, multibranched 
chromosomes, isochromosomes, and translocations that can be found in patients with 
ICF, were not detected in either patients with phenotypic FSHD or their healthy family 
members.[7]  
Figure 2   DNA methylation analysis in families with phenotypic facioscapulohumeral muscular 
dystrophy (FSHD) 
 
(A) NBL2 Southern blot analysis in phenotypic FSHD Families 1 and 2. Numbers in figure correspond with 
numbers in figure 1. NBL2 repeat array is only significantly hypomethylated in I1, a patient with ICF1. (B) 
α-satellite on chromosome 11 Southern blot analysis in phenotypic FSHD Families 2 and 3. Numbers in figure 
correspond with numbers in figure 1. α-satellite 11 repeat array is only significantly hypomethylated in I2, a 
patient with ICF2. 
No hypogammaglobulinemia in patients with phenotypic FSHD. Patients with ICF have 
recurrent infections, as a result of hypogammaglobulinemia, a reduction in serum 
immunoglobulin levels (IgG, IgM, and IgA levels) with B cells. To investigate the 
occurrence of hypogammaglobulinemia in patients with phenotypic FSHD, several 
biomarkers, including serum immunoglobulin levels, were measured in blood of all 
patients with phenotypic FSHD included in this study and in their nonaffected relatives. 
The serum immunoglobulin levels were within the normal range in all phenotypic FSHD 
cases; no significant differences within these immunoglobulin levels between patients 
and healthy control individuals were found (figure 3). Also, the other tested biomarkers 
were within normal range in the patients with phenotypic FSHD and no significant 
differences were observed between patients and controls (data not shown). 
A B
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DNMT1, DNMT3A, DNMT3B, DNMT3L, MTHFS, LMNA, CBX2, CBX5, and SUV39H1 are unlikely 
candidate genes for phenotypic FSHD. In search for a second disease locus that may play 
a role in the pathogenesis of phenotypic FSHD, mutational analyses of several candidate 
genes (table 2) with a role in chromatin structure or methyl cycle were performed in 
three patients with phenotypic FSHD from three different phenotypic families (figure 
1; 1.1, 2.4, and 3.2). DNMT1, DNMT3A, and DNMT3B are all genes that encode a DNA 
methyltransferase, either predominantly func¬tioning in maintenance of DNA methylation 
during cell division or acting as a de novo DNA methyltransferase. As mentioned before, 
60% of ICF cases can be explained by the presence of a mutation in DNMT3B.[8]  DNMT3L 
encodes a catalytically inactive DNA methyltransferase. However, by association with 
DNMT3B it can stimulate DNA methylation.[18]  Interestingly, two DNMT3B mutations have 
been reported that do not affect the methylation activity of the enzyme itself, but rather 
diminish the inter¬action with DNMT3L, also leading to the ICF syndrome.[19]  MTHFS 
(5,10-methenyl-tetra-hydrofolate synthetase) catalyzes the transformation of 5-formyl-
tetrahydrofolate to other reduced folates and as such has an important function in the 
initial step of the folate cycle, thus having an influence on DNA methylation.[20]   
Moreover, this gene is located in a candidate interval that was identified some years 
ago in a possible non-4q-linked FSHD family.[21]  The protein lamin A/C, encoded by 
the LMNA gene, is a component of the nuclear lamina, which provides nuclear stability 
and may also interact with chromatin. Mutations in LMNA may lead to several diseases 
affecting a wide variety of organs, such as muscle, fat, bone, nerve, and skin.[22]  More 
importantly, this protein is required for the proper localization of the FSHD 4qter region 
to the nuclear envelope.[23]  As interconnectivity between the Suv39 h-HP1 histone 
methylation system and DNMT3B in mammals was demonstrated before, the exonic 
regions of the genes CBX2 (chromobox protein homolog 2), CBX5 (chromobox protein 
homolog 5), and SUV39H1 (suppressor of variegation 3-9 homolog 1) were screened for 
mutations.[24]  CBX2 is a component of the polycomb repressive complex 1 (PRC1). This 
complex has a function in the maintenance of the transcriptional repressive state of 
genes during development. It acts via chromatin remodeling and histone modification by 
mediating the monoubiquitination of histone H2A.[25]  CBX5, better known as HP1α, is 
an important component of heterochromatin, as it may recognize and bind to histones H3 
and H1.[26]  SUV39H1 is a histone methyltransferase that methylates lysine 9 of histone 
H3. As a consequence, transcriptional repression may occur by the recruitment of the 
HP1 proteins.[27]  In addition to earlier reported single nucleotide polymorphisms (data 
not shown), no mutations were detected in the exonic regions of all abovementioned 
candidate genes, excluding them as likely candidate genes for phenotypic FSHD.
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Table 3   Methylation status of non-D4Z4 repeat arrays (NBL2, Sat2, Sat3, and α-satellite on 
chromosomes 3, 9, 11, 13/21, and 18) in three phenotypic FSHD families
Individual NBL2 Sat2 Sat3 αsat-3 αsat-9 αsat-11 αsat-13/21 αsat-18
C1 + + + + + + + +
C2 + + + + + + + +
I1 - - - + + + + +
I2 - - - - - - - -
1.1 + + + + + + + +
1.2 + + + + + + + +
1.3 + + + + + + + +
1.4 + + + + + + + +
1.5 + + + + + + + +
2.1 + + + + + + + +
2.2 + + + + + + + +
2.3 + + + + + + + +
2.4 + + + + + + + +
3.1 + + + + + + + +
3.2 + + + + + + + + 
 
Numbers in table correspond with numbers in figure 1. + = methylation of repeat; - = significant hypomethylation 
of repeat. 
Figure 3 Serum immunoglobulin levels 
Serum immunoglobulin levels in g/L in patients with phenotypic FSHD and their unaffected family members 
(shown as mean ± SD).
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Discussion
Patients with phenotypic FSHD present with hypomethylation of the D4Z4 repeats similar 
to the D4Z4 hypomethylation observed in patients with the ICF syndrome. Patients with 
ICF do not present a myopathic phenotype. As patients with ICF die at a very young age, 
before the usual onset of FSHD in the second decade of life, this may explain the lack of 
symptoms of muscular dystrophy in these patients. However, the occurrence of severe 
progressive infantile FSHD argues against this explanation. As D4Z4 hypomethylation 
has been found on both 4qA and 4qB chromosome ends of patients with ICF, the lack 
of muscular dystrophy cannot be explained by the specific association of ICF with the 
4qB-type allelic variant.[28]  We therefore aimed to investigate the commonalities and 
differences between FSHD and ICF at the clinical, molecular, and epigenetic level. 
Unlike in 4q-linked FSHD, the hypomethylation found in patients with phenotypic 
FSHD is present on both D4Z4 alleles and not associated with a contraction of the 
D4Z4 repeat array. In a previous study, we identified five phenotypic FSHD cases with 
hypomethylation of D4Z4.[5]  Consistent with 4q-linked FSHD, these patients carry at 
least one 4qA chromosome. In the current study, we identified additional family members 
and independent cases on the basis of their phenotype. With the exception of Individuals 
1.3 and 7.2, all cases with a phenotype consistent with FSHD including rec-ognizable 
facial weakness carry at least one 4qA allele and show hypomethylation of D4Z4, with 
the restriction enzyme FseI being most informative. Individuals 1.5 and 3.1 also have 
4qB-type alleles only, but there was insufficient clinical certainty of FSHD in these cases. 
Individual 1.5 only showed an asymmetric mouth and her eyelashes on the right side did 
not disappear while closing her eyes tightly and Individual 3.1 showed disputable signs of 
facial weakness and weakness of the right shoulder girdle muscles without wasting. One 
individual (5.2) with a distinct scapuloperoneal phenotype and no facial involvement is 
also hypomethylated and carries a 4qA allele. These individuals at the both ends of the 
clinical and genetic spectrum emphasize our inability to clearly define the boundaries of 
the FSHD spectrum. Moreover, the lack of evidence for hypomethylation, most notably in 
Individual 7.2 and to a lesser extent in Individual 6.2, which have a phenotype consistent 
with FSHD, substantiates these issues. 
As patients with phenotypic FSHD and patients with ICF share a similar epigenetic 
hallmark in D4Z4 hypomethylation, we hypothesized that a more overall impairment of 
DNA methylation of specific repeats – as in ICF – may also be observed in phenotypic 
FSHD, providing clues to its pathogenesis. We therefore compared several epigenetic 
and clinical features between patients with FSHD and patients with ICF. Southern blot 
analyses using methylation-sensitive restriction enzymes showed no hypomethylation of 
the NBL2 repeat, Sat2 repeat, Sat3 repeat, and α-satellite repeat on chromosomes 3, 9, 11, 
13/21, 16, and 18 in three phenotypic FSHD families. The lack of hypomethylation of non-
D4Z4 repeat arrays in patients with phenotypic FSHD is in agreement with the absence of 
DNMT3B mutations in these patients. However, in some 40% of patients with ICF, the so-
called patients with ICF2, DNMT3B mutations have not been detected either, leaving the 
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possibility open that both phenotypic FSHD and ICF2 are caused by a defect in the same 
gene or same molecular path-way.[9]  Considering the very different clinical symptoms 
observed in phenotypic FSHD and ICF, the additional hypomethylation of several repeat 
arrays may well explain these phenotypic differences. However, at this moment, little is 
known about how mutations in the DNMT3B gene and how hypomethylation of several 
repeat arrays can cause the phenotype observed in patients with ICF. ICF-specific 
deregulation of several genes having a role in immune function was reported. However, 
these changes cannot be explained by significant differences in promoter methylation.
[29] 
Compared to the Sat2 repeat, Sat3 repeat, and α-satellite repeat, D4Z4 is of a different 
type, being a non-satellite repeat. Besides the D4Z4 repeat array, NBL2 is the only 
other non-satellite repeat that is reported to be hypomethylated in ICF, making perhaps 
NBL2 the most interesting target for investigation in phenotypic FSHD. However, no 
hypomethylation of the NBL2 repeat array was observed in patients with phenotypic 
FSHD. Since D4Z4 hypomethylation is more prominent in patients with ICF compared to 
patients with phenotypic FSHD, this could also be the case for the NBL2 repeat array. As 
Southern blot analysis using methylation-sensitive restriction enzymes is usually not very 
sensitive to determine hypo-methylation, the NBL2 repeat array was also studied with 
sodium-bisulphite PCR sequencing (data not shown). However, the results from this assay 
were comparable to the results obtained by Southern blot analysis; no hypomethylation 
of the NBL2 repeat was detected in patients with phenotypic FSHD. 
In addition to the comparative analysis of patients with phenotypic FSHD and patients 
with ICF at the epigenetic level, two studies were performed to compare these patients 
at the genotypic and phenotypic level. As D4Z4 hypomethylation is more subtle in 
phenotypic FSHD compared to ICF, subclinical values with relation to pericentromeric 
abnormalities and serum immunoglobulin levels could have gone unnoticed in patients 
with phenotypic FSHD. However, examination of 50 GTG-banded metaphases in each 
patient with phenotypic FSHD revealed no pericentromeric abnormalities. Further, serum 
immunoglobulin levels and other immunologic biomarkers were within normal range in all 
phenotypic FSHD cases and no significant differences between patients with phenotypic 
FSHD and healthy control individuals were identified. These results suggest that there is 
little or no phenotypic overlap between FSHD and ICF, not even at the subclinical level. 
Therefore, it seems very unlikely that both conditions are caused by a disturbance in the 
same molecular pathway. 
Finally, no mutations were detected in the exonic regions of the genes DNMT1, DNMT3A, 
DNMT3B, DNMT3L, MTHFS, LMNA, CBX2, CBX5, and SUV39H1, making them less likely 
candidate genes for phenotypic FSHD. However, since only the exonic regions of these 
genes were analyzed in this study, intronic mutations affecting splicing and mutations in 
the promoter region remain possible. Before studying this in more detail, more substantial 
evidence for the involvement of one of these candidate genes and the occurrence of 
phenotypic FSHD has to be generated. P
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In this study, we showed that the hypomethylation seen in patients with phenotypic 
FSHD is restricted to the D4Z4 repeat array. Apart from the D4Z4 hypomethylation, no 
further commonalities between patients with phenotypic FSHD and patients with ICF 
were identified, either at the epigenetic level or at the phenotypic level. At this moment, 
the cause of the D4Z4 hypomethylation in FSHD, both 4qlinked and phenotypic, remains 
unknown. As hypomethylation of D4Z4 has also been observed in non-penetrant gene 
carriers, we hypothesize that D4Z4 hypomethylation is necessary but not sufficient to 
explain the occurrence of FSHD.[5]  Apparently, other, possibly epigenetic, factors at D4Z4 
differ between FSHD and ICF and as such control for the development of FSHD. For future 
research, the mechanism of D4Z4 methylation needs to be investigated in more detail to 
identify candidate genes that may be disrupted in phenotypic FSHD. 
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Abstract
Objective: An observational cross-sectional study was conducted in a national 
facioscapulohumeral muscular dystrophy (FSHD) expertise center to estimate the 
penetrance of FSHD1 and to evaluate phenotype–genotype correlations.
Methods: Ten FSHD1 probands carrying 4-9 D4Z4 units alleles and 140 relatives 
were examined. All 150 participants were genetically characterized, including D4Z4 
methylation levels in the mutation carriers. Mutation carriers were classified as  
(1) symptomatic: with symptoms of muscle weakness on history and muscle FSHD signs 
on examination; (2) asymptomatic: without symptoms of muscle weakness but with 
muscle FSHD signs on examination; and (3) non-penetrant: without symptoms of muscle 
weakness on history and without muscle FSHD signs on examination. We assessed the 
relationship between age-corrected clinical severity score and repeat size, sex and D4Z4 
methylation levels.
Results: The maximum likelihood estimates of symptomatic and those of symptomatic 
plus asymptomatic FSHD showed that penetrance depends on repeat size and increases 
until late adulthood. We observed many asymptomatic carriers with subtle facial 
weakness with or without mild shoulder girdle weakness (25% [17/69]). Nonpenetrance 
was observed less frequently than in recent population studies (17% [12/69]), and most 
asymptomatic patients reported some shoulder pain. D4Z4 methylation tended to be 
lower in moderately to severely affectedmutation carriers with 7 or 9 repeats.
Discussion: This family-based study detected a lower overall nonpenetrance than 
previously observed, probably due to many asymptomatic mutation carriers identified 
by careful examination of facial and shoulder muscles. The recognition of asymptomatic 
mutation carriers is essential for selection of participants for future trials, and the 
likelihood estimates are helpful in counseling.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD) type 1 (MIM 158,900) is one of the most 
common inherited adult muscular dystrophies characterized by progressive, often
asymmetric muscle weakness.[1,2]  FSHD is in most cases associated with a contraction 
(1–10 units) of the polymorphic D4Z4 macrosatellite repeat in the chromosome 4q 
sub- telomere. This leads to the production of the transcription factor DUX4 with 
numerous downstream myotoxic effects leading to muscular dystrophy.[3,4]  In control 
individuals, the D4Z4 array ranges between 11 and 100 units, a size range in which the 
D4Z4 embedded DUX4 gene is repressed by CpG methylation and other epigenetic 
modifications. DUX4 derepression in FSHD is caused either by a contraction to 1–10
D4Z4 units on a 4qA-specific FSHD-permissive haplotype (FSHD1) or by mutations in 
D4Z4 chromatin repressors SMCHD1 or DNMT3B in combination with a moderately sized 
D4Z4 repeat (11-20 units) on a 4qA allele (FSHD2).[5-7]  FSHD-permissive 4qA haplotypes 
are defined by the presence of a polymorphic DUX4 polyadenylation signal, which is 
necessary for DUX4 RNA stabilization in somatic tissue. Clinically, FSHD1 and FSHD2 are 
largely indistinguishable.[8]
In the premolecular era, estimation of penetrance of FSHD was based on clinical 
diagnostic criteria and examination of large pedigrees, which, in retrospect, were FSHD1 
families. Disease presentation was considered age-dependent with almost complete 
(>95%) penetrance by the age of 20.[1,9]  These studies showed an approximately equal 
distribution of affected and nonaffected sibs in completely examined large sibships. 
With autosomal dominant inheritance and a 50% chance of carrying the mutation, this 
left little room for nonpenetrance. However, selected families were fairly large, with 
many sibs with clinically evident FSHD, as the authors were interested in linkage studies. 
Furthermore, follow-up genetic studies showed that patients in these studies carried 
mutations with moderate D4Z4 contractions (4-8 units). This selection bias is likely to 
have contributed to the assumed high penetrance by the age of 20.
More recent genetic studies have shown penetrance to be incomplete even at older 
age, with nonpenetrance of 32%-53% dependent on repeat size and degree of kinship.
[10–14]  In addition, a recent study in the general population has shown a 1%-2% 
prevalence of a contracted D4Z4 repeat on a permissive 4qA haplotype without an FSHD 
family history.[5,15]
 
Together, these studies point to a role for additional causative (epigenetic) mechanisms 
contributing to developing FSHD1. This is supported by the observation that very large 
pedigrees of this apparently nonlethal disease are less common than would be expected 
based on the high mutation frequency and the high prevalence of the permissive haplo- 
type.[16]  One of these epigenetic mechanisms includes the degree of D4Z4 methylation, 
which was not assessed in the population studies discussed above.[10-14]  Our recent 
studies have shown that D4Z4 methylation significantly correlates with repeat size, but P
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is also likely to be modified by variants of known and unknown chromatin modifiers, 
especially affecting the severity in individuals with repeats of 8–10 units.[3,5,7,17]
We performed a cross-sectional, observational single-center study in 10 families with 
at least 2 affected family members, encompassing 10 probands and 140 first-, second-, 
and third-degree relatives. We aimed to estimate penetrance for FSHD1 for different 
repeat lengths and ages. Different from other population studies, we distinguished 
between (1) mutation carriers with muscle symptoms on history and muscle FSHD signs 
on examination (symptomatic carriers); (2) mutation carriers without muscle symptoms 
but with muscle signs of FSHD on examination (asymptomatic carriers); and (3) mutation 
carriers without muscle symptoms on history and without muscle FSHD signs on 
examination (nonpenetrant carriers). In addition, we assessed the relationship between 
age-corrected clinical severity score (CSS) and repeat size, sex, and D4Z4 methylation 
levels.
Methods
Standard protocol approvals, registrations, and patient consents. The study protocol was 
approved by the local medical ethics committee and informed consent was obtained from 
all participants (CMO 2001/031).
Outcome measures. The primary outcome measures were the maximum likelihood 
estimates of symptomatic and symptomatic plus asymptomatic FSHD. The secondary 
outcome measures were the relationships between age-corrected CSS and repeat size, 
sex, and D4Z4 methylation levels.
Patients. We recruited 11 genetically confirmed FSHD1 probands from families with at 
least 2 adult affected members. This excluded probands with D4Z4 repeats <4 units as 
they are frequently unique cases. One family with compound heterozygous contracted 
D4Z4 allele was excluded, resulting in 10 probands. We aimed to examine all available 
adult first-, second-, and third-degree family members irrespective of their clinical 
condition by home visits. Obligate mutation carriers not included in this study were 
defined as family members with genetically confirmed FSHD (in a diagnostic setting) or 
family members with offspring with genetically confirmed FSHD, both of whom were not 
able or willing to participate.
Clinical evaluation. All participants filled out a questionnaire on symptoms and signs of 
FSHD, including age at onset, initial and current weakness of facial, shoulder, and pelvic 
girdle, and foot extensor muscles. They were also questioned about other symptoms 
and their medical history and medication use. All participants were examined by the 
same well-trained observer (M.W.). Mutation carriers were classified as “symptomatic,” 
“asymptomatic,” and “nonpenetrant” as defined above. Muscle FSHD signs included 
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both weakness and atrophy and related signs (incomplete forceful eye closure “signe 
de cils,” scapular winging, poly hill sign, horizontal axial folds, and Beevor sign).[2,18] 
Facial weakness was scored as 0–2: 0 = no weakness; 1 = moderate weakness; 2 = severe 
weakness of the orbicularis oculi or oris muscles or the zygomaticus major muscles. 
Shoulder and pelvic girdle and foot extensor muscles were tested using manual muscle 
testing. In addition, subtle shoulder girdle weakness was specifically tested by repetition
of slowly lowering the arms forwards and sideward (after maximal shoulder anteflexion 
and abduction). Clinical severity was also scored using the CSS and the age-corrected
CSS.19 When a discrepancy was found between clinical observation and the genetic test, 
participants were evaluated by a second observer (G.W.P.) who was blinded for these 
results.
Genetic testing. All participants were analyzed for D4Z4 repeat size, haplotype, and D4Z4 
methylation. Genomic DNA was isolated from peripheral blood mononuclear cells and 
detailed analysis of the D4Z4 repeat sizes and haplotype on chromosomes 4 and 10 
was done by pulsed field gel electrophoresis (PFGE) and PCR as described.[20]  Further 
haplotype analysis was done by Southern blot hybridization with probes A and B and 
by analysis of simple sequence length polymorphism according to previously described 
protocols.[20]
 
Repeat array sizes ranging from 20 to 60 kb (4–16 units) were accurately determined 
using a modified PFGE program specific for fragment sizes between 5 and 75 kb and 
by adding a 5-kb molecular weight marker to each lane of the genomic DNA samples 
(Bio-Rad, Hercules, CA, 170–3,624).[17]  D4Z4 methylation was established at the FseI 
restriction site in the most proximal unit of the 4 D4Z4 repeat arrays as described 
previously.[6]  We used the delta1-methylation value, which is the difference between the 
predicted D4Z4 methylation level based on the repeat size and the observed methylation 
level.[17]  Control individuals and mutation carriers with an FSHD allele shorter than 7 
units generally have delta1-methylation values between -10% and +10%. For mutation 
carriers with 7-10 unit FSHD alleles, the delta1-methylation value is more variable, which 
has been suggested to contribute to the variation in clinical severity.[17,21]  For FSHD2 
patients, delta1-methylation values typically range between -21% and -45%.
Estimation of penetrance and genotype – phenotype correlations. The demographic, 
clinical, and genetic data were recorded as variables in a SPSS database (SPSS version 
22, SPSS, Chicago, IL). Symptomatic mutation carriers had a self-reported age at onset 
preceding the age at examination. The age at onset of asymptomatic FSHD was unknown; 
by definition, it precedes the age at examination (age at onset is interval censored, type 
I). Nonpenetrant mutation carriers have an unknown age at onset that is always later than 
the age at examination (right- censored).
We determined the maximum likelihood estimates of the penetrance of symptomatic 
and symptomatic plus asymptomatic FSHD for 5, 6, 7, 8, and 9 D4Z4 units (from up 
to down) for age (figure 1). This represents the likelihood of reported symptoms by a P
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patient at a certain age (symptomatic mutation carriership) and of reported symptoms 
by patients or observed signs by the neurologist at a certain age (symp- tomatic and 
asymptomatic mutation carriership). Both penetrances were modeled as Cox regression 
models with a Weibull baseline distribution and the logarithm of the number of D4Z4 
units as a covariate. We estimated the unknown measures in the model by maximizing 
the conditional likelihood (by means of a grid search); the likelihood is conditional on the 
ascertainment event to correct for the selection of families (at least 2 known symptomatic 
mutation carriers).
 
The analysis thus (1) corrected for the selection of families with at least 2 known 
symptomatic mutation carriers; (2) distinguished for different repeat lengths with a 
presumed correlation to disease severity; and (3) took into account the unknown age 
at onset of asymptomatic mutation carriers. No correction for other factors that may 
influence disease severity (environmental, methylation, and epigenetic factors) was 
included. The R-code and mathematical calculations can be obtained on request by the 
corresponding author (Nicol Voermans, unpublished data, December 22, 2017).
Correlation between repeat length and age-corrected CSS was calculated with the 
Spearman correlation coefficient. We assessed the relationship between age-corrected 
CSS and repeat size, sex, and delta1-methylation value by linear re- gression analysis 
(without correction for other environmental and epigenetic factors that may influence 
CSS). The delta1-methylation value of mildly and severely affected patients (age-
corrected CSS <50 and age-corrected CSS ≥50) was visualized in a graph.
Figure 1 Penetrance of each contraction size
Total number of FSHD1 allele carriers grouped by repeat size in units and sorted by clinical status (symptomatic, 
asymptomatic and non-penetrant mutation carriers).
97654
0
2
4
6
8
10
12
N
um
be
r 
of
 p
er
so
ns
D4Z4 units
14
16
18
Symptomatic 
carriers
Asymptomatic 
carriers
Non-penetrant 
mutation carriers
135
Data availability. Anonymized data not published within this article will be made 
available by request from any qualified investigator.
Results
Participants. We studied 10 families and invited 197 family members (95 males). The 
pedigrees of these 10 families are shown at the end of this chapter on page 146-155. 
Forty-seven family-members (29 males) were not able to participate for various reasons 
(living abroad, having lost contact with their family, or not willing to participate). Three of 
them were obligate mutation carriers. Hence, ten probands (5 males) and 140 relatives 
were included (66 males), resulting in an inclusion rate of 76%. The median age was 44.5 
years (range 18-85 years) (table 1: features of FSHD mutation carriers; table 2: distribution 
of mutation carriers and non-carriers by D4Z4 allele size in units).
Genetic analysis identified 69 FSHD1 mutation carriers (28 male), of which 40 were 
symptomatic (10 probands [5 male] and 30 relatives [11 male]), 17 were asymptomatic (8 
male), and 12 were nonpenetrant (4 male). This corresponded with a false-negative rate 
of the clinical assessment of 13% (12/89). In 4 nonmutation carriers, we observed mild 
asymmetrical weakness of the facial (n = 2) or shoulder muscles with shoulder pain (n = 
2). These 4 participants were incorrectly scored by both examiners as asymptomatic with 
a CSS of 1 or 2 (CSS 1: facial weakness only; CSS 2: mild scapular weakness; no limitations 
of abduction or elevation; often asymptomatic). One of them was diagnosed before with 
idiopathic adhesive capsulitis of the shoulder, and one with rheumatoid arthritis. The 
other 2 showed very subtle facial weakness. Hence, the false-positive rate of clinical 
assessment for detection of the carrier status was 5% (4/81) (table 3: results of clinical 
assessment and genetic analysis). The pedigrees of these 10 families are deposited in 
Dryad (Data Dryad Digital Repository, doi:10.5061/dryad.cj4c2s1).
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Table 1 Features of FSHD1 mutation carriers (symptomatic, asymptomatic and non-penetrant) 
Features of FSHD mutation carriers (age 18 and above) N=69
Sex Male n=28 (41%)
 Female n=41 (59%)
Age Median 44.5
Age at onset (patient reported; symptomatic patients only, n=40) Median 20.0 
 (range 8-60)
Symptomatic mutation carriers n = 40 (58%)
Asymptomatic mutation carriers n= 17 (25%)
Non-penetrant mutation carriers n= 12 (17%)
Repeat size (units) (range) 4 - 9
Repeat size (kB) (range) 20 - 38
Delta1-methylation value (range) -29.9 - 11,3
Ta
bl
e 
2 
 D
is
tr
ib
ut
io
n 
of
 m
ut
at
io
n 
ca
rr
ie
rs
 a
nd
 n
on
-c
ar
ri
er
s 
by
 D
4
Z4
 a
ll
el
e 
si
ze
 in
 u
ni
t
 
 
 
 
 
D
4
Z
4 
Fa
m
il
y 
In
vi
te
d 
N
on
- 
Pa
rt
ic
ip
an
ts
 
N
on
-c
ar
ri
er
s 
C
ar
ri
er
s 
N
on
-p
en
et
ra
nt
 
A
sy
m
p
to
m
at
ic
 
Sy
m
p
to
m
at
ic
 
 
un
it
s 
nu
m
b
er
 
su
bj
ec
ts
 
p
ar
ti
ci
p
an
ts
 
(n
um
b
er
 
(n
um
b
er
 
(n
um
b
er
  
ca
rr
ie
rs
 (n
um
b
er
 
ca
rr
ie
rs
 (n
um
b
er
 
ca
rr
ie
rs
 (n
um
b
er
 
 
 
 
 
 
m
al
es
) 
m
al
es
) 
m
al
es
) 
m
al
es
) 
m
al
es
) 
m
al
es
) 
 
4 
20
6 
1
2 
(3
) 
4 
(0
) 
8 
(3
) 
3 
(1
) 
5 
(2
) 
0 
0 
5 
(2
)
 T
ot
al
 
20
6 
12
 (3
) 
4 
(0
) 
8 
(3
) 
3 
(1
) 
5 
(2
) 
0 
0 
5 
(1
0
0%
) (
2)
 
5 
20
2 
25
 (7
) 
5 
(3
) 
20
 (4
) 
11
 (4
) 
9 
(0
) 
0 
0 
9 
(0
)
 
5 
20
3 
23
 (1
3)
  
 9
 (4
) 
1
4 
(9
) 
6 
(3
) 
8 
(6
) 
0 
1 
(0
) 
7 
(6
)
 T
ot
al
 
20
2-
20
3 
4
8 
(2
0)
 
14
 (7
) 
34
 (1
3)
 
17
 (7
) 
17
 (6
) 
0 
1 
(6
%
) (
0)
 
16
 (9
4%
) (
6)
 
6 
20
5 
15
 (6
) 
4 
(2
) 
11
 (4
) 
6 
(2
) 
5 
(2
) 
0 
 
0 
5 
(2
)
 
6 
20
7 
17
 (7
) 
1 
(1
) 
16
 (6
) 
9 
(3
) 
7 
(3
) 
0 
5 
(2
) 
2 
(1
)
 
6 
20
8 
47
 (2
7)
 
1
4 
(1
1)
 
33
 (1
6)
 
20
 (1
0)
 
13
 (6
) 
4 
(2
) 
6 
(4
) 
3 
(0
)
 T
ot
al
 
20
5-
20
8 
79
 (4
0)
 
19
 (1
4)
 
6
0 
(2
6)
 
35
 (1
5)
 
25
 (1
1)
 
4 
(1
6%
) (
2)
 
11
 (4
4%
) (
6)
 
10
 (4
0%
) (
3)
 
7 
20
1 
17
 (1
0)
 
3 
(3
) 
1
4 
(7
) 
9 
(5
) 
5 
(2
) 
1 
(0
) 
1 
(0
) 
3 
(2
)
 
7 
28
9 
8 
(5
) 
0 
8 
(5
) 
5 
(3
) 
3 
(2
) 
0 
 
1 
(1
) 
2 
(1
)
 T
ot
al
 
20
1-
29
8 
25
 (1
5)
 
3 
(3
) 
22
 (1
2)
 
14
 (8
) 
8 
(4
) 
1 
(1
3%
) (
0)
 
2 
(2
5%
) (
1)
 
5 
(6
2%
) (
3)
 
9 
20
9 
21
 (1
1)
 
4 
(4
) 
17
 (7
) 
9 
(5
) 
8 
(2
) 
4 
(0
) 
2 
(1
) 
2 
(1
)
 
9 
21
0 
1
2 
(6
) 
3 
(1
) 
9 
(5
) 
3 
(2
) 
6 
(3
) 
3 
(2
) 
1 
(0
) 
2 
(1
)
 T
ot
al
 
20
9
-2
10
 
33
 (1
7)
  
7 
(5
) 
26
 (1
2)
 
12
 (7
) 
14
 (5
) 
7 
(5
0%
) (
2)
 
3 
(2
1%
) (
1)
 
4 
(2
9%
) (
2)
To
ta
l 4
-9
 
 
19
7 
(9
5)
 
47
 (2
9)
 
15
0 
(6
6)
 
81
 (3
8)
 
6
9 
(2
8)
 
12
 (1
7
%
) (
4)
 
17
 (2
5%
) (
8)
 
4
0 
(5
8%
) (
16
)
 
 
In
vi
te
d 
su
bj
ec
ts
 t
hr
ou
gh
 t
he
 p
ro
b
an
d 
(p
ar
ti
ci
p
an
ts
 p
lu
s 
no
n
-p
ar
ti
ci
p
an
ts
); 
p
ar
ti
ci
p
an
ts
: i
nv
it
ed
 f
am
il
y 
m
em
b
er
s 
p
ar
ti
ci
p
at
in
g 
in
 t
he
 s
tu
d
y;
 n
on
-p
ar
ti
ci
p
an
ts
: 
in
vi
te
d 
fa
m
ily
 m
em
be
rs
 n
ot
 p
ar
ti
ci
pa
ti
ng
 in
 th
e 
st
ud
y;
 o
bl
ig
at
e 
m
ut
at
io
n 
ca
rr
ie
rs
: n
on
-p
ar
ti
ci
pa
nt
s 
w
it
h 
a 
D
4
Z4
 c
on
tr
ac
ti
on
. N
on
-c
ar
ri
er
s:
 f
am
ily
 m
em
be
rs
 w
it
h 
a 
D
4
Z4
 c
on
tr
ac
ti
on
 o
f >
10
un
it
s,
 c
ar
ri
er
s:
 f
am
ily
 m
em
be
rs
 c
ar
ry
in
g 
a 
co
nt
ra
ct
ed
 D
4
Z4
 a
ll
el
e 
se
gr
eg
at
in
g 
in
 th
ei
r f
am
ily
. S
ym
pt
om
at
ic
 c
ar
ri
er
s:
 m
ut
at
io
n 
ca
rr
ie
rs
 
w
it
h 
sy
m
pt
om
s 
an
d 
si
gn
s 
of
 F
SH
D
, a
sy
m
pt
om
at
ic
 c
ar
ri
er
s:
 m
ut
at
io
n 
ca
rr
ie
rs
 w
it
ho
ut
 s
ym
pt
om
s 
bu
t w
it
h 
si
gn
s 
of
 th
e 
di
se
as
e.
 N
on
-p
en
et
ra
nt
: m
ut
at
io
n 
ca
rr
ie
rs
 
w
it
ho
ut
 s
ym
pt
om
s 
an
d 
w
it
ho
ut
 s
ig
ns
 o
f F
SH
D
.
136
137
Clinical evaluation. The variation in estimated age at onset based on the recollection was 
large (median 20.0; range 10–60 years). Shoulder girdle weakness was the most frequent 
initial and current symptom (85%; 34 of the 40 symptomatic mutation carriers) (table 
4: characteristics of individual patients). Pain, both chronic and episodic, was reported 
by 33 of the 40 symp- tomatic carriers, predominantly in shoulder, neck, and lower back 
region. Strikingly, 10 of the 17 asymptomatic carriers spontaneously reported shoulder 
girdle pain. Eight of these 10 had mild weakness of the shoulder girdle muscles (asym- 
metrical movement of the scapula); the other 2 young female patients only had mild facial 
weakness.
 
The questionnaires on concomitant diseases and medication use showed no 
malignancies, and no remarkable other comorbidity or medication use. Four female 
mutation carriers reported worsening of the weakness after pregnancies or after 
menopause, and 2 mutation carriers reported a positive effect on muscle weakness when 
taking oral contraceptives. However, the number of female mutation carriers was too 
small to analyze correlation with hormonal effects.
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Table 3 Results of clinical assessment and genetic analysis 
	 Clinical	 Clinical	 Total	#	of	patients
 assessment:  assessment: non-penetrant
 wihout signs signs of FSHD  asymptomatic,
 of FSHD (non- (asymptomatic + and sympto- 
 penetrant FSHD) symptomatic FSHD) matic FSHD
 Genetic test:    False 
negative    positive 
(numer of patients,  77 4 81 clinical
 [repeat length     assessment: 
> 10 D4Z4 units])    4/81 (5%)
 Genetic test:  
positive
 (number of patients, 12 57 69 
[repeat length   
1-10 D4Z4 units])  
 Total	#	of	patients 
negative and 89 61 150 
pasitive test  
 False  
 negative  
 clinical  
 assessment:  
 12/89 (13%)   
Figure 2 Mild FSHD features on examination in an asymptomatic patient
At rest Pursing of lips showing 
asymmetry of the orbicularis 
oris muscle
Forceful closing of eyes: the 
eyelashes do not disappear:
”signe de cils”
Figure 3 Maximum likelihood curves of the penetrance
Figure 3 shows the maximum likelihood estimates of the penetrance of symptomatic (3A), and symptomatic 
and asymptomatic FSHD (3B) for 5,6,7,8 and 9 D4Z4 units (from up to down) for age. This represents the 
likelihood of reported symptoms by the patient at a certain age (3A: symptomatic mutation carriership) and of 
reported symptoms by the patients or observed signs by the neurologist at a certain age (3B: symptomatic and 
asymptomatic mutation carriership). Both penetrances were modeled as Cox regression models with a Weibull 
baseline distribution and the logarithm of the number of D4Z4 units as a covariate.
Figure 3A: carriers with 8 repeats have a 20% (0.198) chance of being symptomatic at age 70. 
Figure 3B: carriers of repeat size of 8 units have only a 24% (0.236) chance of being detected by clinical 
examination at age 30, which is in agreement with our clinical experience. These likelihood estimates are helpful 
in counseling; however, the number of patients on which the estimates are based calls for cautiousness.
(A) Maximum likelihood estimates of penetrance of symptomatic FSHD (both symptoms + signs). 
(B) Maximum likelihood estimates of penetrance of symptomatic plus asymptomatic FSHD (only signs and both 
symptoms and signs).
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Results of clinical examination are shown in table 2; overall, 40 mutation carriers were 
symptomatic (58%), 17 asymptomatic (25%; 26% in 4–6 units; 23% in 7–9 units), and 
12 had neither symptoms nor signs of muscle weakness (nonpenetrant FSHD) (17%; 9% 
in 4–6 units; 36% in 7–9 units). The median CSS was 3 (range 0–9); the median age-
corrected CSS was 94 (range 0–273).
Relatives with symptomatic muscle weakness who attributed this to other disorders or 
aging were considered symptomatic. For example, we observed a carrier with unilateral 
foot drop and a carrier with a camptocormia, both with mild facial and shoulder girdle 
weakness. The asymptomatic mutation carriers were generally mildly affected (CSS 1–2) 
and all had at least mild facial weakness (figure 2). We did not observe any mutation
carriers with shoulder girdle weakness without facial weakness.
Genetic testing. The disease allele size varied from 4 to 9 D4Z4 units (20–38 kb). Seven of 
the 12 nonpenetrant carriers were from 2 families carrying a 9-unit repeat. Interestingly, 
6 asymptomatic carriers and 4 nonpenetrant carriers were found in family Rf208 with a 5 
units repeat length. Mean age of these nonpenetrant carriers was 24.8 years (range 19–30 
years), whereas the mean age of the asymptomatic carriers in this family was 43.0 (range 
21–56 years). D4Z4 methylation levels were assessed in 66 mutation carriers and were 
variable with a delta1-methylation value range of −29.9 to 11.3.
Table 3A Maximum likelihood estimates of penetrance of symptomatic FSHD (both symptoms + signs).
 Repeat Median age Maximum likelihood estimates
 units of onset (years) of penetrance at age
   30 40 50 60 70
 5 25.5 0.602 0.782 0.895 0.955 0.983
 6 48.7 0.257 0.389 0.517 0.632 0.730
 7 84.0 0.108 0.172 0.244 0.319 0.396
 8 - 0.049 0.079 0.115 0.155 0.198
 9 - 0.024 0.039 0.057 0.078 0.101
 
Table 3B:   Maximum likelihood estimates of penetrance of symptomatic plus asymptomatic FSHD (only 
signs and both symptoms + signs).
 Repeat Median age Maximum likelihood estimates
 units of onset (years) of penetrance at age
   30 40 50 60 70
 5 16.8 0.908 0.988 0.999 1.000 1.000
 6 25.0 0.640 0.849 0.953 0.989 0.998
 7 34.9 0.394 0.604 0.775 0.890 0.953
 8 46.7 0.236 0.392 0.552 0.695 0.808
 9 60 0.144 0.251 0.372 0.497 0.615
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Estimated penetrance and genotype – phenotype correlations
The maximum likelihood estimates of the penetrance for symptomatic and symptomatic 
plus asymptomatic mutation carriers showed that penetrance depends on age and repeat
size (figure 3, A and B). We observed a moderate correlation between the age-corrected 
CSS and the size of the FSHD allele (R = −0.48 [p < 0.01]; figure 4A). We detected large 
differences between individual delta1-methylation values. Reduced methylation tended 
to be associated with a more severe phenotype (age-corrected CSS >50) in the carriers  
of the large size FSHD alleles (9 units) (figure 4B). Linear regression analysis confirmed  
this trend for methylation; in contrast, sex did not contribute to age-corrected CSS  
(β coefficients: −0.55 [p < 0.001], −0.224 [p = 0.06], −0.11
Family 210 is a family with a 9-unit D4Z4 allele. Three of the 6 mutation carriers in this 
family were clinically affected, 2 of whom had strongly reduced delta1-methylation 
valuespointing to severe D4Z4 hypomethylation (patient 201: −28.4 and patient 212: 
–29.9). This suggested the presence of D4Z4 methylation modifiers. Indeed, genetic 
studies identified a pathogenic DNMT3B variant causing D4Z4 hypomethylation in this 
family.[7]
Figure 4A   Correlation between the size of 
the FSHD allele in units and the 
age-corrected CSS. R =- 0.48 
(P<0.01) (Spearman rho).
Ü  Mutation carriers with DNMT3B variant
Figure 4B   D4Z4 methylation (delta1-methylation 
value) and clinical severity (dichotomized 
age-corrected CSS) for each repeat length. 
For each repeat array size, we binned the 
mutation carriers based on their age-
corrected CSS (< 50: mild disease severity; 
≥ 50: moderate – severe disease severity). 
For carriers of a 9-unit repeat, more severe 
disease tended to be associated with a lower 
delta1-methylation value (p = 0.06). 
	
	
Figure 4 Genotype – phenotype correlations
141
P
ar
t 
IV
   
- 
  C
h
ap
te
r 
9 
A
 f
am
il
y-
b
as
ed
 s
tu
d
y 
in
to
 p
en
et
ra
n
ce
 i
n
 F
SH
D
1
Table 4 Characteristics of individual patients
  Family 206 (n=5)
        CSS 
 Nr M/F D4Z4  FseI delta1 AAE AAO (status) ACSS F S  E P
 307 M 4 43 2.7 45 10 5 (S) 111 R R R  
 204 F 4 43 5.2 71 20 8 (S) 113 L L LR LR
   206 * M 4 28 0.5 55 15 7 (S) 127 R R R R
 316 F 4 26 -6.0 29 15 7 (S) 241 L R R R
 208 F 4 26 -10.6 53 15 6 (S) 113 R R   LR
  Family 202 (n=9)
        CSS 
 Nr M/F D4Z4  FseI delta1 AAE AAO (status) ACSS F S  E P
 406 F 5 39 4.3 41 20 5 (S) 122 R LR R  
 306 F 5 41 1.0 73 50 2 (S) 27 R R R  
   308 * F 5 29 -8.3 70 15 8 (S) 114 R R R R
 414 F 5 48 5.9 42 20 4 (S) 95 R R LR  
 310 F 5 45 7.7 68 20 8 (S) 118 L R LR R
 312 F 5 46 8.7 63 15 7 (S) 111 R R LR R
 422 F 5 31 3.7 42 20 7 (S) 167 R R R R
 424 F 5 29 -6.1 39 20 6 (S) 154 R R R R
 426 F 5 18 -9.3 35 15 7 (S) 200 R L L L
  Family 203 (n=8)
        CSS 
 Nr M/F D4Z4  FseI delta1 AAE AAO (status) ACSS F S  E P
 305 M 5 28 -4.5 61 35 7 (S) 115 L L LR L
 307  M 5          
   309* M 5 40 1.0 58 30 7 (S) 121 L L L LR
 409 M 5 21 -14.6 33 20 3 (S) 91 R R   
 414 F 5 33 -6.8 30  0 (AS) 0     
 313 M 5 35 -1.8 53 30 6 (S) 113 R L R R
 421 M 5 48 2.7 22 15 4 (S) 182 L L   
 423 M 5 42 -2.1 20 15 3 (S) 150 R R   
 214 F 5 46 11.3 85 60 8 (S) 94 R R LR LR
  Family 205 (n=5)
        CSS 
 Nr M/F D4Z4  FseI delta1 AAE AAO (status) ACSS F S  E P
 403 M 6 NA NA 27 15 3 (S) 111 R R   
 304 F 6 12 -20.1 58 25 5 (S) 86 R R R LR
 408 F 6 15 -13.5 25 20 2 (S) 80 R R   
 203 M 6 28 -6.0 86 40 8 (S) 93 R R LR R
   310 * F 6 22 -9.1 49 10 8 (S) 163 R R L L
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Table 4 continued
  Family 207 (n=7)
        CSS 
 Nr M/F D4Z4  FseI delta1 AAE AAO (status) ACSS F S  E P
   204 * F 6 39 4.8 55 35 8 (S) 145 L L L LR
 308 F 6 33 2.3 32  4 (AS) 125 L L L  
 312 F 6 NA NA 25  2 (AS) 80 R R   
 205 M 6 23 -2.5 51 50 5 (S) 98 R R LR  
 313 M 6 29 -7.1 29  2 (AS) 69  R   
 321 M 6 24 -12.1 20  1 (AS) 50 R    
 324 F 6 33 -2.6 18   2 (AS) 111 L L    
  Family 208 (n=13)
        CSS 
 Nr M/F D4Z4  FseI delta1 AAE AAO (status) ACSS F S  E P
 202 F 6 28 -12.1 60 40 5 (S) 83 R L L  
   204 * F 6 NA NA 58 30 9 (S) 155 L R L LR
 314 F 6 35 -4.7 30  0 (NP) 0     
 206 F 6 41 2.4 56  1 (AS) 18 R R  
 318 F 6 43 1.3 30  0 (NP) 0     
 211 M 6 36 3.2 49  0 (AS) 0     
 327 M 6 30 -9.0 20  0 (NP) 0     
 220 F 6 42 4.6 44 40 3 (S) 68 L R   
 223 M 6 34 -7.4 43  2 (AS) 47 L R   
 225 M 6 38 -1.2 42  2 (AS) 48  R   
 248 F 6 32 -.7 47   2 (AS) 43 R L    
 355 M 6 36 -4.5 21  2 (AS) 95 L L   
 358 M 6 38 -5.2 19  0 (NP) 0     
  Family 201 (n=5)
        CSS 
 Nr M/F D4Z4  FseI delta1 AAE AAO (status) ACSS F S  E P
 309 M 7 18 -20.9 63 40 9 (S) 143 L R R LR
 420 F 7 48 9.5 34  0 (NP) 59 L L   
 422 F 7 38 -.5 32  2 (AS) 0 L    
 314 F 7 38 -6.6 57 25 8 (S) 140 R R LR R
 429 M 7          
   317 * M 7 42 -2.2 53 15 7 (S) 132 R R R LR
  Family 289 (n=3)
        CSS 
 Nr M/F D4Z4  FseI delta1 AAE AAO (status) ACSS F S  E P
 301 M 7 43 6.0 45  3 (AS) 67  L   
 204 F 7 26 -13.2 72 60 1 (S) 14   L    
   309 * M 7 43 5.9 38 30 6 (S) 158 R R R
143
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Table 4 continued
  Family 209 (n=8)
        CSS 
 Nr M/F D4Z4  FseI delta1 AAE AAO (status) ACSS F S  E P
 302 F 9 36 -7.3 31  0 (NP) 0     
 202 F 9 37 -5.4 55  0 (NP) 0     
 204 F 9 31 -3.4 53 45 3 (S) 57  R   
 205 M 9 33 -7.9 52  2 (AS) 38  R   
   209* M 9 26 -8.3 49 40 6 (S) 122 R R R  
 314 F 9 15 -17.7 22  1 (AS) 45 LR    
 212 F 9 36 -1.8 44   0 (NP) 0        
 214 F 9 35 2.5 45  0 (NP) 0     
  Family 210 (n=6)
        CSS 
 Nr M/F D4Z4  FseI delta1 AAE AAO (status) ACSS F S  E P
 201 M 9 6 -28.4 63 40 7 (S) 111 R R LR LR
 303 M 9 29 -6.1 35  0 (NP) 0     
 208 F 9          
   212 * F 9 11 -29.9 52 30 7 (S) 135 R R R R
 316 F 9 32 -7.6 32  2 (AS) 63 L R   
 317 M 9 28 -8.0 30  0 (NP) 0     
 104 F 9 42 -1.7 70   0 (NP) 0        
 
 
Numbers in grey and Italic are obligate carriers who did not participate in this study. The families are orderd 
according to repeat length. 
 
Nr:  pedigree-number corresponding with the supplemental pedigrees.
*:  index patient in pedigree.
M/F:  male/female.
D4Z4:  number of D4Z4 repeat units. 
FseI:  methylation value at the FseI restriction site of 4q +10q alleles [6]. 
delta1:   log2 delta1 (the predicted D4Z4 methylation based on the repeat size and the observed 
methylation) [17]. 
AAE:  age at examination.
AAO:  age at onset of motor symptoms of FSHD.
CSS:  clinical severity score x2.
Status:  S: symptomatic; AS: asymptomatic; NP: non-penetrant.
ACSS:  age-corrected clinical severity score (=CSS/age at onset x 1000) [37].
 
Based on physical examination:
 F: facial weakness.
 S:  shoulder girdle weakness.
 E: foot extensor weakness.
 P: pelvic girdle muscle weakness.
 R: asymmetry of weakness at the right side.
 L: asymmetry of weakness at the left side.
 LR: no distinct asymmetry.
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Discussion
This family-based study on penetrance in 10 probands and 140 relatives showed that 
prevalence of both symptomatic and asymptomatic FSHD1 increases into late adulthood 
(age >60 years) (figure 3, A and B). These maximum likelihood estimates are helpful in 
counseling; however, the number of patients on which the estimates are based calls for 
caution. We found a high percentage of asymptomatic mutation carriers (25% [17/69];
26% in 4–6 units; 23% in 7–9 units). Nonpenetrance of FSHD1 was lower than in recent 
population studies with similar age ranges (17% [9% in 4–6 units; 36% in 7–9 units] vs 
32%–52%), most likely since nonpenetrant FSHD1 and asymptomatic carriership were 
not distinguished in these studies.[10-14,22]  Furthermore, our approach of home visits 
allowed more family members to participate, resulting in inclusion of 76% of all existing 
first-, second-, and third-degree family members.
All asymptomatic mutation carriers showed at least mild, mostly asymmetric, facial 
weakness with or without mild shoulder girdle weakness. This observation challenges the 
concept of facial-sparing FSHD.[23–27]  Mild facial muscle weakness is likely to remain 
unnoticed both by the patient and the physician.[2]  Subtle weakness of the orbicularis 
oculi muscles leads to a “signe de cils”–– an inability to bury the eyelashes completely 
when attempting to close the eyes tightly. Asymmetrical weakness of the orbicularis oris 
muscles causes asymmetrical pursing of the lips (figure 2). This differs from the normal 
facial asymmetry at rest observed in almost all healthy individuals. Hence, facial function 
should be actively tested, not only assessed by inspection during history. Likewise, subtle 
shoulder girdle weakness can be missed when not specifically tested by repetition of
slowly lowering the arms forwards and sideward (after maximal shoulder anteflexion and 
abduction).[2]
We observed a moderate but significant (p < 0.01) inverse correlation between the size 
of the FSHD allele and the age- corrected CSS (figure 4A), confirming previous studies.
[17,28]  In addition, we observed a great variability of D4Z4 methyl- ation, both within 
and between families. Some moderately to severely affected carriers (age-corrected 
CSS >50) of larger FSHD alleles had very low delta1-methylation values (figure4B). Both 
observations are in accordance with previous findings.[17,29-32]  In patients with repeat 
size of 1–5 units, the disease severity was mainly determined by the size of the FSHD 
allele with a minimal role for additional epigenetic factors.[17]  In contrast, in patients 
with 7–10 units, epigenetic regulation of the repeat, reflected in the delta1-methylation 
value, seems to co-determine the severity of FSHD.[17]  Furthermore, in family 210, a 
DNMT3B variant cosegregating with the D4Z4 contraction contributed to the severe D4Z4 
hypomethylation and to clinical severity. Finally, in this family-based study we did not 
find significant sex differences in penetrance or clinical severity.[17]
This study also resulted in some other clinical observations. First, we confirmed a high 
prevalence of pain, especially shoulder pain, even in asymptomatic patients (75% of
symptomatic and asymptomatic patients).[33–36]  Second, the observation of obviously 
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affected mutation carriers who reported no symptoms (family member with foot drop) 
or had a very recent onset (family member with camptocormia) illustrates the fact that 
retrospective estimation of age at onset by patients is not reliable in all cases. We 
therefore prefer use of the age-corrected CCS.[37]  Indirectly, this study confirms that 
carrier status cannot be determined reliably by clinical examination alone (5% false-
positive clinical assessment; 13% false-negative clinical assessment) and that genetic 
testing is required. Furthermore, because of the gray zone of 8–10 repeats, genetic 
testing in families with isolated cases should be counseled carefully as it is uncertain 
whether mutation carriers represent control or nonpenetrant population.
The main limitation of this study is its cross-sectional design. Furthermore, among 
the asymptomatic carriers were patients under the age of 30, who may still be 
presymptomatic. This underscores the need for longitudinal studies in FSHD.
In short, this study showed that penetrance of FSHD continues to increase in adulthood, 
and that nonpenetrance of FSHD is lower than shown in recent population studies. 
Penetrance and severity are related to both the number of residual D4Z4 units and, 
most likely in patients with longer repeats, to D4Z4 methylation. Assessment of family 
members at risk should include questions on shoulder girdle pain and examination of 
forceful eye closure, lip pouting, and inspection of the shoulder muscles after repeatedly 
and slowly lowering maximally abducted and anteflexed arms.
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Summary
This thesis describes a series of studies on facioscapulohumeral muscular dystrophy 
(FSHD). We here present a summary of the main findings of each chapter and 
subsequently discuss these findings and relate them to other studies in the field. 
The primary aim of this thesis was to assess fenotype-genotype correlations in large 
FSHD families and ultimately to unravel aspects of the (epi-)genetic pathophysiology. 
We therefore conducted an observational study with clinical and genetic testing in large 
families with FSHD. The family-based design allowed us to investigate the full clinical 
spectrum of FSHD and focus on intra- and interfamilial variability. In fact, we learned 
most from the ends of this spectrum: we studied some newly recognized clinical features 
of severely affected patients (Part II); the genetic study of large families enabled us to 
unravel important aspects of the (epi)genetic mechanisms of FSHD (Part III); and the 
thorough clinical assessment of these families enabled assessment of penetrance of both 
symptomatic, asymptomatic and non-penetrant mutation carriers (Part IV).
Respiratory insufficiency and dysphagia
Part II of this thesis focuses on two clinical features observed in severely affected 
patients: respiratory insufficiency and dysphagia. 
Assessment of respiratory function in FSHD with use of spirometry is often complicated 
by the air leakage during blowing due to facial weakness; therefore, we developed 
spirometry equipment with a face mask. We compared the face mask and the 
conventional mouthpiece for the measurement of air flow and respiratory pressures 
in 22 healthy subjects.[1](Chapter 2) With the mask, forced vital capacity and forced 
expiratory volume in one second were 200 mL lower, and maximal expiratory pressure 
was 3.2 kPa lower than with the mouthpiece. Subsequently, new prediction values 
for face mask air flow volumes and maximal respiratory pressures were obtained 
in 252 other healthy subjects, from which new prediction equations were derived. 
It was concluded that the face mask connection to the lung function device is a 
valid alternative, is easy to use and is useful to monitor changes in FSHD patients. 
These face mask-adjusted portable lung function devices have been used in our 
neuromuscular clinic since then. The use of a face mask device has also become one of 
the recommendation in the international standards of care and management in FSHD 
patients: “FVC measurements in patients with FSHD should always be performed with 
a full facial mask rather than a mouthpiece to avoid measurement of falsely low values 
from air leakage due to weakness of lip closure”.[2,3]
In chapter 3 we describe the clinical features of FSHD patients on ventilatory support. 
Respiratory insufficiency in FSHD had not yet been reported at the onset of our study. 
As illustrated by case 1, the need for ventilatory support in severely affected FSHD was 
raised by members of the FSHD community. We therefore contacted the four centres 
of home mechanical ventilation in the Netherlands and identified ten FSHD patients 
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on ventilatory support. All patients were visited at home, their clinical characteristics 
examined, and their medical files studied. All patients were severely affected, wheelchair-
dependent and had a moderate to severe kyphoscoliosis. Respiratory insufficiency often 
had a seemingly acute onset in these patients. Retrospectively, however, most patients 
had suffered from symptoms of nocturnal hypoventilation long before they became 
ventilatory dependent and these symptoms improved after the start of ventilatory 
support. We concluded that 1) respiratory insufficiency is rare in FSHD; 2) severely 
affected patients are at risk, especially in case of kyphoscoliosis, and none of the patients 
requiring ventilatory support were still ambulant; and 3) physicians should be aware of 
(nocturnal) hypoventilation and regularly screen its symptoms.
To test the hypothesis that wheelchair-dependency and (kypho-)scoliosis are risk 
factors for developing respiratory insufficiency in FSHD, we subsequently examined 
81 patients with varying degrees of disease severity ranging from ambulatory patients 
to wheelchair-dependent patients (Chapter 4). Even though none of the patients 
complained of respiratory dysfunction, mild to severe respiratory insufficiency was 
found in almost 40% of the wheelchair-dependent patients. Maximal inspiratory 
pressures and especially maximal expiratory pressures were decreased in most patients. 
The greatest impairment in vital capacity was found in wheelchair-bound patients 
with (kypho-)scoliosis. These patients had an earlier onset of disease, an early age of 
wheelchair dependency and smaller D4Z4 repeat sizes. In conclusion, in FSHD1 patients 
severe proximal lower extremity muscle weakness with wheelchair dependency and 
(kypho-) scoliosis are early indicators for respiratory muscles involvement.  
We recommend periodic screening of wheelchair-dependent FSHD patients (with 
(kypho-)scoliosis)), even in the absence of symptoms of respiratory insufficiency, given 
its high prevalence and the therapeutic consequences. These recommendations have 
been included in the international guidelines for patient care in FSHD. 
Ten wheelchair-dependent patients in this study also reported difficulties swallowing. 
Dysphagia carries the risk of aspiration and pulmonary infections, especially in 
patients with pulmonary dysfunction who have reduced coughing strength. However, 
involvement of the lingual and pharyngeal muscles was at that time still considered 
an exclusion criterion for FSHD. We therefore investigated eight of the FSHD patients 
who reported swallowing problems (Chapter 5). We examined them clinically, we 
visualized oropharyngeal swallowing by videofluoroscopy, and performed MRI-images 
of the tongue. We found that these patients with advanced disease showed mild 
involvement of the jaw and lingual muscles. Dysphagia is seldom life threatening in 
these patients. We concluded that dysphagia does occur in FSHD and should not be 
considered an exclusion criterion for FSHD. Referral to a speech therapist experienced 
in neuromuscular diseases is recommended in symptomatic patients.
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Genetic studies
The genetic studies in Part III are initiated by the observation of large clinical differences 
within the FSHD spectrum and focus on genetic and epigenetic factors contributing to the 
disease severity. The results of these studies served as building blocks for the unifying 
genetic model of FSHD presented by Lemmers et al. in 2010.[4] 
Among the patients on ventilatory support one female patient was compound 
heterozygous for two FSHD alleles. She was severely affected and wheelchair dependent 
since the age of 12. So far, homozygosity or compound heterozygosity for FSHD alleles 
had not been observed, and it was debated whether the absence of such subjects was 
because of the rarity or the lethality of the disorder. We reported the family of the patient 
mentioned above and a second, unrelated family in which the probands were compound 
heterozygous for two FSHD-sized alleles (Chapter 6). Clinical examination, PFGE studies 
of DNA with probes proximal and distal to D4Z4, and cytogenetic analysis of metaphase 
chromosomes by FISH were performed. Complementary molecular and cytogenetic 
approaches confirmed the chromosome 4qA-origin of all FSHD-sized repeat arrays 
which segregated with FSHD in the families. We therefore concluded that compound 
heterozygosity for FSHD-sized alleles is compatible with life, both in men and women. 
Furthermore, a possible dosage effect was observed in both probands in which each 
4qA allele contributed to the FSHD phenotype: in the first family, the presence of a 5 
units allele in addition to a 3 units allele resulted in an extremely severe phenotype with 
contractures and respiratory insufficiency; in the second family, the additive effect of 
two contracted alleles caused an intermediate disease severity, while each of the alleles 
themselves was not sufficient to cause FSHD in the children. Since at least one of the 
FSHD alleles in both families was associated with a unusually low disease penetrance, we 
proposed that susceptibility for FSHD is partly determined by intrinsic properties of the 
disease allele other than the residual D4Z4 repeat size alone. With advancing insight in 
permissive alleles we suggested that one of the 4qA alleles in one of the families (Family 
A), the 4qA166 allele is not pathogenic. Further research on these 4qA166 alleles is 
currently taking place; further haplotyping of the 4qA alleles in family B is available.
The next contribution to the unifying genetic model of FSHD consisted of the proof of 
non-pathogenecity of the 4qB allel by segregation analysis (Chapter 7). During the family 
study we encountered some family members with a contracted 4qB allele. By that time 
(2002) two allelic variants of chromosome 4q exist were recognized that differ in the 
region distal to D4Z4 (4qA and 4qB). Although both variants are almost equally frequent 
in the normal population, FSHD alleles are exclusively of the 4qA type.[5]  We identified 
three FSHD families in which each proband carried two FSHD-sized alleles and was 
heterozygous for the 4qA and 4qB allel. Segregation analysis showed that only FSHD-
sized 4qA (and not 4qB) alleles were associated with disease. Therefore, in addition to 
a contraction of D4Z4, additional cis-acting elements on 4qA are required to develop 
FSHD (such as the 4qA alleles that provides a PolyAdenylation Signal (PAS) allowing the 
expression of the most distal copy of the DUX4 gene as turned out later). Alternatively, 
4qB subtelomeres contain elements that prevent FSHD pathogenesis. 
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Furthermore, in FSHD1 the D4Z4 contraction was associated with significant allele-
specific hypomethylation of the repeat. Hypomethylation of D4Z4 was also observed 
in patients with phenotypic FSHD without contraction of D4Z4 and in patients with 
the immunodeficiency, centromeric instability, and facial anomalies (ICF) syndrome, 
an unrelated disease that does not present with muscular dystrophy. In chapter 8 we 
aimed to identify the gene defect and the epigenetic pathways in phenotypic FSHD 
without contraction of D4Z4, and ICF patients by 1) investigation of DNA methylation 
of non-D4Z4 repeat arrays; 2) analysis of mitogen-stimulated lymphocytes to detect 
pericentromeric abnormalities involving chromosomes 1, 9, and 16; 3) determination 
of IgA, IgG, and IgM levels; and 4) mutational analysis of candidate genes to identify a 
second disease locus involved in the pathogenesis of phenotypic FSHD. Our results did 
not show epigenetic or phenotypic similarities between phenotypic FSHD and ICF other 
than the earlier observed D4Z4 hypomethylation. We could not identify any mutations in 
the candidate genes tested. Our data suggested that in phenotypic FSHD (later classified 
as FSHD2) hypomethylation is restricted to D4Z4; that FSHD2 and ICF do not share a 
defect in the same molecular pathway; and that hypomethylation of D4Z4 is not the only 
condition for developing FSHD. Subsequently, hypomethylation of the D4Z4 in FSHD2-
affected families was instrumental in identifying mutations in SMCHD1.[6] 
Family studies
The genetic phenomena studied in Chapter 5 and 6 were observed during our large 
family-based study on FSHD. This study was set up to investigate large families with FSHD, 
similarly as what Padberg had done in the 80s but now with the availability of genetic 
testing. In the pre-molecular era, statistical estimation of penetrance of FSHD was based 
on clinical diagnostic criteria and examination of large sibships. It was considered age-
dependent with almost complete (>95%) penetrance by the age of 20.[2,7,8]  Common 
practice at that time was to exclude the presence of disease when no motor signs were 
observed by the age of 30. In contrast, more recent studies based on genotyping reported 
penetrance to be incomplete even at older age, with non-penetrance of 32%-53% 
dependent on repeat size.[9-13]
The aim of our family-based study was therefore to assess penetrance in a non-selected 
cohort and to unravel aspect of the genetic pathophysiology. Ten FSHD families with a 
least two members carrying 4-9 D4Z4 units alleles were examined. All family members 
were genetically characterized, including methylation values in the FSHD mutation 
carriers. Mutation carriers were classified as (1) symptomatic: with muscle symptoms 
on history and muscular FSHD signs on examination; (2) asymptomatic: without muscle 
symptoms but with muscular signs of FSHD on examination; and (3) non-penetrant: 
without muscle symptoms on history and without muscular FSHD signs on examination. 
We observed many asymptomatic carriers with only subtle facial weakness or shoulder 
girdle weakness (25% [17/69]; 26% in 4-6 units; 23% in 7-9 units), which is in agreement 
with previous reports.[7,8,10]  Most asymptomatic patients reported shoulder pain. 
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Prevalence of non-penetrance was 17%, which is lower than in recent population studies.
[9-13]  The maximal likelihood curves of the penetrance of symptomatic and symptomatic 
plus asymptomatic mutation carriers showed that penetrance depends on repeat size 
and age. Repeat size correlated statistically significantly to age-corrected clinical severity 
score (ACSS).[14]  Only for the long repeats, methylation tended to be lower in moderately 
to severely affected mutation carriers (ACCS≥50) than in those who were only mildly 
affected (ACCS<50).
Non-penetrance was lower (17%) than previously observed. This was probably due to a 
smaller selection bias caused by the home visits and the identification of a larger group 
of asymptomatic mutation carriers (25%) by the experienced eye of the examiners. This 
observation is essential for genetic counseling and for identification of participants for 
future trials. Important lessons learnt are:
1)  Physicians should be aware that absence of motor signs of FSHD in (early) adulthood 
is not an exclusion for carrier-ship of the FSHD mutation; 
2)   Subtle facial weakness and shoulder girdle weakness can easily be overlooked;
3)   Although shoulder pain is frequently encountered in the normal population, our 
results stresses attention for this symptom in families with FSHD;
4)   Penetrance is dependent on age, D4Z4 repeat size and epigenetic factors influencing 
the degree of D4Z4-chromatin relaxation (and hence the D4Z4-repeat size). 
  The pathogenic mechanism is determined by the interaction of the D4Z4-repeat size, 
the presence of a 4qA allel that provides a PAS, and variations in genes that modify 
the D4Z4 epigenetic state. This interaction provides a firm basis for understanding 
reduced disease penetrance in the FSHD population.[15]
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General discussion 
After the summary of my thesis, I will discuss the main findings and potential clinical 
implications and present my suggestions for future research.
Clinical lessons from the severe end of the FSHD spectrum
Respiratory insufficiency. 
At the start of our studies, respiratory insufficiency had been described only in 
few severely affected patients.[16,17]  The prospective study on home mechanical 
ventilation showed that respiratory insufficiency was rare in the Dutch FSHD population 
(approximately 1%). It develops relatively late in the disease course and only in patients 
at the severe end of the FSHD spectrum. Subsequently, we prospectively examined 
the respiratory function in 81 patients to confirm the risk factors identified in this first 
study (severe muscle weakness with wheelchair dependency and kyphoscoliosis). 
Severely affected patients with spine deformities were indeed at risk to develop 
respiratory dysfunction. Moreover, in 39% of the moderately to severely affected 
patients respiratory function was mildly to moderately reduced in absence of symptoms 
of nocturnal hypoventilation. This has implications when considering surgery requiring 
general anaesthesia. 
Over the past years a number of other studies have supported our data. Severe 
respiratory involvement requiring non-invasive ventilation was found in only 1%-3% of 
the patients in two other populations (USA, France).[18,19]  Mild respiratory insufficiency 
occurs in approximately 10% of the FSHD population, and in 40% of the wheelchair 
dependent FSHD patients.[19-22]
The involvement of respiratory muscles (diaphragm, intercostal muscles, and accessory 
muscles of respiration) might be considered as part of the axial involvement of FSHD. 
A recent total body CT study in 70 FSHD patients showed frequent fatty infiltration 
of back extensor muscles, in addition to the involvement of the abdominal muscles, 
emphasizing the extent of trunk involvement.[23]  This was supported by a MRI-study in 
50 FSHD patients that showed significant involvement of paraspinal muscles. In this study 
involvement of paraspinal muscles correlated with D4Z4 repeat size.[24]  Another study, 
focusing on bent spine syndrome in six patients with FSHD, found severe paraspinal 
fat infiltration in these selected patients.[25]  Furthermore, sleep studies in FSHD have 
shown that nocturnal hypoventilation due to respiratory insufficiency is part of a broader 
syndrome of sleep-disordered breathing including obstructive sleep apnoeas syndrome 
(OSAS).[26,27]  This occurs more frequently (14%) than previously thought, even early in 
the disease course.[26]  and needs to be studied in more detail. 
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These findings on respiratory function have contributed to the current FSHD standards 
of care, which recommends baseline screening for respiratory involvement in moderately 
to severely affected patients (Clinical severity score ≥ 6).[2,28]  Annual screening with 
clinical assessment and spirometry is warranted in the subgroup with wheelchair use or 
pelvic girdle weakness. As in other neuromuscular disorders, physicians should actively 
ask for symptoms of nocturnal hypoventilation because they are often not reported 
spontaneously. Measurements should be performed with a facial mask interface, to avoid 
false positive results of hypoventilation due to air leakage around the mouthpiece in 
patients with facial muscle weakness.[1]  Furthermore, in case of severe disease (CSS ≥ 
6) or symptoms or sleep disordered breathing, polysomnography should be included in 
the clinical assessment of patients with FSHD.[2,28]  It is recommended to refer patients 
who do not get regular pulmonary function testing to be tested prior to such surgical 
procedures requiring general anaesthesia, as such testing may reveal asymptomatic 
respiratory restriction.[28]
Further investigation on sleep studies is necessary to estimate the prevalence and 
characteristics of sleep disorders in general including obstructive and central sleep 
apnoeas syndrome in FSHD using polysomnography. Moreover, the mechanisms behind 
these observations needs to be studied.
Dysphagia
For long, dysphagia was neglected as part of the symptoms in FSHD and impairment 
of swallowing was even considered an exclusion criteria for FSHD.[2,29]  In 2001 a 
series of 151 Japanese FSHD patients was published, including seven early-onset FSHD 
patients (5%) with an dystrophic tongue, two of whom had difficulty swallowing.[30] 
Subsequently, we showed that also adult-onset FSHD patients with prominent facial 
muscle weakness reported mild dysphagia and had mild involvement of the jaw and 
lingual muscles. Dysphagia was no longer considered an exclusion criterion for FSHD. The 
recruitment of patients was biased, hindering a proper estimation of the prevalence of 
dysphagia.
Succeeding studies have confirmed our findings. In a study on pharyngoesophageal 
function in 20 patients with FSHD at various stages of disease, patients did not 
spontaneously report complaints of deglutition.[31]  However, when specifically 
asked, five patients reported intermittent oropharyngeal dysphagia (difficulty to 
initiate swallowing, cough after swallowing, sensation of food stuck in the throat, or 
nasal regurgitation), and three patients reported intermittent esophageal dysphagia 
(difficulty swallowing both liquids and solids). Using conventional cineradiography 
and intraluminal esophageal manometry the reported and observed minor esophageal 
dysmotility did not meet the criteria for dysphagia and was not related to the severity 
of muscular dystrophy.[31]  Furthermore, in a study of nine early-onset FSHD patients 
two had swallowing difficulties for which one required a gastrostomy.[32]  Statland and 
Tawil showed that difficulties swallowing were reported in approximately 10% of the 
population in the US FSHD registry in 2014; these symptoms were not further specified. 
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In a recent, observational study by the same authors, 13 of 41 patients reported 
swallowing difficulties and had a significantly shorter endurance of tongue muscle 
elevation compared to patients without swallowing difficulties.(Statland 2017 personal 
communication)
Based on these studies and supported by our extensive clinical experience, we conclude 
that swallowing difficulties are not rare in FSHD. We expect that research over the 
last decade will enhance recognition of swallowing problems in FSHD, not only in the 
early-onset cases. We advise to specifically ask for difficulties in speech, chewing and 
swallowing in all patients with facial weakness. In case of reported difficulties, we advise 
referral to a speech therapist with neuromuscular experience for education on effective 
compensation strategies. In conclusion the studies on respiratory function and on 
swallowing have improved patient management and have been incorporated in national 
and international guidelines to improve quality of life (Box 1 and Box 3).
It would be interesting to investigate chewing and swallowing in a larger cohort of 
severely affected FSHD patients, including children focussing on prevalence and 
treatment therapies. Longitudinal data is most important, because of the discussion if 
there is a developmental issue and a dystrophy on top.
Clinical lessons from the mild end of the FSHD spectrum
The symptoms of respiratory involvement and dysphagia highlighted above were 
observed in the most severely affected individuals. The second part of this thesis includes 
important lessons learnt from the mild end of the FSHD spectrum: the high prevalence 
of asymptomatic and non-penetrant mutation carriers and the clinical features in the 
asymptomatic patients. 
High prevalence of asymptomatic and non-penetrant mutation carriers
The family study was set up to estimate the penetrance of FSHD in the light of new data 
on genetics and the onset of methylation studies in 2003. At that time, penetrance 
had been estimated by clinical assessment in large pedigrees only, with the estimation 
of full penetrance of mutation carriers at the age of 30.[7]  These studies showed an 
approximately equal distribution of affected and non-affected sibs in completely 
examined large sibships.[7,33]  With autosomal dominant inheritance and a 50% chance 
of carrying the mutation, this left little room for non-penetrance. More recent genetic 
studies have shown penetrance to be incomplete even at older age, with non-penetrance 
of 32% to 53% dependent on repeat size.[9-13]
To understand the difference between these premolecular and molecularly-based 
studies, we performed a cross-sectional, observational single centre study in 10 families 
with at least two affected family members, encompassing 10 probands and 140 first 
and second degree relatives. We aimed to estimate penetrance for FSHD1 for different 
repeat lengths and ages. In contrast to other population studies, we distinguished 
between (1) mutation carriers with muscle symptoms on history and muscle FSHD P
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signs on examination (‘symptomatic carriers’); (2) mutations carriers without muscle 
symptoms but with muscle signs of FSHD on examination (‘asymptomatic carriers’); and 
(3) mutations carriers without muscle symptoms on history and without muscle FSHD 
signs on examination (‘non-penetrant carriers’). All family members were visited at home 
to facilitate participation and to reduce the selection bias.
Our study showed that the prevalence of both symptomatic and asymptomatic FSHD1 
increases into late adulthood. It is unclear whether the dystrophic process is progressive 
in later life. The maximum likelihood estimates are helpful in counselling, however the 
number of patients on which the estimates are based ask for caution. Different from other 
population studies [9-13], we distinguished between asymptomatic and non-penetrant 
mutation carriers. This resulted in a lower non-penetrance (17%) but high percentage of 
asymptomatic mutation carriers (25%). Indirectly, our study confirmed that carrier status 
cannot be determined reliably by clinical examination alone (5% false positive clinical 
assessment; 13% false negative clinical assessment) and that genetic testing is required. 
Based on our observations and other studies [23] and in line with the FSHD clinical score 
[34], we suggest a set of five tests for screening of asymptomatic relatives in a counselling 
setting (Table 1).
Table 1 Clinical key features of FSHD
  Short physical examination for screening asymptomatic FSHD family members in a counselling 
setting. When ≥ 1 of the tests are positive then there is a risk for carriership.  
Test Result suggestive of FSHD
1.  Forceful closure of the eyes ‘Signe de cils’
2.  Pouting of the lips Asymmetric pouting
3.   Shoulder girdle testing: slowly lowering Asymmetrical scapular winging 
the arms forwards and sidewards maximal  
anteflexion and abduction
4.   Rising from or flexion of the neck Beevor sign [35] 
in supine position
5.   Lower leg / hip girdle testing:  Weakness of knee flexion 
knee flexion in prone position
Subtle shoulder girdle weakness in asymptomatic mutations carriers
Subtle weakness of the shoulder muscles was observed in most asymptomatic carriers. 
Moreover, in our study we did not find mutation carriers with shoulder girdle involvement 
without facial muscles weakness. At examination subtle weakness generally becomes 
visible when slowly lowering the arms after full shoulder anteflexion or abduction.[36] 
Mild shoulder muscle weakness often remains unnoticed, and a winging scapula can 
be missed during a routine neurological examination when the physician only takes an 
anterior view (Table 1).
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Mild facial weakness in asymptomatic mutation carriers
Facial weakness is suggested to be one of the first and most characteristic signs of FSHD.
[7]  Our data support the importance of facial muscles weakness in the clinical diagnosis: 
in some asymptomatic mutation carriers only subtle weakness of the orbicularis oculi and 
oris muscles was visible, presenting with a ‘signe de cils’ when closing the eyes tightly, or 
showing an asymmetrical mouth when pouting the lips.[36]  Importantly, most patients 
are not aware of facial weakness at the time of diagnosis, and it is only occasionally 
presented by the patient as manifesting symptom.[7]  Physicians should proactively ask 
for it and test it (Box 1). The photos below illustrate that facial weakness can be subtle and 
easily missed both by the patient and physician (Figure 1). 
 
Figure 1 Mild facial weakness in FSHD
  This 63-year old patient was diagnosed with FSHD more than 20 years ago, with obvious 
asymmetrical shoulder muscle weakness, a positive family history and carrying a 6 units allele. 
He doesn’t experience diminished facial expression, contrary to other affected relatives. 
The photos show subtle weakness of the orbicularis oculi muscles on the right (‘signe de cils’). 
There is an asymmetrical pouting of the lips, but of dubious significance, showing a wrinkled 
 mouth as can be seen in older age.
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In a recent review in early-onset patients (defined as age of onset < 10 years) 25% of 
patients showed symptoms of facial weakness in the first year of life, mainly resulting in 
feeding difficulties and inadequate eye closure.[37]  Facial weakness is roughly inversely 
correlated to the D4Z4 repeat length. In patients with 1-3 D4Z4 repeats, often early 
onset patients, the facial muscles can be almost completely immobile, in contrast with 
the subtle facial weakness in asymptomatic patients encountered in the family study. 
Moreover the facial muscle weakness in FSHD is predominant congenital and displays 
characteristics of a developmental disorder rather than of a progressive muscular 
dystrophy. Longitudinal studies however are lacking, as is a rating scale for changes in 
facial expression over time. One of the suggestions is that the toxic damage of DUX4 
already affects the facial muscles in utero. In contrast, the weakness in the shoulder girdle 
and the lower extremity gradually increases in the course of the disease.
The concept of facial sparing FSHD however is topic of current debate. Previous reports 
observed facial-sparing in carriers in the longer D4Z4 repeat sizes: 8-10 units,[38] 8 
units and 9 units, [39] and 10 units.[40]  Recently, in a large Chinese cohort 8% facial 
sparing FSHD patients (21/251) was reported.[41]  The D4Z4 repeats ranged from 4-9 
units and > 50% showed mild disease with CSS <3. Felice et al. reported absence of facial 
weakness in 10 patients, even in patients carrying repeats < 8 units (range 5-10 units 
alleles and mean 8 units). At the photos in this publication facial weakness is visible in 
both patients, demonstrating how difficult it is to recognize subtle weakness.[42]. In these 
previous reports, facial sparing was defined as no facial weakness on clinical examination. 
Nevertheless, facial sparing, if it exists, is rare and predominantly occurs in the longer 
repeat sizes, 8-10 units and needs to be studied by ultrasound and MRI.
Future research on facial weakness
A new field of research is the severity and progression of facial weakness and the effect 
of facial weakness on aspects of communication beyond speech. We discuss this shortly 
below. Despite the frequency and relevance of facial weakness in FSHD, studies on the 
progression and consequences of facial weakness are lacking. One of the main issues in 
research on facial weakness, is that there are currently no biomarkers or clinical outcome 
measures available, i.e. facial weakness cannot be measured properly. Since clinical trials 
in FSHD are expected to emerge in the upcoming years, there is now a high need for the 
development of measurement instruments, including objective quantitative measures of 
the degree of weakness, as well as measures on the functional disabilities related to facial 
weakness. The development of quantitative biomarkers that are able to detect differences 
in the degree of facial weakness, together with a patient-reported outcome that measures 
the functional disability associated with facial weakness, will enable future clinical trials 
to include facial weakness as an outcome. A prospective study on facial weakness as 
an outcome measure in trials is in preparation, including 2D and 3D video recording of 
facial movements; quantitative ultrasound of selected facial muscles; and a preliminary 
patient-reported outcome measure on the disabilities related to facial weakness.[43,44] 
All measurements will be repeated after six months, the expected maximum duration of 
clinical trials (Mul 2018 personal communication). 
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Furthermore, even though facial weakness is one of the main symptoms, research 
into the emotional and social consequences is unavailable. Bakker et al. performed a 
qualitative study on the illness experiences of FSHD patients.[45]  In this study, facial 
weakness was mentioned being a major downside, constantly affecting their non-verbal 
communication. Currently, Mu et al is performing a quantitative study on the personal, 
social and emotional consequences of the facial weakness. This research is important for 
several reasons. First of all, there is a quest from the patients part for more awareness 
about this aspect of FSHD. Therefore, initiatives were taken by patient organizations 
to draw attention to this aspect of the disease, in particular to facial weakness and its 
consequences (Lachspierbal 14 september 2018[46]). Moreover, understanding among 
medical professionals of role the reduced facial muscle strength in a FSHD patients life 
needs to improve. Finally, this research will be the beginning for further research into the 
symptomatic treatment and support for the patients.
A next step in research would be to investigate the central adaptation of facial weakness 
by functional and structural cerebral MR studies. Recently, a few brain imaging studies 
have been performed in a much more common cause of (mostly unilateral) facial 
weakness: Bell’s palsy.[47, 48]  Since the natural course of facial weakness of Bell’s 
palsy is essentially different from that of facial weakness in FSHD, these findings cannot 
be applied to FSHD but call for a similar approach in FSHD patients with severe facial 
weakness. 
Shoulder girdle pain 
In addition, our study has shown that both chronic and episodic pain were highly 
prevalent (33 of 40 symptomatic carriers), predominantly in shoulder, neck and lower 
back region. Chronic shoulder pain was also reported by 10 of the 17 asymptomatic 
patients. These results are in accordance with other studies.[49-54]  Bushby et al. 
described four adult patients with FSHD in whom pain was a presenting complaint and 
even remained their most disabling symptom. Furthermore, physicians should be aware 
that pain can be the manifesting symptom in mutation carriers in absence of functional 
motor impairment, as illustrated by case 4 in the introduction.
Although pain in FSHD has been recognised better in recent years, there is much that we 
still do not understand. The recent Dutch guideline advices to assess pain at every visit 
at the clinic by a numeric rating scale (0 to 10), and to distinguish between nociceptive 
and neuropathic pain and central sensitization. Furthermore, pain management should 
be considered when treating FSHD1 patients, but specific expertise on how to approach 
this is limited to expert opinions.[28,54]  Maximal isometric force training and salbutamol 
appear to have no effect on pain.[51]  The effect of surgical fixation of the scapula on 
pain has not been investigated sufficiently.[55,56]  Referral to a physiotherapist or 
rehabilitation centre may prove helpful. The Dutch guideline indeed refers to the general 
guidelines for treatment of chronic pain (NHG standard) for common pain symptoms 
in FSHD, and to the rehabilitation team in the Radboudumc expertise centre for FSHD 
specifically for shoulder pain. Most importantly, there is lack of understanding the P
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basic physiological and biological mechanisms of muscle pain. Cytokines are released 
in pathologically unaffected muscle and they could very be the trigger to start a pain 
cascade in FSHD muscle.[57]  With the new animal model for FSHD this should be an 
important topic of research in the near future.
Future research on pain and pain management in FSHD
The recent Dutch guideline on FSHD focused on topics which were identified by the 
patients: pain, fatigue, mobility, communication and organization of health care services.
(https://www.spierziekten.nl/fileadmin/user_upload/VSN/documenten/
Hulpverlenersinformatie/Richtlijnen/R035-RichtlijnFSHD-2018.pdf) 
This guideline is based on evidence from an extensive literature review and expert 
opinions, and has served as a starting point for e-learnings and information brochures for 
health care providers and patients.
The review identified the following knowledge gaps on pain and pain management  
in FSHD:
• Prevalence of specific causes of shoulder girdle and arm pain;
• Effect of training on pain;
• Effect of use of tape or brace on shoulder pain;
• Effect of use of TENS on shoulder pain;
•  Effect of a multidisciplinary program on managing pain (in parallel with the program 
ENERGIEK focused on fatigue);
• Use of pain medication (FSHD Guideline, Chapter 3, page 22-28).[58]
Following these recommendations for future research, a multidisciplinary study on pain 
management in FSHD is under preparation. Presumed determinants of pain are: reduced 
sleep quality, fatigue, mood disorders and overuse of shoulder girdle muscles. The aim 
of the study would be to reduce pain and to improve participation in daily life. The input 
of the representatives of the patient organisation for the design of this study is crucial. 
We expect to initiate this study in 2019. Another initiative is a future study on the use 
of a shoulder brace in pain management in collaboration with Rehabilitation Centre 
Roessingh.  
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A    Patient with FSHD wearing a custom made 
shoulder brace to improve shoulder position. 
This has resulted in significant shoulder pain 
relief and improved functional abilities of  
upper limb.
B    Example of a shoulder brace.
A B
Figure 2 Example of a shoulder brace 
Large inter- and intra-familial variability within and between families
One of the characteristics of the disease is the large inter- and intra-familial variability 
in disease severity. Various (epi)genetic factors are likely to contribute to this variability. 
In our family study we observed a moderate but significant inverse correlation between 
the size of the FSHD allele and the age-corrected CSS confirming previous studies.[33, 
59,60]  In addition, we observed a great variability of D4Z4 methylation, both within and 
between families. Some moderately to severely affected carriers (age-corrected CSS>50) 
of larger size FSHD alleles had very low delta1-methylation values than mildly affected or 
nonpenetrant carriers [59], which was also found in other studies.[61-63]
Furthermore, sex differences have been observed in different studies, with females being 
less severely affected than males and presenting a higher proportion of asymptomatic 
carriers.[10,64-66]  Little is known about the influence of female hormones on the 
muscular dystrophy. Recently, in vitro studies demonstrated that estrogens improve the 
differentiation properties of FSHD-derived myoblasts by antagonizing DUX4 activity.
[67]  In our study female patients indeed reported hormonal influences; four patients 
experienced worsening of the weakness after pregnancies and after menopause, and two 
patients reported a positive effect on muscle weakness when taking oral anticonceptives. 
Young female patients expressed their fear about difficulties carrying their child after 
delivery and were uncertain about their ability to nurse their baby. However, the number 
of patients (24 symptomatic females of a total of 41 female mutation carriers) was too 
small to draw firm conclusions. Limited data are available from studies on pregnancy 
outcomes in FSHD.[68,69]  In both studies about 25% of the women with FSHD reported P
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subjective, persistent worsening of motor function after pregnancy.[68]  The most 
common complaints were worsening of muscle weakness and worsening or new onset 
pain. This corresponds with what many women report in our neuromuscular clinic.[70] 
Repeat length, methylation level, disease duration, and gender can only partly explain the 
differences in clinical severity. Most likely, other epigenetic and environmental disease 
modifying factors are involved and are presently unknown. This calls for a more extensive 
family study preferably with long-term follow up, also in de asymptomatic and non-
penetrant mutation carriers. Furthermore, natural history studies can provide additional 
insight in the epigenetic and environmental disease modifying factors.
A final lesson is the difficulty of estimation of age of clinical onset of FSHD, which in many 
studies is determined retrospectively. The age at disease onset ranges from infancy to 
middle age with the majority becoming symptomatic in the second and third decade 
of life. Since patients and their relatives do not always recognize the early symptoms 
or signs, it is difficult to identify an exact age of onset. Furthermore in our study some 
patients with considerable weakness did not contribute their weakness to FSHD. For 
example we encountered mutation carriers with an unilateral foot drop or a camptocormia 
who did not realize this was a manifestation of FSHD. Unusual phenotypes may be 
misdiagnosed by patients and physicians and are often being contributed to the normal 
aging process. An alternative to assessing the age at onset or disease duration is the use 
of the age corrected clinical severity score.[14]
Despite the advances made in our knowledge of DUX4 misexpression as the most likely 
cause of FSHD, the striking clinical variability in disease onset, disease course and 
penetrance is still not explained. We do not fully understand the cause and consequences 
of DUX4 expression in muscle tissue. The high percentage of asymptomatic and non-
penetrant carriers is suggestive for (epi)genetic and/or environmental factors influencing 
the penetrance and clinical phenotype. In 2014 our study was followed by the FOCUS 
study designed to identify (epi)genetic and environmental disease modifying factors that 
contribute to the variable clinical phenotype of FSHD. Following our results, the FOCUS 
study included asymptomatic carriers and included spirometry and assessment of facial 
weakness as outcome measures.
New insights from genetic studies
Permissive alleles
At the beginning of this thesis project, FSHD1 was known to be associated with a 
contraction of the polymorphic D4Z4 macrosatellite repeat array to 1-10 units on a 4qA 
haplotype and to segregate as a dominant trait.[5,71,72]  The family and genetic studies 
described in this thesis have contributed to the increasing insight of the pathogenic 
mechanism for FSHD. We will discuss this below.
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At the start of our studies, we identified three families with FSHD in which each proband 
carried two FSHD-sized alleles (repeat contractions ≤ 10 units) and were heterozygous 
for the 4qA and 4qB polymorphism. This enabled segregation analysis of the 4qA and 
4qB alleles with the disease, showing that only 4qA allele carriers develop FSHD and 4qB 
allele carriers do not (chapter 7). This supported the previous observation that only D4Z4 
repeat contractions on a 4qA chromosomes are associated with FSHD.[5]  In subsequent 
studies, many more short-sized 4qB alleles have been reported and none was shown 
to be pathogenic.[73]  In 2011 a study in the Chinese, Japanese and Korean population 
confirmed that D4Z4 contractions on the 4qB variant do not cause FSHD.[74]
Later, we encountered two non-related severely affected FSHD patients with compound 
heterozygous mutations on 4qA chromosomes (families A and B; chapter 6). This 
observation suggested that compound heterozygosity is compatible with life. We 
proposed that two FSHD sized alleles contributed to a more severe phenotype as 
the result of a dosage effect of the D4Z4 contracted alleles and presumably of DUX4 
expression. Surprisingly, in both families at least one of the FSHD alleles was also 
associated with non-penetrance in some individuals. On the other hand, Tonini et al in 
2004 reported an FSHD patient that carried two 5 unit FSHD1 alleles in a consanguineous 
family, where the homozygous state did not result in a more severe clinical presentation 
(CSS of ≤ 4).[75]  Tonini et al hypothesized that one of the short 4qA alleles was not 
pathogenic. However, both FSHD1 alleles were probably identical as the proband’s 
parents were first cousins and segregation analysis in this family also showed that both 
alleles were pathogenic.[75]  Another hypothesis for compound heterozygosity being 
compatible with life was a low disease penetrance of one or both repeat contractions, 
because of the high prevalence of non-penetrant single mutation carriers in these 
families. In one of the families in our study (family B) the D4Z4 repeat sizes were 8 D4Z4 
units and 9 D4Z4 units respectively, sizes indeed more likely to be associated with non-
penetrance.[12,33,63]
The above mentioned studies[10,76] were conducted while the knowledge of permissive 
and nonpermissive 4qA haplotypes and the role of DUX4 in the disease process was 
not available yet.[4]  Subsequent genetic studies, identified multiple different 4qA 
haplotypes based on sequence variations proximal to D4Z4 (SSLP and D4F104S1/p13E-
11), distal and within D4Z4. All 4qA haplotypes were associated with FSHD except for one, 
haplotype 4A166.[73,77]  Advancing insight showed that the 3 unit D4Z4 allele in family 
A of our study was a permissive 4qA allele (4A161), thus causing the disease. In contrast, 
the second contracted allele of 5 D4Z4 units was the nonpermissive 4A166 haplotype.
[73]  Therefore the other families reported need to be studied in the same way to solve 
this discussion. 
181
In 2012, a study of the Italian National Registry for FSHD (INRF) also reported a high 
prevalence of compound heterozygosity.[78]  The haplotypes of 11 families with at least 
one family member with compound heterozygote D4Z4-reduced alleles were studied, 
and four different haplotypes were identified: 4A161, 4A166, 4A180 and 4qB163. From 
these four haplotypes, only the 4A161 alleles were shown to be associated with FSHD. 
Four of the 11 compound heterozygous families carried two of these permissive (4A161) 
alleles. The authors describe overall a more severe phenotype in the patients carrying 
two contracted D4Z4 repeats, but they do not differentiate between permissive and 
non-permissive alleles. Based on the current knowledge only two FSHD1-sized permissive 
alleles might result in a more severe phenotype, like in family B (chapter 6). 
Together, our families studies have contributed to the insight that D4Z4 contractions 
on both 4qA166 and on 4qB alleles do not cause FSHD. In a subsequent genetic study 
(not included in this thesis) the two allelic variants of chromosome 4q in the region 
distal to D4Z4 (4A and 4B) were examined. Genetic studies of the proximal and distal 
ends of the D4Z4 repeat array and its flanking sequences allowed the identification of 
polymorphisms that were associated with FSHD permissive haplotypes in contrast to  
non-permissive haplotypes.[73,77]  The most striking difference between permissive 
and non-permissive haplotypes was the polymorphic DUX4 polyadenylation signal.[4,79]  
Only 4qA haplotypes provide the necessary polyadenylation signal (PAS) to stabilize 
the DUX4 transcript and are thus disease-permissive, except for the 4A166 haplotype, 
which for at present unknown reasons appears to be nonpermissive or having reduced 
penetrance compared to other 4qA haplotypes.[73]
Hypomethylation
The next important step in understanding the pathogenesis of FSHD was the recognition 
of the chromatin state of the D4Z4 locus. It was anticipated that due to the repeat 
contraction the D4Z4 locus adapts toward a more open chromatin structure. One of the 
markers of chromatin relaxation is a loss of CpG methylation which was studied for D4Z4. 
Patients with FSHD1 showed significant FSHD1 allele-specific hypomethylation of the 
repeat.[14]  This was the first evidence for an epigenetic disease mechanism in FSHD. 
Subsequently, individuals with an identical clinical phenotype in absence of D4Z4 repeat 
array contraction, termed FSHD2, were also studied for D4Z4 methylation. Interestingly, 
FSHD2 patients showed a strong reduction of D4Z4 methylation on both chromosomes 4 
and 10.[80,81]  Hypomethylation observed in both FSHD1 and FSHD2 appeared to be an 
important step in the elucidation of the pathogenesis in FSHD.
In order to improve understanding of the mechanism of hypomethylation, we investigated 
the differences and similarities in two unrelated diseases both associated with severe 
hypomethylation of the repeat: FSHD2 and immunodeficiency, centromeric instability, 
and facial anomalies (ICF) syndrome, which is not characterized by muscular dystrophy. 
The results showed no other epigenetic or phenotypic similarities between FSHD2 and 
ICF, and no mutations in candidate genes for hypomethylation were identified. Hence, 
FSHD2 and ICF do not share a defect in the same molecular pathway.[82]  FSHD2-affected 
individuals often carry smaller but normal sized D4Z4 repeat arrays (8-20 units), and this 
might make them more susceptible for further D4Z4 hypomethylation.[59,83] Subsequent 
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analysis of the D4Z4 repeat sizes in ICF1-affected families showed that about half of the 
heterozygous DNMT3B carriers do not carry a FSHD-permissive chromosome.  
For those who do have a permissive (DUX4 PAS containing) chromosomes, the arrays 
are well beyond the size of what is typically found in FSHD2 individual: the smallest 
D4Z4 repeat that was found contained 32 units. Suggesting that these individuals might 
be protected from somatic DUX4 expression because of their long repeat arrays. This 
combined with the relatively young age at which ICF1 individuals typically give way to 
their immunodeficiency, might explain the absence of muscle weakness in ICF1-affected 
families.[84] 
Hypomethylation was subsequently identified as an epigenetic determinant of the 
striking variability in disease onset and progression.[14,59,61,81,84]  Recently it was 
shown that affected carriers of a disease array of 7-10 D4Z4 units, but not familial 
non-penetrant mutation carriers, have a greater reduction of D4Z4 CpG methylation 
than might be expected based on the size of the pathogenic D4Z4 repeat array. This 
supports the concept of epigenetic susceptibility to disease presentation in both FSHD1 
and FSHD2.[59]  In our final study (chapter 9), we also showed that reduced methylation 
tended to be associated with a more severe phenotype (age-corrected CSS>50) in the 
carriers of the larger size FSHD alleles (8-10 units).[85]
Building blocks for the unifying genetic model of FSHD
Hence, genetic lessons learned by examining patients at both the mild and the severe 
end of the clinical spectrum have together generated important building blocks 
for the unifying genetic model of FSHD (permissivity of haplotypes and D4Z4 CpG 
hypomethylation). In both FSHD1 and FSHD2 a common loss of CpG methylation in the 
D4Z4 region and epigenetic derepression of a normally silenced gene, DUX4 (a double 
homeobox 4), causes disease through a toxic gain-of-function mechanism.[4,86,87]
FSHD2
Subsequent whole exome sequencing in selected FSHD2 families based on 
hypomethylation at all D4Z4 arrays identified mutations in the Structural Maintenance 
of Chromosome Hinge Domain Containing 1 (SMCHD1) gene.[6]  Reducing SMCHD1 levels 
in skeletal muscle results in contraction-independent DUX4 expression. FSHD2 is caused 
by the digenic inheritance of a normal sized D4Z4 repeat array on a permissive 4qA allele 
(chromosome 4) and a heterozygous SMCHD1 mutation on chromosome 18.[6,88]   
A permissive 4qA haplotype is required for FSHD. In case of FSHD1 D4Z4 repeat 
contraction must occur at the permissive 4qA allele and for FSHD2 at least one of the 
chromosome 4 alleles needs to be permissive. SMCHD1 mutation carriers with two 
nonpermissive alleles have no risk to develop FSHD.
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Figure 4 Schematic of the FSHD locus both FSHD1 and FSHD2
The molecular and genetic mechanisms of FSHD types 1 and 2. Normal, unaffected individuals carry 8–100 
repeat units (triangles) within the highly condensed D4Z4 macrosatellite elements on the subtelomeric region 
of chromosome 4q35. Contraction of D4Z4 repeats in FSHD1 (less than 10 repeats) relaxes the chromatin 
structure and induces the expression of DUX4 from the most distal repeat unit. DUX4 transcripts expressed 
from the non-permissive chromosomal allele without a poly(A) signal (red bar) does not become polyadenylated 
and are unstable, whereas polyadenylated DUX4 transcripts expressed from the permissive allele (green bar) 
are stable and translate into a toxic transcription factor, DUX4. SMCHD1 establishes D4Z4 methylation. In 
FSHD2, pathogenic variants in SMCHD1 hampers the methylation of D4Z4 and suppression of DUX4 in somatic 
cells. Abbreviations: DUX4, double homeobox 4; FSHD, facioscapulohumeral dystrophy; SMCHD1, structural 
maintenance of chromosome flexible hinge domain containing protein.
Recent studies reported that SMCHD1 mutations also modify the penetrance of FSHD1.
[89-91]  In 2013 a study in three families with 8 or 9 unit FSHD1 alleles identified family 
members who were more severely affected than their mildly affected relatives. This more 
severe phenotype co-segregated with the presence of a SMCHD1 mutation and increased 
D4Z4 hypomethylation.[89]  In 2016 it was demonstrated that mutations in DNA 
methyltransferase 3B (DNMT3B) can act as a modifier in FSHD1. We propose that, like for 
SMCHD1, the effect of DNMT3B mutations on DUX4 expression and disease presentation 
depends on the presence of a DUX4 PAS and on the size of the D4Z4 repeat array.[84]
Clinical implications for geneticists
With the increasing complexity of the genetics of FSHD, the molecular testing methods 
have become more important in atypical cases. Furthermore, if a physician wants to 
confirm non-penetrance in a asymptomatic sib older than 18 years without signs of FSHD, 
genetic testing is required. For FSHD2 mutation screening of SMCHD1 have
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Figure 5 Schematic diagnostic workflow for patients with a typical FSH phenotype
FSH phenotype: asymmetrical weakness of facial and or shoulder girdle weakness ( with or without footextensor 
and axial muscle weakness, see Table 1). Up to 95% of FSHD cases can be explained by contractions in the D4Z4 
repeat array (FSHD1), for the remaining cases FSHD2 should be investigated. At present if the D4Z4 repeat is >10 
units and the repeat and the methylation is > 25% FSHD can be ruled out. FSHD2 can be diagnosed in patients 
carrying one permissive allele by sequencing for pathogenic variants in SMCHD1 gene and if negative for DNMT3B 
mutations. When FSHD1 and FSHD2 testing is negative, we recommend to perform a whole-exome sequencing 
(WES) Myopathy panel. Perhaps in the future other (epi)gentic variants are found to define a FSHD3 form.
Clinical FSH phenotype
D4Z4 contraction
No FSHD
FSHD1
FSHD2
FSHD3 ?
D4Z4
methylation
WES Screening
Myopathy panel
Permissive
haplotype
no
yes yes
yes
yes
no
no
no
Permissive
haplotype
> 25%
SMCHD1
mutations
1-10 D4Z4 units 11-150 D4Z4 units
Remark:
•  8-10 unit FSHD1, also found in 1%-2%  
control population
•  Vey severe FSHD with 7-10 units, check  
for SMCHD1 and DNMT3B mutations
185
 
become standard practise in many labs (NL, UK, Spain, France, USA) We propose the 
following test to be part of the routine FSHD diagnostics in all labs worldwide: haplotype 
characterization to exclude fals positive gene carriers and to estimate the risk of 
developing the disease in carriers of SMCHD1 mutations, methylation status of D4Z4 to 
exclude false positive SMCHD1 mutation carriership.
However, the complexity of the genetic cause of FSHD causes a number of pitfalls in 
the genetic diagnosis that can result in false negative or false positive results. Prenatal 
diagnosis is available all familial FSHD1 patients, but requires the availability of DNA 
from the affected parents or other affected family members. Because genetic diagnosis 
for FSHD can take several weeks to complete, diagnosis on DNA isolated from chorionic 
villi is preferred over amniocentesis. Permissive 4qA allele with a repeat size of 8-10 
repeats form a greyzone, as they are identified in FSHD1 patients, but also in 1%-2% 
of the control population. Consequently, genetic testing in families with isolated cases 
and these long repeat sizes should be counseled carefully as it is uncertain whether 
mutation carriers represent control or non-penetrant cases. The results from chapter 9 
support previous studies on hypomethylation as modifying factor contributing to more 
severe disease, predominantly in the larger repeat sizes (D4Z4 repeats 8-10 units). But the 
contribution of CpG methylation at D4z4 was only shown at the group level. Counseling 
based on D4Z4 methylation in individual FSHD1 cases is not reliable yet.
Caution should be taken with preimplantation genetic diagnosis (PGD) for FSHD1 as the 
Southern blot genetic test is not applicable to single cell PGD. Consequently, the disease-
associated D4Z4 repeat can only be detected indirectly with the use of polymorphic 
markers, but the relatively high recombination frequency and the availability of few 
polymorphic markers specific for the region proximal to D4Z4 hampers PGD significantly. 
Therefore PGD is not yet available for FSHD1 in the Netherlands. In addition, counselling 
in a prenatal setting is complex, because of the possibility of asymptomtic /non-penetrant 
carriership in offspring of a symptomatic parent. On the other hand, the heterozygous 
SMCHD1 variants in FSHD2, enables the use of PGD for this patient population.
Penetrance and severity are related to both the number of residual D4Z4 units and, most 
likely in patients with longer repeats, to D4Z4 methylation. However, many questions 
remain unanswered; the complexity of genetic and epigenetic characteristics and the 
role of DUX4 together with the clinical variability and course of the disease are still 
challenging. See Box 2 for an overview of suggestions for the geneticist.
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Future perspectives
The major advances in our understanding of the molecular mechanisms underlying 
FSHD made throughout this thesis have paved the way for the design of treatment trials 
which are expected to be initiated in the near future. The amount of work to optimize 
trial preparedness are huge, while the complexity of the genetic and epigenetic 
characteristics, the complicated role of DUX4, and the large clinical variability in disease 
severity and course are challenging. Nevertheless, the observations in this thesis offer a 
number of tips for future studies as described in this chapter.
The high prevalence of asymptomatic mutation carries in the family-based study calls for 
longitudinal patient studies to learn more about this carrier state with currently unknown 
future course. The risk for FSHD to become manifest in the greyzone repeat sizes (8-10 
D4Z4 units) is unclear. Patient studies in this D4Z4 range are necessary and the results 
need to be connected to epigenetic characteristics. Other outcome measures than the 
clinical severity score are needed to support future development of new treatment trails, 
especially in this population. The available data on muscle imaging using localized MRI 
and ultrasound is promising for detection of subclinical disease.[43,44,92-94]  and are 
challenging for future treatment trials.
There is an urgent need for further research on pain and pain management. Pain is a 
disabling symptom in a majority (79%) of FSHD patients. Currently the pathophysiology/ 
molecular biology mechanisms which causes the pain (typically musculoskeletal in 
origin) is unknown More research on pain mechanisms is needed to initiate trials on pain 
management to reduce symptoms and increase quality of life. Moreover, pain can be a 
candidate for secondary outcome in new treatment strategies, if connection can be made 
to the molecular biology.
Although DUX4 misexpression should be considered the most likely cause for FSHD, 
many observation have not been adequately explained yet. The existence of a separate 
mechanism for D4Z4 chromatin relaxation (FSHD2) strongly suggests that other factors 
must be involved in this disease. The relevance of the epigenetic state of the repeat 
for disease severity was shown in multiple studies that found a difference in D4Z4 
CpG methylation levels between affected and unaffected carriers. Further research 
is needed, for other (epi)genetic and environmental factors might contribute to the 
clinical presentation. For a better understanding of the underlying pathophysiological 
mechanisms integration of clinical and (epi)genetical studies is essential, with a persistent 
need for population studies as described in this thesis. Current knowledge about disease 
course are mainly derived from retrospective studies. Prospective studies will be 
needed to understand disease modifying factors that contribute to the variable clinical 
phenotype and to the reduced penetrance within families. 
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B O X  1 : 
Lessons for physicians
 Respiratory involvement
•  Respiratory insufficiency due to respiratory muscle weakness occurs in 
approximately 10% of FSHD patients and is more likely in moderate-to-severe 
disease with kyphoscoliosis and wheelchair-dependency [1]; nevertheless, it 
needs to be considered in all patients.
•  Annual screening by spirometry with a face mask is recommended in all patients 
with pelvic girdle weakness, wheelchair dependency, or kyphoscoliosis.
 Dysphagia
•  Patients with FSHD do not always spontaneously report problems in chewing, 
speaking or swallowing.
•  Dysphagia is seldom life-threatening; severe pharyngeal and esophageal 
involvement has not been observed.
•  Referral to a speech therapist experienced in neuromuscular disorders is 
recommended in case of dysarthria or dysphagia.
 Mucsuloskeletal pain
•  The majority of patients with FSHD (up to 79%) experience pain that is typically 
musculoskeletal in origin. The most common areas affected by pain include the 
lower back, legs, shoulders, and neck.
•  Pain might be the manifesting symptom in mutation carriers; in a context of a 
FSHD family it might warrant genetic testing.
 Recognizing asymptomatic individuals
•  Both facial and shoulder girdle weakness can be subtle and should be carefully 
examined. 
•  Facial weakness may be visible only as asymmetrical pouting of the lips or a 
‘signe de cils’—an inability to bury the eyelashes completely when attempting to 
close the eyes tightly. 
•  The most sensitive way to detect subtle weakness of the shoulder muscles with 
scapular winging is to observe the scapula while the patient slowly lowers the 
arms forwards and/or sidewards.
 Genetic features
•  Physicians should be aware of a high proportion of asymptomatic and non-
penetrant mutation carriers, especially in families with larger D4Z4 repeat sizes 
(≥ 8 units).
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•  Clinicians cannot rely on physical examination to determine whether a member of 
a FSHD family is a mutation carrier, even at the age > 30 years.
•  In the setting of atypical or sporadic cases, genetic confirmation is important 
for genetic counseling, especially with the discovery of two genetically distinct 
forms of FSHD. Additional 4qA/4qB haplotyping is required. 
•  Furthermore, because of the overlap between FSHD1 and controls for 8-10 unit 
permissive alleles, genetic testing in FSHD families with these greyzone FSHD1 
alleles should be counseled carefully as it is uncertain whether these alleles are 
pathogenic in all carriers.
•  A patient with a classical FSHD phenotype without a family history of FSHD1 
and in absence of a contracted D4Z4 repeat (FSHD1) subsequent sequencing of 
SMCHD1 ( FSHD2) is advised. 
 
B O X  2 : 
Lessons for geneticist
 FSHD 1
• The genetic pathophysiology of FSHD is complex.
•  The most common form, FSHD1, is caused by contraction of the D4Z4 repeat array 
on permissive 4qA alleles to a size of 1-10 units. 
•  Repeat contraction to 1-10 D4Z4 units on 4qB alleles is non-pathogenic; 
therefore additional analysis of 4qA and 4qB contracted alleles is recommended 
in asymptomatic relatives.
•  Contraction of the D4Z4 repeat array coincides with a loss of repressive 
chromatin markers and reduced DNA (CpG) methylation levels at D4Z4.
•  Borderline repeats/grey zone mutation carriers carry 8-10 unit permissive alleles, 
which can also be found in 1-2% of the control population.
•  A severe course is most often seen in early onset patients and associated with 
reduced D4Z4 repeat arrays (1-3 units). 
•  A rough inverse correlation is found between the clinical severity and D4Z4 
repeat size. In patients with 1-6 units , disease severity is mainly determined by 
the size of the repeat while inpatients with 7-10 units epigenetic regulation of 
the repeat, reflected in the delta1 methylation value, appears to co-determine 
the severity of FSHD.
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FSHD2
•  FSHD2 is caused by the digenic inheritance of a normal sized D4Z4 repeat array 
on a DUX4 PAS containing chromosome 4 and a heterozygous SMCHD1 mutation 
on chromosome 18.
•  It two families, the digenic inheritance of a normal sized D4Z4 repeat array on a 
DUX4 PAS containing chromosome 4 and a heterozygous DNMT3B mutation on 
chromosome 20 are identified to cause FSHD.
•  SMCHD1 or DNMT3B pathogenic variant without a permissive allele do not result 
in an FSHD phenotype
•  Comparable to FSHD1, repeat size also plays an important role in the severity of 
FSHD2, where mostly 8-20 unit (mean 12 units) D4Z4 repeat are identified
•  Co-segregation of SMCHD1 mutations or DNMT3B mutations with an FSHD1-sized 
allele can contribute to more severe hypomethylation and to a more severe 
phenotype than expected based on the repeat size.
 
B O X  3 : 
Lessons for patients
 
 Genetic testing
•  Genetic testing is required to rule out FSHD in family members who report no 
symptoms. Even in family members older than 30 years, the absence of symptoms 
of muscle weakness or atrophy cannot exclude carriership
•  Due to the incomplete penetrance even in late adulthood, pedigrees might not 
show a dominant pattern, in other words, you might be carrier even if your father 
or mother is clinically not affected.
•  If mutation carrier ship has been present, the likelihood curves present the 
likelihood of having symptoms or signs at a specific age. Reliable prognostic 
information is still difficult, because of the wide intrafamilial variability, except 
for the allele sizes of 1-3 D4Z4 units, which predict severe or early onset FSHD.
•  We advise FSHD patients with a wish to have children to be referred to a clinical 
geneticist early.
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  Symptoms and signs
•  Pain can be present early in the course of the disease, especially shoulder pain 
even in absence of muscle weakness. When experiencing persisting pain ask your 
general practitioner, rehabilitation doctor or neurologist for advice.
•  FSHD can present in patterns other that its name suggests. If FSHD is routinely 
thought of, especially in a FSHD family context, the physician can perform 
specific clinical tests (Table 1) and consider FSHD genetic testing.
 Rehabiliation
•  Patients with pelvic girdle weakness, wheelchair dependency and/or kypho-
scoliosis should be annually screened for respiratory involvement. Patients 
should be informed about symptoms of nocturnal hypoventilation: disturbed 
sleep, morning headache and daytime fatigue. Moreover, pulmonary function 
testing is recommended prior to surgery requiring general anaesthesia. 
•  Swallowing problems can occur because of oral-facial weakness. Referral to a 
speech therapist experienced in neuromuscular disorders might be of help.
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 Chapter 11  
 
  Du tch  Summar y 
  Neder l ands t a l ige 
s amenvat t ing 
Dutch Summary - Nederlandstalige samenvatting
Facioscapulohumerale spierdystrofie  (FSHD)  is een van de meest voorkomende erfelijke 
spierziekten onder volwassenen. De geschatte prevalentie is 1:8000.[1]  Dit betekent dat 
er naar schatting 2000 FSHD patiënten in Nederland zijn. De term FSHD refereert aan 
progressieve spierzwakte in de gelaatspieren (facio), schoudergordelspieren (scapulo) en 
bovenarmspieren (humeraal). Daarnaast zijn de bekkengordel, romp en beenspieren ook 
vaak aangedaan. De ziekte wordt gekenmerkt door asymmetrische spierzwakte. Meestal 
beginnen de eerste klachten tussen het 15e en 30e levensjaar, hoewel dit kan variëren 
van de kinderleeftijd tot ouder dan 60 jaar. Er bestaat een grote variatie in de ernst en in 
het beloop van de ziekte: ongeveer 1/3 van de mensen die de genetische verandering 
in het DNA hebben, krijgt nooit klachten en ongeveer 20% van de patiënten wordt 
in de loop van het ouder worden rolstoelafhankelijk.[2,3]  De ernst van de ziekte kan 
worden weergegeven met de Clinical Severity Score (CSS) van 1 tot 10 ( 1= alleen zwakte 
van de aangezichtsspieren; 10 = niet zelfstandig kunnen lopen met volledig rolstoel 
afhankelijkheid).[4] 
FSHD wordt veroorzaakt door specifieke chromatine veranderingen in het DNA op het 
uiteinde van chromosoom 4. Hierdoor ontstaat een meer open chromatine structuur 
waardoor  DUX4 eiwit wordt aangemaakt, waarvan de expressie normaal gesproken 
onderdrukt is in skeletspieren. Het gen voor DUX4 bevindt zich in de D4Z4 repeat op 
chromosoom 4 en de ziekte treedt alleen op in geval van een ’permissief’ 4qA haplotype. 
De permissieve haplotypes voorzien het DUX4 transcript van een stabiliserend 
polyadenylatie signaal, dat directe afbraak van het transcript voorkomt.[5]
Er zijn verschillende genetische mechanismen die zorgen voor onvoldoende remming van 
het DUX4 gen en dit leidt tot twee vormen van de ziekte, FSHD1 en FSHD2. Deze twee 
vormen zijn klinisch niet van elkaar te onderscheiden. 
In de gezonde bevolking varieert de lengte van de D4Z4 repeat tussen de 8 en 100 
D4Z4 eenheden. Bij de meest voorkomende vorm FSHD1 zijn er slechts 1-10 eenheden 
op één van de twee chromosomen 4. Ongeveer 5% van de FSHD patiënten heeft geen 
verkorting van de D4Z4 repeat, maar wel een open chromatine structuur door een 
mutatie in het ‘structural maintenance of chromosomes flexible hinge domain containing 
1’ (SMCHD1) gen op chromosoom 18 of in zeldzame gevallen door een mutatie in het 
‘methyltransferase 3B’ (DNMT3B) gen op chromosoom 20. Door een verstoring van een 
remmend signaal (DNA methylering of epigenetische onderdrukking) wordt ook in FSHD2 
DUX4 eiwit geproduceerd.[5-8]  Hoe DUX4 eiwit uiteindelijk leidt tot spierzwakte is nog 
grotendeels onbekend. Daarnaast is de grote variatie in ziekte-ernst en incomplete of 
non-penetrantie (het niet manifest worden van ziektesymptomen bij dragerschap van een 
FSHD mutatie) nog niet verklaard. 
Vanaf begin jaren ‘90 is het mogelijk om DNA-onderzoek te verrichten om een klinische 
verdenking op FSHD te bevestigen. FSHD1 erft autosomaal dominant over en kan 
genetisch worden vastgesteld door de lengte van de D4Z4 repeat te bepalen. De repeat 
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lengte wordt aangegeven met een EcoRI  band van kleiner of gelijk aan 38kb (kleiner of 
gelijk aan 10 units).[3,7]  Voor de genetische diagnostiek van FSHD2 kan worden getest op 
SMCHD1 mutaties.[6]
In hoofdstuk 1 van dit proefschrift wordt een algemene inleiding gegeven, met een 
beschrijving van de klinische en genetische kenmerken van FSHD (samenvatting in BOX1, 
BOX2 en figuur 1-3 in hoofdstuk 1).
In 2002 besloten wij een nieuwe FSHD studie op te zetten als vervolg op het familie 
onderzoek uit de jaren 80 toen het nog niet mogelijk was om de klinische diagnose  
FSHD genetisch te bevestigen.[2]  Tien grote nog niet eerder onderzochte families  
werden uitgenodigd om deel te nemen aan dit onderzoek om klinische observaties uit  
het eerdere onderzoek te bevestigen en nieuw materiaal te verzamelen voor genetisch  
en epigenetisch onderzoek dat inmiddels beschikbaar was geworden (hoofdstuk 10). 
Tijdens deze familie onderzoeken kwamen wij enkele klinische problemen tegen die  
niet eerder waren onderzocht. Dit wordt geïllustreerd door onderstaande casus. 
Casus 1: Respiratoire betrokkenheid in FSHD?
Tijdens een eerste polibezoek in 2001 uitte een 40-jarige FSHD patiënt zijn zorgen over 
zijn toekomstige longfunctie. Zijn 65-jarige moeder was recent geopereerd en sindsdien 
respiratoir insufficiënt geworden, waarvoor zij niet-invasieve ademhalingsondersteuning 
nodig had. Haar longarts informeerde hen dat de spierziekte de oorzaak was van 
de zwakte van de ademhalingsspieren. Wij waren echter niet eerder patiënten 
tegengekomen met respiratoire insufficiëntie en deze uiting van FSHD was in de literatuur 
nog niet beschreven. Wij konden deze patiënt op dat moment geen onderbouwd 
antwoord geven op zijn vragen. 
Casus 2: Genotype – fenotype correlatie?
Twee asymptomatische kinderen van een FSHD patiënt, een broer en een zus van 
respectievelijk 22 en 25 jaar, werden naar ons neuromusculair centrum verwezen voor 
counseling in 2007. Genetisch onderzoek bevestigde een 9 units D4Z4 allel in beiden. 
Een dergelijk allel gaat in het algemeen gepaard met een mild ziektebeloop. Hun vader 
en zijn oudere zus echter waren ernstig aangedaan met rolstoel afhankelijkheid voor hun 
50e. Met de toenmalige kennis was het gebruikelijk om mutatiedragers te informeren dat 
er een globaal  verband bestaat tussen de lengte van de repeat en de ernst van de ziekte. 
Echter deze familie met slechts een lichte contractie van de D4Z4 repeat is op deze regel 
een grote uitzondering. Wij waren niet in staat om onderbouwde informatie te geven over 
het verwachte  ziektebeloop van beide kinderen met de wetenschap van toen. 
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Casus 3: Non-penetrantie  in volwassenheid?
Een van de eerste patiënten die deelnam in het familieonderzoek was een FSHD patiënt 
en zijn twee asymptomatische dochters van 30 jaar en 32 jaar. Er werd op dat moment van 
de studie nog verondersteld dat familieleden geen FSHD zouden ontwikkelen als ze op de 
leeftijd van ouder dan 30 jaar geen verschijnselen van de spierziekte hadden. Hun vader 
had klachten gekregen vanaf de leeftijd van 14 jaar en de diagnose FSHD was bij hem 
gesteld op de leeftijd van 37 jaar. Na genetische counseling gaven beide dochters aan 
geïnformeerd te willen worden over de uitslag van het genetische onderzoek. Tot ieders 
verbazing bleken beide dochters draagster van de FSHD mutatie. Dit leidde tot de vraag 
naar de frequentie van het voorkomen van non-penetrantie in volwassenen > 30 jaar en 
het risico op het krijgen van kinderen met symptomatisch FSHD.
Casus 4: Wel of niet aangedaan bij het ontbreken van klachten op de leeftijd van 30 jaar?
 
Deze casus is eveneens illustratief voor de variabele penetrantie in FSHD bij 
volwassenen. Het betreft een vrouwelijke patiënt van 58 jaar die naar ons centrum werd 
verwezen. Zij presenteerde zich met chronische lage rugpijn en moeite om haar armen 
te heffen boven schouderhoogte, zij had tevens moeite met lopen en langer stilstaan. 
Haar broer van 63 jaar had de diagnose FSHD gekregen toen hij 30 jaar was. Er was hem 
medegedeeld (in het pre-genetische tijdperk) dat zijn broers of zussen niet aangedaan 
zouden zijn, als zij geen klachten hadden boven de leeftijd van 30 jaar. Daarom had deze 
patiënte en de dokters die haar hadden onderzocht, de klachten niet in verband gebracht 
met FSHD en had het lang geduurd voor de diagnose gesteld werd. Bij lichamelijk 
onderzoek vonden wij evidente spierzwakte passend bij FSHD, met een FSHD score 
van 7/10. Na de genetische bevestiging van de diagnose werd zij verwezen naar een 
revalidatiearts die haar naar tevredenheid heeft kunnen begeleiden. 
Bovenstaande klinische problemen waren reden voor het onderzoek dat beschreven 
wordt in dit proefschrift. Het resulteerde in een aantal belangrijke lessen die wij geleerd 
hebben door patiënten te onderzoeken aan zowel het lichte als ernstige einde van het 
ziektespectrum. 
Het belangrijkste doel van dit proefschrift was fenotype-genotype correlaties te 
bestuderen door middel van onderzoek van grote FSHD families en ernstig aangedane 
patiënten. Het familieonderzoek werd opgezet voor het schatten van de penetrantie 
van FSHD voor verschillende repeat lengtes, inclusief repeat lengtes van 8-10 units. Het 
ultieme doel was om meer inzicht te krijgen in de opvallende inter- en intra-individuele 
variatie in FSHD.  Enkele observaties tijdens het familieonderzoek hebben vervolgens 
weer geleid tot verder onderzoek. Deze studies illustreren tevens het belang van familie 
onderzoek voor het bestuderen van genetische aspecten in FSHD. 
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Respiratoire insufficiëntie en slikstoornissen
In deel II van dit proefschrift beschrijven wij twee klinische kenmerken die door ons 
werden geobserveerd in ernstig aangedane patiënten: respiratoire insufficiëntie en 
slikstoornissen.
Het meten van de longfunctie met behulp van een spirometer wordt vaak bemoeilijkt 
door zwakte van de aangezichtsspieren. Doordat tijdens het blazen lekkage van lucht 
langs het mondstuk kan ontstaan door onvoldoende lipsluiting hebben wij eerst een 
spirometer ontwikkeld aangepast met een gezichtsmasker. In hoofdstuk 2 hebben wij de 
conventionele longfunctie apparatuur vergeleken met een spirometer en een manometer 
aangepast met een gezichtsmasker. Longvolumia en maximale respiratoire monddrukken 
werden gemeten en vergeleken in 22 gezonde personen. Met het gezichtsmasker waren 
de metingen van de geforceerde vitale capaciteit en het geforceerde expiratoire volume 
in één seconde gemiddeld 200 mL lager, en de maximale expiratoire mondruk was 3.2 kPa 
lager dan gemeten met het standaard mondstuk. De maximale inspiratoire monddrukken 
waren niet significant verschillend. Vervolgens hebben wij nieuwe normaalwaardes 
verkregen voor de spirometer en de manometer met een gezichtsmasker in 252 andere 
gezonde personen en konden wij voorspellende formules opstellen. Wij concludeerden 
dat het gebruik van draagbare longfunctie apparatuur aangepast met een gezichtsmasker 
een betrouwbaar alternatief is en makkelijk in gebruik om de longfunctie in FSHD 
patiënten te meten. Deze aangepaste longfunctie apparatuur wordt sindsdien gebruikt 
in onze neuromusculaire kliniek. Vervolgens is het gebruik van een gezichtsmaker 
meegenomen in de aanbevelingen van de internationale richtlijn voor behandeling 
en begeleiding van FSHD patiënten: “FVC metingen in patiënten met FSHD moeten 
altijd worden uitgevoerd met een volledig gezichtsmasker en niet met een standaard 
mondstuk om vals negatieve metingen te vermijden door lekkage van lucht door zwakke  
lipsluiting”.[7]
In hoofdstuk 3 beschrijven wij de klinische kenmerken van FSHD patiënten die 
respiratoire (ademhalings) ondersteuning krijgen. Respiratoire insufficiëntie was niet 
eerder in detail beschreven en de prevalentie was niet bekend. Het onderzoek naar 
respiratoire insufficiëntie in FSHD patiënten werd geïnitieerd door vragen vanuit de 
patiëntenvereniging. Hierop hebben wij de vier centra voor thuisbeademing in Nederland 
benaderd en werden tien FSHD patiënten met (nachtelijke) ademhalingsondersteuning 
geïdentificeerd. Alle tien patiënten werden thuis bezocht, lichamelijk onderzocht 
en hun medische dossiers bestudeerd. Alle patiënten waren ernstig aangedaan met 
rolstoelafhankelijkheid en zij hadden een matige tot ernstige vergroeiing van de 
wervelkolom (kyphoscoliose). De meeste patiënten presenteerde zich met vrij acuut 
ontstane respiratoire insufficiëntie. Echter, retrospectief hadden de meeste patiënten 
van tevoren al klachten van nachtelijke hypoventilatie zoals hoofdpijn bij het wakker 
worden die snel verdwijnt na opstaan, het niet uitgerust wakker worden, vermoeidheid en 
concentratie problemen overdag,  nachtmerries,  nachtzweten en nachtelijke onrust. Deze 
klachten bestonden soms al jaren voorafgaand aan de ademhalingsondersteuning en P
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deze verbeterden ook na het starten van de ademhalingsondersteuning. Conclusies uit dit 
onderzoek waren: (1) respiratoire insufficiëntie is zeldzaam in FSHD (ongeveer 1% in de 
Nederlandse FSHD populatie); (2) ernstig aangedane patiënten lopen meer risico op het 
ontwikkelen van ademhalingsproblemen, vooral als er sprake is van een kyphoscoliose en 
rolstoel afhankelijkheid; en (3) zorgverleners moeten bewust zijn op het voorkomen van 
ademhalingsproblemen en actief en regelmatig vragen naar symptomen van nachtelijke 
hypoventilatie in ieder geval bij patiënten met risicofactoren.
 
Vervolgens hebben wij een studie verricht om de hypothese te toetsen dat rolstoel-
afhankelijkheid en het hebben van een kyphoscoliose risicofactoren zijn voor het 
ontwikkelen van respiratoire insufficiëntie. Hiervoor hebben wij 81 patiënten onderzocht 
variërend in ziekte ernst van ambulant (zelfstandig kunnen lopen) tot volledig rolstoel 
afhankelijkheid (hoofdstuk 4). Ondanks dat geen van de deelnemende patiënten klachten 
had van respiratoire dysfunctie, vonden wij in 40% van de rolstoel afhankelijke patiënten 
lichte tot ernstige respiratoire insufficiëntie. Maximale inspiratoire en expiratoire 
monddrukken waren verminderd in de meeste patiënten. De grootste beperking in 
longfunctie (de vitale capaciteit) werd gevonden in de groep rolstoelafhankelijke 
patiënten met een (kypho-) scoliose. Deze patiënten hadden een eerder ziektebegin, een 
jongere leeftijd waarop ze rolstoelafhankelijk werden en een kortere repeat-lengte.  
Wij concludeerden dat ernstige zwakte van de bovenbeenspieren en rolstoel-
afhankelijkheid vroege indicatoren zijn voor betrokkenheid van de ademhalingsspieren 
in FSHD1. Op grond van deze resultaten adviseren wij regelmatige screening van 
de longfunctie in rolstoelafhankelijke patiënten (met een kyphoscoliose), zelfs in 
afwezigheid van symptomen van respiratoire insufficiëntie, vanwege de hoge prevalentie 
en de therapeutische consequenties.
 
De afgelopen jaren zijn er meerdere studies verricht naar de respiratoire functie in FSHD 
met vergelijkbare resultaten. Inmiddels zijn de resultaten meegenomen in de richtlijnen 
voor de behandeling en begeleiding van FSHD patiënten en is bij zorgverleners meer 
aandacht voor ademhalingsproblemen bij FSHD.[7] Vroege herkenning is belangrijk om 
acute problemen bijvoorbeeld een verslechtering ten gevolge van een luchtweginfectie, 
te voorkomen. Behandeling door middel van ademhalingsondersteuning in de nacht kan 
klachten van vermoeidheid en daarmee de kwaliteit van leven verbeteren. Belangrijk 
is dat de longfunctie adequaat wordt gemeten bij voorkeur met een masker omdat 
patiënten met zwakte van de aangezichtsspieren minder goed op een standaard 
mondstuk kunnen blazen. Bij aanwijzingen voor een gestoorde ademhaling tijdens 
de slaap kan naast longfunctieonderzoek, een slaaponderzoek worden verricht (een 
polysomnografie).
Onder de patiënten die deelnamen in de longfunctie studie in hoofdstuk 4 waren 
10 patiënten die slikklachten rapporteerden. Slikstoornissen zijn een risico voor het 
optreden van aspiratie en het optreden van luchtweginfecties zoals een pneumonie, 
vooral in patiënten met een verminderde longfunctie die minder krachtig kunnen 
ophoesten. Ten tijde van de studie werd betrokkenheid van de tong en de keel spieren 
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nog als een exclusie criterium beschouwd voor FSHD. Wij hebben daarom acht patiënten 
met slikklachten in detail onderzocht (hoofdstuk 5). Deze patiënten werden klinisch 
beoordeeld door een in neuromusculaire aandoeningen gespecialiseerde logopedist, er 
werd een slikvideo (videofluoroscopie) verricht om de  slikactie te beoordelen en er werd 
een MRI verricht van de tong. Deze patiënten met een vergevorderde ziekte toonden 
lichte betrokkenheid van de kaak- en tong spieren, zonder functionele betrokkenheid 
van de keel- en slokdarmspieren.  Slikstoornissen zijn daarom zelden levensbedreigend 
in deze patiënten. We concludeerde dat slikstoornissen kunnen optreden in FSHD en niet 
als een exclusie criterium kunnen worden beschouwd. Wij adviseren om patiënten met 
slikklachten naar een logopedist met ervaring met neuromusculaire ziekten te verwijzen. 
Genetische studies
De genetische studies in Deel III vloeiden voort uit het observeren van grote klinische 
verschillen in het FSHD spectrum en benadrukken de genetische en epigenetische 
factoren die bijdragen aan de ziekte ernst. De resultaten van deze studies hebben als 
bouwstenen bijgedragen aan het verenigde genetisch model van FSHD (”unifying genetic 
model of FSHD”) zoals door Lemmers en andere gepresenteerd werd in 2010.[9] 
Onder de patiënten met ademhalingsondersteuning bevond zich een patiënte met 
twee verschillende FSHD allelen. Zij was ernstig aangedaan en volledig rolstoel 
afhankelijk vanaf haar 12e jaar. Homozygotie (twee dezelfde FSHD allelen) of compound 
heterozygotie (twee verschillende FSHD allelen) voor FSHD was nog niet eerder 
beschreven. In die tijd werd gedacht dat het voorkomen van deze dubbele genetische 
verandering zeer zeldzaam was of wellicht niet verenigbaar met het leven is. In hoofdstuk 
6 rapporteren wij over deze familie (familie A) en een tweede niet-gerelateerde familie 
(familie B) waarvan beide patiënten compound heterozygoot bleken voor 2 FSHD 
allelen. Naast lichamelijk onderzoek werden er uitgebreide genetische analyses gedaan. 
Hiermee konden wij de chromosoom 4qA-oorsprong van alle FSHD-allelen die in deze 
FSHD families voor kwamen bevestigen. Dit leidde tot de conclusie dat compound 
heterozygotie voor FSHD allelen wel verenigbaar is met leven. Bovendien, observeerden 
wij een mogelijk dosis effect in beide patiënten, waarin elk 4qA allel mogelijk bijdraagt 
aan het FSHD fenotype: in de eerste familie resulteerde de combinatie van een 5-units 
en een 3-units allel in een zeer ernstig fenotype met contracturen en respiratoire 
insufficiëntie; in de tweede familie veroorzaakte de combinatie van een 8-units en een 
9-units allel een gemiddelde ernst van de ziekte, terwijl de allelen ieder apart in geen 
van zijn kinderen FSHD veroorzaakten. Wij suggereerden dat ten minste één van de FSHD 
allelen in beide families geassocieerd was met een ongewoon lage ziekte penetrantie, 
dat de gevoeligheid om FSHD te ontwikkelen gedeeltelijk wordt bepaald door intrinsieke 
eigenschappen van het FSHD allel anders dan alleen de repeat-lengte. Voortschrijdend 
inzicht in permissieve allelen is suggestief dat één van de 4qA allelen in familie A, 
4qA166, niet pathogeen is. Vervolgonderzoek naar deze 4qA166 allelen in deze familie 
vind op dit moment plaats. Aanvullende haplotypering van de 4qA allelen in familie B is 
helaas niet beschikbaar. P
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De volgende bijdrage aan het ”unifing genetic model of FSHD” was het bewijs van non-
pathogeniciteit van het 4qB allel door segregatie-analyse (hoofdstuk 7). Tijdens het 
familieonderzoek kwamen wij familieleden tegen met een verkort 4qB allel. In die tijd 
(2002) konden we twee varianten van chromosoom 4q onderscheiden die verschillen in 
de regio distaal van D4Z4 (4qA en 4qB). Hoewel beide varianten gelijk voorkomen in de 
normale populatie, zijn FSHD allelen exclusief van het 4qA type.[10] Wij identificeerden 
drie FSHD families waarbij een FSHD allel segregeert met een korte D4Z4 repeat op een 
4qB chromosoom. De combinatie van dergelijke korte allelen leidt echter niet tot een 
ernstiger FSHD fenotype. Aangezien de korte 4qB allelen ook werden waargenomen 
bij gezonde familieleden kon geconcludeerd worden dat 4qB chromosomen niet 
geassocieerd zijn met ziekte. Dus, naast een verkorting van D4Z4 is een 4qA haplotype 
vereist om FSHD te ontwikkelen (zo wordt het DUX4 transcript voorzien van een 
stabiliserend polyadenylatie signaal (PAS) waardoor het DUX4 eiwit tot expressie kan 
komen, hetgeen later bekend zou worden).[9]  Anderzijds bevatten 4qB subtelomeren 
elementen die FSHD pathogenese voorkomen. 
Daarnaast bleek dat in patiënten met FSHD minder methylgroepen aanwezig zijn 
op het DNA van de eerste D4Z4 repeat in vergelijking met controle patiënten. Wat 
deze ontdekking interessanter maakte was dat deze lage DNA methylatie ook werd 
waargenomen zonder contractie van D4Z4 in een kleine groep patiënten die klinisch niet 
te onderscheiden waren van FSHD (FSHD2).[11]  Daarnaast werd lage DNA methylatie ook 
gevonden in patiënten met het immunodeficiëntie, centromeerinstabiliteit, en faciale 
anomalieën (ICF) syndroom. Patiënten met ICF syndroom hebben herhaaldelijke infecties 
als gevolg van een immuundeficiëntie, maar hebben geen spierklachten en daarom was 
de rol van DNA methylatie in het ontstaan van FSHD onduidelijk.[12,13]  In hoofdstuk 8 
hebben we een studie uitgevoerd waarin wij FSHD2 patiënten hebben vergeleken met ICF 
patiënten. Doel van deze studie was om te onderzoeken of deze twee patiëntengroepen 
mogelijk een defect in hetzelfde DNA methylatie mechanisme hebben. Naast lage DNA 
methylatie (hypomethylatie) op de D4Z4 repeat is aangetoond dat in ICF patiënten 
verschillende andere repeterende stukken DNA ook minder methylgroepen bevatten. 
Dit kan worden verklaard doordat een deel van de ICF patiënten een defect in één van 
de DNA methyltransferase enzymen hebben.[14]  In FSHD2 patiënten bleek het DNA 
methylatie niveau van deze andere repeats niet verlaagd en dus is de DNA methylatie 
overeenkomst tussen FSHD2 en ICF gelimiteerd tot de D4Z4 repeat. We hebben geen 
mutaties kunnen aantonen in de kandidaat genen die we getest hebben in FSHD2. 
Concluderend: DNA hypomethylatie in FSHD2 is beperkt tot de D4Z4 regio; FSHD2 en ICF 
hebben geen gemeenschappelijk moleculair defect en geen klinische overeenkomsten; 
hypomethylatie van D4Z4 alleen is onvoldoende om FSHD te ontwikkelen. Vervolgens 
heeft verder onderzoek naar hypomethylatie van de D4Z4 in FSHD2 families geleid tot 
het identificeren van mutaties in SMCHD1.[6] 
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Familie onderzoek
De genetische fenomenen beschreven in hoofdstuk 6 en 7 werden waargenomen tijdens 
het grote FSHD familieonderzoek (Deel IV,hoofdstuk 8). De studie werd opgezet om 
grote families met FSHD te onderzoeken, vergelijkbaar met de studie van Padberg uit 
de jaren 80, nu met de mogelijkheid van genetische analyses. In het pre-moleculaire 
tijdperk was de statistische schatting van de penetrantie  gebaseerd op klinische 
diagnostische criteria en door grote gezinnen te onderzoeken.[2]  De penetrantie bleek 
vooral afhankelijk van de leeftijd, met bijna volledige (>95%) penetrantie bij de leeftijd 
van 20.[2,15]  In die tijd was het op basis van deze resultaten  gebruikelijk om de ziekte uit 
te sluiten indien er geen motore verschijnselen werden geobserveerd boven de leeftijd 
van 30. Dit staat in contrast met recente populatie studies die het voorkomen van non-
penetrantie rapporteren ook op latere leeftijd en afhankelijk van de repeat-lengte.[16-20]
Het doel van het familieonderzoek was om de penetrantie te beoordelen in een niet- 
geselecteerd cohort en om meer inzicht te krijgen in de genetische pathofysiologie.
Tien FSHD families met ten minste twee aangedane familieleden met een 4-9 units allel 
werden onderzocht. Alle familieleden werden lichamelijk onderzocht, genetisch in kaart 
gebracht, inclusief DNA methylatie in de mutatiedragers.
Mutatiedragers werden geclassificeerd als (1) symptomatisch: met symptomen van 
spierzwakte in de anamnese en tekenen van spierzwakte passend bij FSHD bij lichamelijk 
onderzoek; (2) asymptomatisch: zonder klachten van spierzwakte maar met verschijnselen 
van FSHD bij lichamelijk onderzoek; en (3) non-penetrant: zonder symptomen van zwakte 
in de anamneses en zonder spierzwakte passend bij FSHD bij lichamelijk onderzoek. In 
andere studies wordt de groep asymptomatische mutatiedragers niet onderscheiden van 
non-penetrante mutatiedragers.  We observeerden veel asymptomatische mutatiedragers 
met alleen subtiele faciale zwakte of schoudergordelzwakte (25% [17/69]; 26% in 4-6 
units; 23% in 7-9 units). De meeste asymptomatische mutatiedragers rapporteerden 
schouderpijn. De prevalentie van non-penetrantie was 17%, dit is lager dan in recente 
populatie studies.[18-20]  De maximale waarschijnlijkheidscurves van de penetrantie 
van symptomatische en symptomatische plus asymptomatische mutatiedragers toonden 
dat penetrantie afhankelijk is van de repeat-lengte en de leeftijd. De repeat-lengte was 
statistisch significant gecorreleerd aan de leeftijd-gecorrigeerde FSHD ernst score (age-
corrected clinical severity score (ACSS).[21]  Alleen voor de langere repeats was er een 
trend dat de methylatie waarde lager was in de matig tot ernstigere aangedane mutatie 
dragers (ACCS≥50) dan in diegene met een mildere ziekte ernst (ACCS<50).
De lagere non-penetrantie vergeleken met eerdere studies is waarschijnlijk het 
gevolg van een kleinere selectie bias door het bezoeken van personen aan huis en het 
onderscheiden van asymptmatische mutatiedragers (25%) door het geoefende oog van 
de onderzoekers. Onze bevindingen zijn onmisbaar voor genetische counseling en voor 
de herkenning van deelnemers aan toekomstige trials. 
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De belangrijke lessen die wij geleerd hebben van het grote familieonderzoek zijn:
1)   Motore verschijnselen van FSHD kunnen afwezig zijn in volwassenen en een normaal 
neurologisch onderzoek op volwassen leeftijd sluit genetisch dragerschap niet uit; 
2)  Subtiele faciale zwakte en schoudergordel zwakte kunnen makkelijk over het hoofd 
worden gezien;
3)  Hoewel schouderpijn vaak voorkomt in de algemene bevolking vragen onze resultaten 
om extra aandacht hiervoor in families met FSHD, omdat dit een symptoom kan zijn 
dat door de patiënt (nog) niet herkend wordt;
4)   De penetrantie is afhankelijk van leeftijd, D4Z4 repeat lengte en epigenetische 
factoren die de mate van de D4Z4-chromatine structuur beïnvloeden (en daarmee de 
D4Z4-repeat lengte of open chromatine structuur). Het pathogene mechanisme wordt 
in ieder geval ten dele bepaald door de interactie tussen de D4Z4-repeat lengte, de 
aanwezigheid van een 4qA allel waardoor het DUX4 transcript van een stabiliserend 
polyadenylatie signaal wordt voorzien en de variatie in genen die de epigenetische 
status van D4Z4 wijzigen. Deze interactie vormt de basis voor het begrijpen van het 
voorkomen van een verminderde ziekte penetrantie in de FSHD populatie. 
Tot slot wordt in hoofdstuk 9 een beschouwing gegeven op de bovenstaande 
hoofdstukken en de implicaties daarvan voor vervolgonderzoek.
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 Abbreviations 
BlnI Restriction enzyme for DNA analyses
CSS Clinical severity score, grading 0 to 10
CV Coefficient of variation
D4Z4 Specific part of chromosome 4q35 indicated by D4Z4 array
DMD  Duchenne Muscular Dystrophy
DNA  Deoxyribonucleid acid (double helix molecule which contains the hereditary of 
living cells)
DNMT3B  DNA (cytosine-5-)-methyltransferase 3 beta, is a protein associated with 
immunodeficiency, centromere instability and facial anomalies syndrome
DOSS Dysphagia Outcome Severity Scale, see page 70, Table 2
DUX4  Double homeobox 4, gene which is located in the subtelomeric region of 
chromosome 4q35
EcoRI Restriction enzyme for DNA analyses
EDTA Ethylenediaminetetraacetic acid (used in electrophoresis techniques)
FEV1 Forced expiratory volume in one second
FISH Fluorescence in situ hybridization
FRG1 FRG1 is a protein encoded by the FRG1 gene (specific for chromosome 4q35)
FSHD Fasioscapulohumeral muscular dystrophy
FSHD1 Fasioscapulohumeral muscular dystrophy type 1
FSHD2 Fasioscapulohumeral muscular dystrophy type 2
FVC Forced vital capacity
HindIII Restriction enzyme for DNA analyses
ICF syndrome Immunodeficiency, centro instability and facial anomalies syndrome
kb kilobase
KpnI Restriction enzyme for DNA analyses
KTW syndrome Klippel-Trenaunay-Weber syndrome
LVR Lung volume recruitment
MEP Maximal expiratory mouth pressure
MIP Maximal inspiratory mouth pressure
MRC Medical Research Council
MRC grade Scale to assess muscle strength, grading 1 to 5 
NotI Restriction enzyme for DNA analyses
PaCO2 Arterial carbon dioxide tension
PAX3  Paired box gene 3, member of the paired box or PAX family of transcription 
factors
PCR  Polymerase Chain Reaction, method to amplify or copy samples or segments of 
DNA
PEmax Maximal expiratory pressure
PFGE Pulsed-field gel electrophoresis
PFT Pulmonary function test
PFT(s) Pulmonary function test(s)
PImax Maximal inspiratory pressure
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PRC1 Polycomb Repressive Complex 1, belongs to the Polycomb-group proteins
SaO2 Arterial oxygen saturation
SD Standard deviation
SDS Sodium dodecyl sulfate, is a synthetic organic compound
SE Standard error
SMCHD1 Structural maintenance of chromosomes flexible hinge domain containing 1
TBE Tris, borate and EDTA (is a buffer solution used in electrophoresis techniques)
VC Vital capacity
XapI Restriction enzyme for DNA analyses
 Legend of the pedigrees 
 open represents non mutation-carrier male
 open represents non mutation-carrier female
 open represents non mutation-carrier sex unknown 
 close represents mutation-carrier male
  close represents mutation-carrier female
 close represents mutation-carrier sex unknown
 arrow indicatest the probandus (=index case)
 strikeout indicates deceased
  ? unknown, not assessed
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St. Augustinus College in Beverwijk and finsihed her secondary education in 1990. In the 
same year, she started medical school at the University of Amsterdam. She performed a 
scientific internship at the University of Connecticut Health Center, Hartford, Connecticut 
in the United States, where she studied neutralizing human monoclonal antibodies 
against HIV I, under supervision of dr. J.E. Robinson. 
After graduation in 1997 she worked as a resident at the department of Neurology of 
the Leyenburg Ziekenhuis (Haga Ziekenhuizen) in Den Haag. In 1999 she started her 
specialization at the department of Neurology of the Radboud University Medical 
Centre in Nijmegen. In 2002 she started this PhD-project, resulting in this thesis under 
supervision of  Prof. G.W.A.M. Padberg. 
Since 2008 she works as a neurologist at the department of Neurology in the Elisabeth 
Tweesteden Ziekenhuis (ETZ) in Tilburg. She is married with Roeland de Gruyter and they 
have two children, Sebastiaan and Isabella.
Mariëlle Wohlgemuth is geboren in Heemskerk in 1971. Zij volgde haar VWO opleiding 
aan het St. Augustinus College te Beverwijk. In 1990 begon zij aan haar studie 
geneeskunde aan de Universiteit van Amsterdam. Haar wetenschappelijk stage voerde zij 
uit aan de University of Connecticut Health Center  in Hartford Connecticut, Verenigde 
Staten. Zij bestudeerde neutraliserende humane monoclonale antilichamen tegen 
primaire HIV 1 isolaten onder leiding van dr. J.E. Robinson.
Na haar artsexamen in 1997 werkte zij als arts-assistent neurologie niet in opleiding in 
het Leyenburg Ziekenhuis, tegenwoordig Haga Ziekenhuizen in Den Haag. In 1998 begon 
zij als arts-assistent  neurologie in het UMCN St Radboud te Nijmegen en begon in 1999 
aan haar opleiding tot neuroloog (opleiders: prof. dr. G.W.A.M. Padberg en dr. M.J. Zwarts).
Vanaf 2002 combineerde zij haar opleiding tot neuroloog met wetenschappelijk 
onderzoek onder leiding van prof. dr. G.W.A.M. Padberg. Dit onderzoek resulteerde in dit 
proefschrift.  
Sinds 2008 werkt zij als Neuroloog in het Elisabeth TweeSteden Ziekenhuis (ETZ) te 
Tilburg. Zij is gehuwd met Roeland de Gruyter en samen hebben zij twee kinderen, 
Sebastiaan en Isabella.
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Dankwoord
Mijn grote dank gaat in de eerste plaats uit naar alle mensen met de spierziekte FSHD 
en hun familieleden. Zonder jullie medewerking was dit proefschrift niet tot stand 
gekomen. Bijzonder zijn de gastvrije bezoeken bij jullie thuis geweest. De persoonlijke 
ontmoetingen hebben niet alleen bijgedragen in de kennis en lessen die uit de 
onderzoeken naar voren zijn gekomen, maar ook in mijn persoonlijke vorming als 
neuroloog. Ik hoop van harte dat er snel zicht komt op een behandeling.  
George Padberg, mijn promotor en opleider. Vanaf het begin heb je mij enthousiast 
gemaakt voor deze bijzondere spierziekte. Ik heb vooral veel geleerd van onze 
besprekingen nadat ik een familie thuis bezocht had. Ik heb veel bewondering voor je 
kennis, enthousiasme en enorme drive, waarbij je altijd oog hebt voor de patiënt. Dit blijkt 
ook uit je voortdurende betrokkenheid bij de patiëntenvereniging. Ik wil je bedanken 
voor de vrijheid die ik heb gekregen om dit onderzoek met mijn opleiding te combineren. 
Tot slot wil ik je bedanken als persoon die mij vertrouwen heeft gegeven dat ik dit 
proefschrift zou voltooien.
Baziel van Engelen, je bent pas later betrokken geraakt als promotor. Fijn dat je deze taak 
op je wilde nemen. Daarnaast wil ik je bedanken voor alles wat ik tijdens mijn opleiding 
van je heb geleerd.
Nicol Voermans, jij hebt twee jaar geleden spontaan je hulp aangeboden en ik ben 
trots dat jij nu een van mijn copromotoren bent. Ik heb grote bewondering voor je 
gedrevenheid en kennis. Indrukwekkend hoe snel je inhoudelijk de juiste verbanden 
wist te leggen op reeds door mij verkregen resultaten. Je weet mensen te motiveren 
en hebt een onmiskenbare bijdrage geleverd aan het analyseren en publiceren van het 
familieonderzoek. Door jouw steun heb ik dit proefschrift af kunnen ronden.
Richard Lemmers, vanaf het begin van het onderzoek heb jij alle genetische data 
verzameld van de patiënten en familieleden. Vol enthousiasme kon je mij vertellen over 
blots en repeats als er weer een bijzonder of nog onduidelijk genotype werd gevonden. 
Onze gezamenlijke inspanning heeft mooie publicaties opgeleverd, met de publicatie 
van het familieonderzoek als bekroning op al ons werk. Ik wil je bedanken voor de fijne 
samenwerking en ben vereerd dat je mijn copromotor wilt zijn. 
Silvère van der Maarel, ik heb veel bewondering voor je enthousiasme en gedrevenheid 
waarmee je het genetisch en epigenetisch onderzoek naar deze fascinerende ziekte hebt 
vorm gegeven. Het is van ongekende waarde wat jouw onderzoeksgroep de afgelopen 
jaren voor FSHD en de FSHD patiënten heeft bereikt. Met de ontdekking van DUX4 is 
er eindelijk zicht op een potentiele behandeling. Ik wil je heel hartelijk bedanken, jouw 
bijdrage is essentieel geweest in het voltooien van mijn studies.
Dank aan de leden van de manuscriptcommissie, prof. J. van Bokhoven, prof. M. Nijhuis-
van de Sanden en dr. N. Cobben voor hun kritische beoordeling en goedkeuring van het 
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manuscript. Ook de bijdrage van de overige leden van de promotiecommissie op deze 
voor mij zo belangrijke dag waardeer ik zeer.
Mijn collega arts-assistenten en opleiders wil ik bedanken voor de fijne tijd in Nijmegen, 
zowel op het werk als daarbuiten. Daarnaast wil ik graag Danielle en Anouk bedanken 
voor de vele gezellige uurtjes tijdens het carpoolen tussen Driebergen en Nijmegen. 
Alle medeauteurs van de publicaties wil ik hartelijk bedanken voor hun inzet en bijdrage 
aan de onderzoeken uit dit proefschrift. In het bijzonder wil ik de collega’s van het FSHD 
onderzoeksteam van de afdeling Humane Genetica in Leiden bedanken voor de fijne 
samenwerking en de bijdrage aan de onderzoeken.
Mijn collega neurologen in Tilburg wil ik graag bedanken voor de prettige werksfeer. Een 
betere werkomgeving kan ik mij niet wensen. Dank  jullie voor het vertrouwen en de steun 
om dit proefschrift af te ronden. 
Elly, dank voor de gezellige opleiding- en onderzoektijd. Het was fijn om een collega te 
hebben die onderzoek deed naar dezelfde spierziekte. Mijn eerste FSHD patiënt ben ik 
samen met jou gaan bezoeken en dat was het begin van vele gezamenlijke onderzoek 
uurtjes, bijeenkomsten en congresbezoeken.  Dank je wel voor het kritisch doorlezen van 
de Nederlandse samenvatting, maar vooral wil ik je bedanken voor de fijne vriendschap al 
die jaren, ook al woon jij in het noorden en ik in het zuiden van Nederland. Ik vind het fijn 
dat jij nu als paranimf naast mij staat. 
Nicola, dank je voor onze vriendschap. We hebben de afgelopen jaren veel gedeeld en we 
beseffen steeds meer dat het leven gevierd moet worden. Ik kijk uit naar onze volgende 
vakantie samen met onze gezinnen. Ik vind het bijzonder dat je nu naast mij staat.
Familie en vrienden dank voor jullie interesse en geduld, zeker het afgelopen jaar toen 
alles in het teken van het proefschrift stond. Lieve Eefje en zusje, je bent er altijd voor mij, 
dank je wel.
Lieve papa en mama, dank voor jullie onvoorwaardelijke steun en liefde voor mij en mijn 
gezin. Jullie hebben mij geleerd om nooit op te geven en je doelen na te streven. Lieve 
papa, in het bijzonder, jammer dat je het sluitstuk niet meer mee kan maken.
Lieve Roel, het beste bewaar ik voor het laatst. Jij bent mijn grote liefde, mijn rustige en 
stevige thuisbasis. Zonder jouw enorme steun, relativeringsvermogen en humor had ik 
dit proefschrift niet kunnen volbrengen. Dank je voor je grote interesse, vertrouwen en 
geduld tijdens dit lange traject. Dank voor je vele uren werk in het doorlezen, corrigeren 
van de manuscripten en al je IT ondersteuning. Ik verheug mij op een heerlijke toekomst 
samen. 
Sebastiaan en Isabella, jullie zijn mijn grootste geluk. Dank voor jullie engelengeduld al 
die avonden en weekenden, “Het boekje is eindelijk klaar.”
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Donders Graduate School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young 
scientists. To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour 
established the Donders Graduate School for Cognitive Neuroscience (DGCN), which was 
officially recognised as a national graduate school in 2009. The Graduate School covers 
training at both Master’s and PhD level and provides an excellent educational context 
fully aligned with the research programme of the Donders Institute. 
The school successfully attracts highly talented national and international students in 
biology, physics, psycholinguistics, psychology, behavioral science, medicine and related 
disciplines. Selective admission and assessment centers guarantee the enrolment of the 
best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni 
show a continuation in academia with postdoc positions at top institutes worldwide, e.g. 
Stanford University, University of Oxford, University of Cambridge, UCL London, MPI Leipzig, 
Hanyang University in South Korea, NTNU Norway, University of Illinois, North Western 
University, Northeastern University in Boston, ETH Zürich, University of Vienna etc.
Positions outside academia spread among the following sectors: 
-  specialists in a medical environment, mainly in genetics, geriatrics, psychiatry and 
neurology,
-  specialists in a psychological environment, e.g. as specialist in neuropsychology, 
psychological diagnostics or therapy, 
- higher education as coordinators or lecturers. 
A smaller percentage enters business as research consultants, analysts or head of 
research and development. Fewer graduates stay in a research environment as lab 
coordinators, technical support or policy advisors. Upcoming possibilities are positions in 
the IT sector and management position in pharmaceutical industry. In general, the PhDs 
graduates almost invariably continue with high-quality positions that play an important 
role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please visit:
http://www.ru.nl/donders/graduate-school/phd/
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